>MS912635.1 Sequence 327 from Patent WO2017021541
TTAATTTGTCACG
>MS912627.1 Sequence 319 from Patent WO2017021541
TTTTGATGCATAT
>MS912583.1 Sequence 275 from Patent WO2017021541
GGGAAATGTAAAA
>MS994124.1 Sequence 120 from Patent EP3159409
CCGCCATTTCTCA
>MS994123.1 Sequence 119 from Patent EP3159409
GTGTCTTTCTGAG
>MS824974.1 Sequence 26 from Patent WO2017085175
CGCCACCTGGTGG
>MS824468.1 Sequence 3 from Patent WO2017085210
CACCGTCAAAATG
>MS910544.1 Sequence 109 from Patent WO2017060731
AGTTGCTTCATCT
>MS823204.1 Sequence 22 from Patent WO2017091811
CAATCCCCGAGCT
>MS823196.1 Sequence 14 from Patent WO2017091811
CCATCACCGTGCT
>MS823197.1 Sequence 15 from Patent WO2017091811
CAATCCCCGAGCT
>MS870370.1 Sequence 368 from Patent EP3173092
GGGTTTTTTTGGG
>MS870359.1 Sequence 357 from Patent EP3173092
GGTTTTTTTTTGG
>MS842518.1 Sequence 17 from Patent EP3130682
GACGCATCTAGCA
>MS842516.1 Sequence 15 from Patent EP3130682
GACCGATCTAGCA
>MS842504.1 Sequence 3 from Patent EP3130682
GCAGTGCCACAGA
>MS817216.1 Sequence 61 from Patent WO2017087724
AGATGTTTCTCAA
>MS799107.1 Sequence 2 from Patent WO2017009347
CCCCACCTCCCCG
>MS799106.1 Sequence 1 from Patent WO2017009347
CCCCWCCWCCVND
>MS661710.1 Sequence 30 from Patent EP3165086
CCACTGGCATCCC
>MS993290.1 Sequence 573 from Patent EP3107373
CGCCATGCTCATC
>MS993289.1 Sequence 572 from Patent EP3107373
CGCCATGCTCTTC
>MS993275.1 Sequence 558 from Patent EP3107373
ACGTTGCGGCGCC
>MS993274.1 Sequence 557 from Patent EP3107373
ACGTTGCAGCGCC
>MS912687.1 Sequence 379 from Patent WO2017021541
CAAGTGCATCATC
>MS912682.1 Sequence 374 from Patent WO2017021541
CTAATCCAATAAA
>MS912680.1 Sequence 372 from Patent WO2017021541
GACTGCAACAAAA
>MS912659.1 Sequence 351 from Patent WO2017021541
TTATTACCCCACC
>MS912320.1 Sequence 12 from Patent WO2017021541
TTTTTTTTTTTTT
>MS904735.1 Sequence 359 from Patent EP3138577
GGGTTTTTTTGGG
>MS904725.1 Sequence 348 from Patent EP3138577
GGTTTTTTTTTGG
>MS880073.1 Sequence 10071 from Patent EP3173092
GCCGCCACCATGG
>MS835665.1 Sequence 27 from Patent EP3112465
WMWWBTCAATAAB
>MS835646.1 Sequence 8 from Patent EP3112465
DAVAGCCATCAVT
>MS835644.1 Sequence 6 from Patent EP3112465
GTGATWTTNCWNS
>MS831782.1 Sequence 36 from Patent EP3176183
TTCGGCAGCCTCC
>LX057991.1 JP 2015533835-A/15: ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU
GGCCCAGCCGGCC
>LX057198.1 JP 2015532097-A/24: HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF
NGCTGCTCCTTGA
>LX057136.1 JP 2015528282-A/14: METHOD AND KIT FOR NUCLEIC ACID SEQUENCING
ACCTTGATGAACC
>LX057126.1 JP 2015528282-A/4: METHOD AND KIT FOR NUCLEIC ACID SEQUENCING
TAGCCTTTGGCCA
>LX077775.1 WO 2017047741-A/89: Antisense Nucleic Acid for Treatment of Amyotrophia
TTCAGAGATCGGA
>LX077769.1 WO 2017047741-A/83: Antisense Nucleic Acid for Treatment of Amyotrophia
TTGTAGGAGTCTC
>LX077607.1 WO 2017047707-A/74: Antisense Nucleic Acid
GTTTGCCGCTGCC
>LX077606.1 WO 2017047707-A/73: Antisense Nucleic Acid
TCCTGGAGTTCCT
>LX056635.1 JP 2015529469-A/90: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NGTCTATGTATAG
>LX056632.1 JP 2015529469-A/87: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NAATCCATGGNAG
>LX056631.1 JP 2015529469-A/86: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
GGCAAGCATCNTG
>LX056617.1 JP 2015529469-A/72: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
GNATTGGTATTNA
>LX056614.1 JP 2015529469-A/69: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
TNNTCGGCCTNTG
>LX056576.1 JP 2015529469-A/31: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NNTCTATGTANNN
>LX056573.1 JP 2015529469-A/28: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NNATCCATGGNNN
>LX056572.1 JP 2015529469-A/27: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NNCAAGCATCNNN
>LX056558.1 JP 2015529469-A/13: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NNATTGGTATNNN
>LX056555.1 JP 2015529469-A/10: MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
NNNTCGGCCTNNN
>LX077336.1 WO 2017043639-A/15: Chimera Decoy
AGGGGATTTCCCC
>LX077240.1 WO 2017043497-A/19: Method for the detection of cololectal tumor
CCGCGGTCAACGC
>LX077234.1 WO 2017043497-A/13: Method for the detection of cololectal tumor
CCGGGCCACACAC
>LX056114.1 JP 2015523864-A/96: TARGET DETECTION AND SIGNAL AMPLIFICATION
CGANNNNNNTACC
>LX076890.1 WO 2017038682-A/6: Analysis method of template nucleic acid, analysis method of target substance, kit for analyzing template nucleic acid or target substance, and device for analyzing template nucleic acid or target substance
CGGGGNCCGCTGC
>LX064175.1 JP 2017051111-A/6: Method For Detecting Gene
ATGCGGTGGTCGA
>LX063522.1 JP 2016501523-A/3: DIAGNOSTIC MARKERS FOR TREATING CELL PROLIFERATIVE DISORDERS WITH TELOMERASE INHIBITORS
TAGGGTTAGACAA
>LX062484.1 JP 2015533510-A/29: RETROVIRAL VECTOR WITH MINI-PROMOTER CASSETTE
CCCCGTTGCCCGG
>LV578930.1 JP 2015130858-A/6: METHODS AND APPARATUS FOR MEASURING ANALYTES USING LARGE SCALE FET ARRAYS
GTCGTACGGCTAA
>LV709072.1 JP 2016027825-A/128: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
AACGACGGCCAGT
>LV709065.1 JP 2016027825-A/121: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GGGTATAGCAGCA
>LV709063.1 JP 2016027825-A/119: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GAGTATAGCAGCT
>LV709055.1 JP 2016027825-A/111: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
TGACTACGGTGGT
>LV709052.1 JP 2016027825-A/108: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
TGACTACAGTAAC
>LV709031.1 JP 2016027825-A/87: Identification of Clonal Cells by Repeats in T-Cell Receptor V/D/J Genes
GGTATAGTGGGAG
>LV708647.1 JP 2016026503-A/85175: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
TGCTGGCCGTCCA
>LV708203.1 JP 2016026503-A/84731: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
TGCGGCTCCACCA
>LV745700.1 JP 2016025875-A/56: Detection of Nucleic Acids from Multiple Types of Human Papillomaviruses
GTAGAAACCTCGC
>LV578226.1 JP 2017500870-A/15: Production system
ACAGCCACCTAGG
>LV578225.1 JP 2017500870-A/14: Production system
ACAGCCACCATGG
>LV578219.1 JP 2017500870-A/8: Production system
ACAGCCACCATGG
>LV577641.1 JP 2017500865-A/1: LEPTIN MRNA COMPOSITIONS AND FORMULATIONS
GCCGCCRCCATGG
>LV577549.1 JP 2017500035-A/46: CAS VARIANTS FOR GENE EDITING
ATTATTATTATTC
>LV577547.1 JP 2017500035-A/44: CAS VARIANTS FOR GENE EDITING
ATTATTATTATTC
>LV575969.1 JP 2017500887-A/35: Methods for the surveillance, diagnosis and screening of bladder cancer
CCCGGAAGGGGTC
>LV575968.1 JP 2017500887-A/34: Methods for the surveillance, diagnosis and screening of bladder cancer
CCCGGAAGGGGCT
>LV573070.1 JP 2017501684-A/30: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573065.1 JP 2017501684-A/25: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573064.1 JP 2017501684-A/24: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573062.1 JP 2017501684-A/22: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573061.1 JP 2017501684-A/21: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573060.1 JP 2017501684-A/20: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573058.1 JP 2017501684-A/18: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573057.1 JP 2017501684-A/17: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573055.1 JP 2017501684-A/15: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573054.1 JP 2017501684-A/14: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573053.1 JP 2017501684-A/13: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573045.1 JP 2017501684-A/5: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573044.1 JP 2017501684-A/4: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573043.1 JP 2017501684-A/3: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV573041.1 JP 2017501684-A/1: ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LV572827.1 JP 2017502075-A/115: Means and methods for hte treatment of nephropathy
GGGGGGCGCGACC
>LV572717.1 JP 2017502075-A/5: Means and methods for hte treatment of nephropathy
GGGGGRCGCGAYC
>LV572692.1 JP 2017501683-A/33: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
GAGCTGATGGCGT
>LV572691.1 JP 2017501683-A/32: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
GAGCTGATGGCGT
>LV572679.1 JP 2017501683-A/20: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
GCGGTGGTCGAGG
>LV572677.1 JP 2017501683-A/18: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
GGAGCTTGTGGCG
>LV572676.1 JP 2017501683-A/17: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
GGAGCTCGTGGCG
>LV572675.1 JP 2017501683-A/16: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
GGAGCTAGTGGCG
>LV572673.1 JP 2017501683-A/14: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572672.1 JP 2017501683-A/13: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572671.1 JP 2017501683-A/12: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572670.1 JP 2017501683-A/11: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572669.1 JP 2017501683-A/10: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572668.1 JP 2017501683-A/9: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572667.1 JP 2017501683-A/8: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
CTCGACGACCGCA
>LV572666.1 JP 2017501683-A/7: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572665.1 JP 2017501683-A/6: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572664.1 JP 2017501683-A/5: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572663.1 JP 2017501683-A/4: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572662.1 JP 2017501683-A/3: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572661.1 JP 2017501683-A/2: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572660.1 JP 2017501683-A/1: Method for the Detection of multiple target nucleic acids using Clamping Probes and Detection Probes
ACGCCAGCAGCTC
>LV572217.1 WO 2017026496-A/232: Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule
GGTCTTTTCAATG
>LV571655.1 WO 2017018408-A/8: Oxidant and use thereof
GATAGTGTGGAAG
>LV542747.1 JP 2017036258-A/8: ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS
GGCCTCTGCGGCC
>LV542746.1 JP 2017036258-A/7: ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS
GGCCCAGCCGGCC
>LV506953.1 JP 2017000158-A/93: TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, TYPE I, ALPHA SUBUNIT (SCN1A) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCN1A
GCCAGTCACAAAT
>LV500671.1 JP 2017000006-A/16: Method for aiding determination of efficacy of Methotrexate in rheumatoid arthritis patients
CGCGGCGTAACGA
>LV500670.1 JP 2017000006-A/15: Method for aiding determination of efficacy of Methotrexate in rheumatoid arthritis patients
CGCGGCATAACGA
>LV540061.1 JP 2016537423-A/1: METHODS AND MATERIALS FOR TREATING HEMATOLOGICAL MALIGNANCIES
TAGGGTTAGACAA
>LV539739.1 JP 2016538865-A/123: Novel genome alteration system for microorganisms
CNGTRTCNGCRTA
>LV539720.1 JP 2016538865-A/104: Novel genome alteration system for microorganisms
TTTTAGTAGTTGG
>LV539716.1 JP 2016538865-A/100: Novel genome alteration system for microorganisms
TCTTAGTAATGCC
>LV539711.1 JP 2016538865-A/95: Novel genome alteration system for microorganisms
GCCCTAATCTACG
>LV539703.1 JP 2016538865-A/87: Novel genome alteration system for microorganisms
TATACTTCAGGGT
>LV539693.1 JP 2016538865-A/77: Novel genome alteration system for microorganisms
CCCTAGCGTAACT
>LV539692.1 JP 2016538865-A/76: Novel genome alteration system for microorganisms
CAGGGTAATATAG
>LV539689.1 JP 2016538865-A/73: Novel genome alteration system for microorganisms
GTAATAACTAGTG
>LV539684.1 JP 2016538865-A/68: Novel genome alteration system for microorganisms
TAGCTGTTTGCCA
>LV539683.1 JP 2016538865-A/67: Novel genome alteration system for microorganisms
GGGTATTATGGGT
>LV539675.1 JP 2016538865-A/59: Novel genome alteration system for microorganisms
CCCGTACACACCC
>LV539658.1 JP 2016538865-A/42: Novel genome alteration system for microorganisms
CCATATCATTTTT
>LV539649.1 JP 2016538865-A/33: Novel genome alteration system for microorganisms
CAAAACGTCGTAA
>LV539630.1 JP 2016538865-A/14: Novel genome alteration system for microorganisms
GTGCCAAACCTTC
>LV539629.1 JP 2016538865-A/13: Novel genome alteration system for microorganisms
ATGTCGGCTCATC
>LV539620.1 JP 2016538865-A/4: Novel genome alteration system for microorganisms
TTGAGGAGGTTTC
>LV538981.1 JP 2016537005-A/30: DETECTION OF NUCLEIC ACIDS
ACCGCAGGAAACG
>LV532201.1 JP 2016539627-A/18: DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING
TTTCTCTCCACAG
>LV514221.1 WO 2017010500-A/664: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCGGATGCATCAG
>LV514220.1 WO 2017010500-A/663: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGGATGCATCAGT
>LV514219.1 WO 2017010500-A/662: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGATGCATCAGTT
>LV514218.1 WO 2017010500-A/661: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GATGCATCAGTTT
>LV514217.1 WO 2017010500-A/660: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCAGAGAACTG
>LV514216.1 WO 2017010500-A/659: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCAGAGAACTGT
>LV514215.1 WO 2017010500-A/658: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAACTGTGTTCC
>LV514214.1 WO 2017010500-A/657: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAACTGTGTTCCT
>LV514213.1 WO 2017010500-A/656: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGTGTTCCTTG
>LV514212.1 WO 2017010500-A/655: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGTGTTCCTTGA
>LV514211.1 WO 2017010500-A/654: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGTTCCTTGAA
>LV514210.1 WO 2017010500-A/653: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTCCTTGAAGC
>LV514209.1 WO 2017010500-A/652: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTCCTTGAAGCA
>LV514208.1 WO 2017010500-A/651: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCATTCCATTCT
>LV514207.1 WO 2017010500-A/650: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCTCTCCTTG
>LV514206.1 WO 2017010500-A/649: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCTCTCCTTGG
>LV514205.1 WO 2017010500-A/648: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCTCCTTGGT
>LV514204.1 WO 2017010500-A/647: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCCTTGGTAC
>LV514203.1 WO 2017010500-A/646: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCCTTGGTACAC
>LV514202.1 WO 2017010500-A/645: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTGGTACACC
>LV514201.1 WO 2017010500-A/644: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTGGTACACCA
>LV514200.1 WO 2017010500-A/643: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTACACCACAGT
>LV514199.1 WO 2017010500-A/642: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACACCACAGTGGC
>LV514198.1 WO 2017010500-A/641: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTTGGCATGGC
>LV514197.1 WO 2017010500-A/640: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTTGGCATGGCA
>LV514196.1 WO 2017010500-A/639: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTGGCATGGCAG
>LV514195.1 WO 2017010500-A/638: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCATGGCAGAC
>LV514194.1 WO 2017010500-A/637: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCATGGCAGACC
>LV514193.1 WO 2017010500-A/636: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATGGCAGACCA
>LV514192.1 WO 2017010500-A/635: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATGGCAGACCAG
>LV514191.1 WO 2017010500-A/634: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCAGACCAGTT
>LV514190.1 WO 2017010500-A/633: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCAGACCAGTTT
>LV514189.1 WO 2017010500-A/632: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGACCAGTTTCCC
>LV514188.1 WO 2017010500-A/631: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GACCAGTTTCCCA
>LV514187.1 WO 2017010500-A/630: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCAGTTTGGTAC
>LV514186.1 WO 2017010500-A/629: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TATCCATCATGGC
>LV514185.1 WO 2017010500-A/628: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATCATGGCAGC
>LV514184.1 WO 2017010500-A/627: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAATGTGGCTT
>LV514183.1 WO 2017010500-A/626: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AATGTGGCTTTAT
>LV514182.1 WO 2017010500-A/625: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGTGGCTTTATC
>LV514181.1 WO 2017010500-A/624: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCATTGTCTGG
>LV514180.1 WO 2017010500-A/623: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCATTGTCTGGT
>LV514179.1 WO 2017010500-A/622: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATTGTCTGGTC
>LV514178.1 WO 2017010500-A/621: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATTGTCTGGTCT
>LV514177.1 WO 2017010500-A/620: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGCATGTTGTGGC
>LV514176.1 WO 2017010500-A/619: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATGTTGTGGCA
>LV514175.1 WO 2017010500-A/618: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGTTTCCAGCTG
>LV514174.1 WO 2017010500-A/617: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTTCCAGCTGA
>LV514173.1 WO 2017010500-A/616: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCAGCTGATGGC
>LV514172.1 WO 2017010500-A/615: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGCTGATGGCT
>LV514171.1 WO 2017010500-A/614: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGCTGATGGCTT
>LV514170.1 WO 2017010500-A/613: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCTGATGGCTTA
>LV514169.1 WO 2017010500-A/612: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTCCTCAGTGC
>LV514168.1 WO 2017010500-A/611: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTCAGTGCACT
>LV514167.1 WO 2017010500-A/610: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTCAGTGCACTT
>LV514166.1 WO 2017010500-A/609: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGCACTTGGCAG
>LV514165.1 WO 2017010500-A/608: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGGATATTCAA
>LV514164.1 WO 2017010500-A/607: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGGATATTCAAA
>LV514163.1 WO 2017010500-A/606: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGGATATTCAAAA
>LV514162.1 WO 2017010500-A/605: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAAGGACATACTC
>LV514161.1 WO 2017010500-A/604: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGGACATACTCT
>LV514160.1 WO 2017010500-A/603: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACATACTCTGG
>LV514159.1 WO 2017010500-A/602: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGTTGATGGGCC
>LV514158.1 WO 2017010500-A/601: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAGCCCGGCTTG
>LV514157.1 WO 2017010500-A/600: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCCCGGCTTGC
>LV514156.1 WO 2017010500-A/599: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCCGGCTTGCA
>LV514155.1 WO 2017010500-A/598: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCCTGGCTCAT
>LV514154.1 WO 2017010500-A/597: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCATCTGGCTTGG
>LV514153.1 WO 2017010500-A/596: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGGCTTGGGACA
>LV514152.1 WO 2017010500-A/595: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTCCGTCCTGCA
>LV514151.1 WO 2017010500-A/594: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCGTCCTGCAA
>LV514150.1 WO 2017010500-A/593: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCGTCCTGCAAT
>LV514149.1 WO 2017010500-A/592: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCTGCAATAGC
>LV514148.1 WO 2017010500-A/591: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTGCAATAGCA
>LV514147.1 WO 2017010500-A/590: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTGCAATAGCAA
>LV514146.1 WO 2017010500-A/589: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAATAGCAACAT
>LV514145.1 WO 2017010500-A/588: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAATAGCAACATG
>LV514144.1 WO 2017010500-A/587: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAGCAACATGGC
>LV514143.1 WO 2017010500-A/586: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCAACATGGCA
>LV514142.1 WO 2017010500-A/585: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTAGGTTCCTTGG
>LV514141.1 WO 2017010500-A/584: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGGTTCCTTGGA
>LV514140.1 WO 2017010500-A/583: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGTTCCTTGGAT
>LV514139.1 WO 2017010500-A/582: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTTCCTTGGATG
>LV514138.1 WO 2017010500-A/581: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTCCTTGGATGA
>LV514137.1 WO 2017010500-A/580: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTGGATGAAC
>LV514136.1 WO 2017010500-A/579: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTGGATGAACA
>LV514135.1 WO 2017010500-A/578: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGTGTGACATTT
>LV514134.1 WO 2017010500-A/577: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTGTGACATTTT
>LV514133.1 WO 2017010500-A/576: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGGAATCTGAA
>LV514132.1 WO 2017010500-A/575: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCTTTACATCG
>LV514131.1 WO 2017010500-A/574: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTTACATCGG
>LV514130.1 WO 2017010500-A/573: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTTTACATCGGA
>LV514129.1 WO 2017010500-A/572: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTACATCGGATGC
>LV514128.1 WO 2017010500-A/571: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TACATCGGATGCA
>LV514127.1 WO 2017010500-A/570: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACATCGGATGCAT
>LV514126.1 WO 2017010500-A/569: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCGGATGCATC
>LV514125.1 WO 2017010500-A/568: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCGGATGCATCA
>LV514124.1 WO 2017010500-A/567: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCGGATGCATCAG
>LV514123.1 WO 2017010500-A/566: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGGATGCATCAGT
>LV514122.1 WO 2017010500-A/565: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGATGCATCAGTT
>LV514121.1 WO 2017010500-A/564: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GATGCATCAGTTT
>LV514120.1 WO 2017010500-A/563: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCATCAGTTTTC
>LV514484.1 WO 2017010568-A/57: RNA-Protein Complex and use thereof
GGTCCCGACTCGC
>LV514222.1 WO 2017010500-A/665: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCGGATGCATCA
>LV513844.1 WO 2017010500-A/287: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGAAATTGGACT
>LV513843.1 WO 2017010500-A/286: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCGATGTTTGGAA
>LV513842.1 WO 2017010500-A/285: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAACATGCGATGT
>LV513841.1 WO 2017010500-A/284: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CACAACATGCGAT
>LV513840.1 WO 2017010500-A/283: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCACAACATGCGA
>LV513839.1 WO 2017010500-A/282: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCACAACATGCG
>LV513838.1 WO 2017010500-A/281: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCCACAACATGC
>LV513837.1 WO 2017010500-A/280: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTTGCCACAACA
>LV513836.1 WO 2017010500-A/279: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTTGCCACAAC
>LV513835.1 WO 2017010500-A/278: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAATGTTTGCCAC
>LV513834.1 WO 2017010500-A/277: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGAATGTTTGCCA
>LV513833.1 WO 2017010500-A/276: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CACAGCAGTTTTT
>LV513832.1 WO 2017010500-A/275: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACACAGCAGTT
>LV513831.1 WO 2017010500-A/274: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGCTGGAAACAA
>LV513830.1 WO 2017010500-A/273: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCAGCTGGAAACA
>LV513829.1 WO 2017010500-A/272: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCAGCTGGAAAC
>LV513828.1 WO 2017010500-A/271: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATCAGCTGGAA
>LV513827.1 WO 2017010500-A/270: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCATCAGCTGGA
>LV513826.1 WO 2017010500-A/269: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCATCAGCTGG
>LV513825.1 WO 2017010500-A/268: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGCCATCAGCTG
>LV513824.1 WO 2017010500-A/267: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAAGCCATCAGCT
>LV513823.1 WO 2017010500-A/266: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAAGCCATCAGC
>LV513822.1 WO 2017010500-A/265: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CACTGAGGAAGGA
>LV513821.1 WO 2017010500-A/264: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCACTGAGGAAGG
>LV513820.1 WO 2017010500-A/263: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCACTGAGGAAG
>LV513819.1 WO 2017010500-A/262: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGCACTGAGGAA
>LV513818.1 WO 2017010500-A/261: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTGCACTGAGGA
>LV513817.1 WO 2017010500-A/260: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGTGCACTGAGG
>LV513816.1 WO 2017010500-A/259: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGTGCACTGAG
>LV513815.1 WO 2017010500-A/258: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCAAGTGCACTG
>LV513814.1 WO 2017010500-A/257: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCCAAGTGCACT
>LV513813.1 WO 2017010500-A/256: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGCCAAGTGCAC
>LV513812.1 WO 2017010500-A/255: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTGCCAAGTGCA
>LV513811.1 WO 2017010500-A/254: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCTGCCAAGTGC
>LV513810.1 WO 2017010500-A/253: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGAATATCCCAAC
>LV513809.1 WO 2017010500-A/252: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGAATATCCCAA
>LV513808.1 WO 2017010500-A/251: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTTGAATATCCCA
>LV513807.1 WO 2017010500-A/250: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTTTGAATATCCC
>LV513806.1 WO 2017010500-A/249: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGAAAATGGAGC
>LV513805.1 WO 2017010500-A/248: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAGTATGTCCTTT
>LV513804.1 WO 2017010500-A/247: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAGTATGTCCTT
>LV513803.1 WO 2017010500-A/246: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGAGTATGTCCT
>LV513802.1 WO 2017010500-A/245: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGAGTATGTCC
>LV513801.1 WO 2017010500-A/244: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCCCATCAACAC
>LV513800.1 WO 2017010500-A/243: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCCCATCAACA
>LV513799.1 WO 2017010500-A/242: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGGCCCATCAAC
>LV513798.1 WO 2017010500-A/241: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGGCCCATCAA
>LV513797.1 WO 2017010500-A/240: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGCCCTCTCACA
>LV513796.1 WO 2017010500-A/239: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGGGCTATGTGTC
>LV513795.1 WO 2017010500-A/238: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCGGGCTATGTGT
>LV513794.1 WO 2017010500-A/237: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGCCGGGCTATG
>LV513793.1 WO 2017010500-A/236: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGCCGGGCTAT
>LV513792.1 WO 2017010500-A/235: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAAGCCGGGCTA
>LV513791.1 WO 2017010500-A/234: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCAAGCCGGGCT
>LV513790.1 WO 2017010500-A/233: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGCAAGCCGGGC
>LV513789.1 WO 2017010500-A/232: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTGCAAGCCGGG
>LV513788.1 WO 2017010500-A/231: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTGCAAGCCGG
>LV513787.1 WO 2017010500-A/230: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGAGCCAGGAGA
>LV513786.1 WO 2017010500-A/229: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TATGAGCCAGGAG
>LV513785.1 WO 2017010500-A/228: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTATGAGCCAGGA
>LV513784.1 WO 2017010500-A/227: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCAGATGATTT
>LV513783.1 WO 2017010500-A/226: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGCCAGATGATT
>LV513782.1 WO 2017010500-A/225: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGCCAGATGAT
>LV513781.1 WO 2017010500-A/224: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAGCCAGATGA
>LV513780.1 WO 2017010500-A/223: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCAAGCCAGATG
>LV513779.1 WO 2017010500-A/222: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCCAAGCCAGA
>LV513778.1 WO 2017010500-A/221: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTCCCAAGCCAG
>LV513777.1 WO 2017010500-A/220: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGTCCCAAGCCA
>LV513776.1 WO 2017010500-A/219: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTGTCCCAAGCC
>LV513775.1 WO 2017010500-A/218: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACCTGTCCCAA
>LV513774.1 WO 2017010500-A/217: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGGACCTGTCCCA
>LV513773.1 WO 2017010500-A/216: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGGACGGACCTG
>LV513772.1 WO 2017010500-A/215: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAGGACGGACCT
>LV513771.1 WO 2017010500-A/214: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCAGGACGGACC
>LV513770.1 WO 2017010500-A/213: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGCAGGACGGAC
>LV513769.1 WO 2017010500-A/212: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATTGCAGGACGGA
>LV513768.1 WO 2017010500-A/211: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTATTGCAGGAC
>LV513767.1 WO 2017010500-A/210: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCTATTGCAGGA
>LV513766.1 WO 2017010500-A/209: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGCTATTGCAGG
>LV513765.1 WO 2017010500-A/208: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGTTGCTATTGC
>LV513764.1 WO 2017010500-A/207: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATGTTGCTATTG
>LV513763.1 WO 2017010500-A/206: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCATGTTGCTAT
>LV513762.1 WO 2017010500-A/205: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCCATGTTGCTA
>LV513761.1 WO 2017010500-A/204: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGCCATGTTGCT
>LV513760.1 WO 2017010500-A/203: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGTGCTCATCT
>LV513759.1 WO 2017010500-A/202: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCCAGTGCTCA
>LV513758.1 WO 2017010500-A/201: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCTCCAGTGCTC
>LV513757.1 WO 2017010500-A/200: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTAGGTTCCTTGG
>LV513756.1 WO 2017010500-A/199: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGGTTCCTTGGA
>LV513755.1 WO 2017010500-A/198: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGTTCCTTGGAT
>LV513754.1 WO 2017010500-A/197: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTTCCTTGGATG
>LV513753.1 WO 2017010500-A/196: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTCCTTGGATGA
>LV513752.1 WO 2017010500-A/195: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTGGATGAAC
>LV513751.1 WO 2017010500-A/194: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTGGATGAACA
>LV513750.1 WO 2017010500-A/193: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGTGTGACATTT
>LV513749.1 WO 2017010500-A/192: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTGTGACATTTT
>LV513748.1 WO 2017010500-A/191: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGGAATCTGAA
>LV513747.1 WO 2017010500-A/190: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCTTTACATCG
>LV513746.1 WO 2017010500-A/189: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTTACATCGG
>LV513745.1 WO 2017010500-A/188: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTTTACATCGGA
>LV513744.1 WO 2017010500-A/187: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTACATCGGATGC
>LV513743.1 WO 2017010500-A/186: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TACATCGGATGCA
>LV513742.1 WO 2017010500-A/185: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACATCGGATGCAT
>LV513741.1 WO 2017010500-A/184: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCGGATGCATC
>LV513740.1 WO 2017010500-A/183: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCGGATGCATCA
>LV513739.1 WO 2017010500-A/182: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCGGATGCATCAG
>LV513738.1 WO 2017010500-A/181: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGGATGCATCAGT
>LV513737.1 WO 2017010500-A/180: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGATGCATCAGTT
>LV513736.1 WO 2017010500-A/179: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GATGCATCAGTTT
>LV513735.1 WO 2017010500-A/178: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCATCAGTTTTC
>LV513734.1 WO 2017010500-A/177: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATCAGTTTTCC
>LV513733.1 WO 2017010500-A/176: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGCCAGAGAACT
>LV513732.1 WO 2017010500-A/175: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCAGAGAACTG
>LV513731.1 WO 2017010500-A/174: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCAGAGAACTGT
>LV513730.1 WO 2017010500-A/173: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGAGAACTGTG
>LV513729.1 WO 2017010500-A/172: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGAGAACTGTGT
>LV513728.1 WO 2017010500-A/171: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAGAACTGTGTT
>LV513727.1 WO 2017010500-A/170: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAGAACTGTGTTC
>LV513726.1 WO 2017010500-A/169: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAACTGTGTTCC
>LV513725.1 WO 2017010500-A/168: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAACTGTGTTCCT
>LV513724.1 WO 2017010500-A/167: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGTGTTCCTT
>LV513723.1 WO 2017010500-A/166: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGTGTTCCTTG
>LV513722.1 WO 2017010500-A/165: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGTGTTCCTTGA
>LV513721.1 WO 2017010500-A/164: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGTTCCTTGAA
>LV513720.1 WO 2017010500-A/163: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGTTCCTTGAAG
>LV513719.1 WO 2017010500-A/162: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTCCTTGAAGC
>LV513718.1 WO 2017010500-A/161: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTCCTTGAAGCA
>LV513717.1 WO 2017010500-A/160: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGAAGCATTTGG
>LV513716.1 WO 2017010500-A/159: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCTACACTTCT
>LV513715.1 WO 2017010500-A/158: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCTACACTTCTT
>LV513714.1 WO 2017010500-A/157: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCATTCCATTCT
>LV513713.1 WO 2017010500-A/156: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATTCCATTCTT
>LV513712.1 WO 2017010500-A/155: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTACTCTCTCTCC
>LV513711.1 WO 2017010500-A/154: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TACTCTCTCTCCT
>LV513710.1 WO 2017010500-A/153: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTCTCTCTCCTT
>LV513709.1 WO 2017010500-A/152: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCTCTCCTTG
>LV513708.1 WO 2017010500-A/151: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCTCTCCTTGG
>LV513707.1 WO 2017010500-A/150: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCTCCTTGGT
>LV513706.1 WO 2017010500-A/149: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCTCCTTGGTA
>LV513705.1 WO 2017010500-A/148: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCCTTGGTAC
>LV513704.1 WO 2017010500-A/147: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCCTTGGTACA
>LV513703.1 WO 2017010500-A/146: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCCTTGGTACAC
>LV513702.1 WO 2017010500-A/145: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTGGTACACC
>LV513701.1 WO 2017010500-A/144: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTGGTACACCA
>LV513700.1 WO 2017010500-A/143: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTGGTACACCAC
>LV513699.1 WO 2017010500-A/142: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGTACACCACA
>LV513698.1 WO 2017010500-A/141: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGTACACCACAG
>LV513697.1 WO 2017010500-A/140: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTACACCACAGT
>LV513696.1 WO 2017010500-A/139: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTACACCACAGTG
>LV513695.1 WO 2017010500-A/138: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACACCACAGTGGC
>LV513694.1 WO 2017010500-A/137: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCACAGGTACTTT
>LV513693.1 WO 2017010500-A/136: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTTTACAACTTG
>LV513692.1 WO 2017010500-A/135: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACAACTTGGCATG
>LV513691.1 WO 2017010500-A/134: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAACTTGGCATGG
>LV513690.1 WO 2017010500-A/133: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTTGGCATGGC
>LV513689.1 WO 2017010500-A/132: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTTGGCATGGCA
>LV513688.1 WO 2017010500-A/131: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTGGCATGGCAG
>LV513687.1 WO 2017010500-A/130: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGCATGGCAGA
>LV513686.1 WO 2017010500-A/129: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCATGGCAGAC
>LV513685.1 WO 2017010500-A/128: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCATGGCAGACC
>LV513684.1 WO 2017010500-A/127: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATGGCAGACCA
>LV513683.1 WO 2017010500-A/126: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATGGCAGACCAG
>LV513682.1 WO 2017010500-A/125: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGGCAGACCAGT
>LV513681.1 WO 2017010500-A/124: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCAGACCAGTT
>LV513680.1 WO 2017010500-A/123: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCAGACCAGTTT
>LV513679.1 WO 2017010500-A/122: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAGACCAGTTTC
>LV513678.1 WO 2017010500-A/121: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGACCAGTTTCCC
>LV513677.1 WO 2017010500-A/120: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GACCAGTTTCCCA
>LV513676.1 WO 2017010500-A/119: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACCAGTTTCCCAG
>LV513675.1 WO 2017010500-A/118: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGTTTCCCAGT
>LV513674.1 WO 2017010500-A/117: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGTTTCCCAGTT
>LV513673.1 WO 2017010500-A/116: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTTCCCAGTTTG
>LV513672.1 WO 2017010500-A/115: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTTCCCAGTTTGG
>LV513671.1 WO 2017010500-A/114: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCCAGTTTGGT
>LV513670.1 WO 2017010500-A/113: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCCAGTTTGGTA
>LV513669.1 WO 2017010500-A/112: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCAGTTTGGTAC
>LV513668.1 WO 2017010500-A/111: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATATCCATCATGG
>LV513667.1 WO 2017010500-A/110: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TATCCATCATGGC
>LV513666.1 WO 2017010500-A/109: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCATCATGGCA
>LV513665.1 WO 2017010500-A/108: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCATCATGGCAG
>LV513664.1 WO 2017010500-A/107: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATCATGGCAGC
>LV513663.1 WO 2017010500-A/106: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCATGGCAGCC
>LV513662.1 WO 2017010500-A/105: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAATGTGGCTT
>LV513661.1 WO 2017010500-A/104: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AATGTGGCTTTAT
>LV513660.1 WO 2017010500-A/103: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGTGGCTTTATC
>LV513659.1 WO 2017010500-A/102: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGGCTTTATCCT
>LV513658.1 WO 2017010500-A/101: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTTATCCTTG
>LV513657.1 WO 2017010500-A/100: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGTTTTGCAGGA
>LV513656.1 WO 2017010500-A/99: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTTTTGCAGGAT
>LV513655.1 WO 2017010500-A/98: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAGGATAGTTCA
>LV513654.1 WO 2017010500-A/97: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AATCCATTGTCTG
>LV513653.1 WO 2017010500-A/96: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCATTGTCTGG
>LV513652.1 WO 2017010500-A/95: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCATTGTCTGGT
>LV513651.1 WO 2017010500-A/94: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATTGTCTGGTC
>LV513650.1 WO 2017010500-A/93: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATTGTCTGGTCT
>LV513649.1 WO 2017010500-A/92: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATTGTCTGGTCTT
>LV513648.1 WO 2017010500-A/91: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCCTGCATTCT
>LV513647.1 WO 2017010500-A/90: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCCTGCATTCTG
>LV513646.1 WO 2017010500-A/89: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCTGCATTCTGG
>LV513645.1 WO 2017010500-A/88: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTCCAATTTCCA
>LV513644.1 WO 2017010500-A/87: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCAAACATCGC
>LV513643.1 WO 2017010500-A/86: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACATCGCATGTTG
>LV513642.1 WO 2017010500-A/85: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCGCATGTTGTG
>LV513641.1 WO 2017010500-A/84: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCGCATGTTGTGG
>LV513640.1 WO 2017010500-A/83: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGCATGTTGTGGC
>LV513639.1 WO 2017010500-A/82: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATGTTGTGGCA
>LV513638.1 WO 2017010500-A/81: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTGTGGCAAAC
>LV513637.1 WO 2017010500-A/80: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTGTGGCAAACA
>LV513636.1 WO 2017010500-A/79: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGGCAAACATTC
>LV513635.1 WO 2017010500-A/78: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCAAACATTCA
>LV513634.1 WO 2017010500-A/77: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAAAACTGCTGTG
>LV513633.1 WO 2017010500-A/76: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGCTGTGTCC
>LV513632.1 WO 2017010500-A/75: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGTTTCCAGCTG
>LV513631.1 WO 2017010500-A/74: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTTCCAGCTGA
>LV513630.1 WO 2017010500-A/73: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTTCCAGCTGAT
>LV513629.1 WO 2017010500-A/72: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCAGCTGATGG
>LV513628.1 WO 2017010500-A/71: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCAGCTGATGGC
>LV513627.1 WO 2017010500-A/70: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGCTGATGGCT
>LV513626.1 WO 2017010500-A/69: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGCTGATGGCTT
>LV513625.1 WO 2017010500-A/68: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCTGATGGCTTA
>LV513624.1 WO 2017010500-A/67: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTGATGGCTTAT
>LV513623.1 WO 2017010500-A/66: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTCCTCAGTG
>LV513622.1 WO 2017010500-A/65: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTCCTCAGTGC
>LV513621.1 WO 2017010500-A/64: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTCCTCAGTGCA
>LV513620.1 WO 2017010500-A/63: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCTCAGTGCAC
>LV513619.1 WO 2017010500-A/62: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTCAGTGCACT
>LV513618.1 WO 2017010500-A/61: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTCAGTGCACTT
>LV513617.1 WO 2017010500-A/60: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCAGTGCACTTG
>LV513616.1 WO 2017010500-A/59: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGTGCACTTGGC
>LV513615.1 WO 2017010500-A/58: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTGCACTTGGCA
>LV513614.1 WO 2017010500-A/57: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGCACTTGGCAG
>LV513613.1 WO 2017010500-A/56: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCACTTGGCAGA
>LV513612.1 WO 2017010500-A/55: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCACTTGGCAGAA
>LV513611.1 WO 2017010500-A/54: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTGGGATATTCA
>LV513610.1 WO 2017010500-A/53: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGGATATTCAA
>LV513609.1 WO 2017010500-A/52: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGGATATTCAAA
>LV513608.1 WO 2017010500-A/51: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGGATATTCAAAA
>LV513607.1 WO 2017010500-A/50: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTCCATTTTCTA
>LV513606.1 WO 2017010500-A/49: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAAGGACATACTC
>LV513605.1 WO 2017010500-A/48: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGGACATACTCT
>LV513604.1 WO 2017010500-A/47: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGACATACTCTG
>LV513603.1 WO 2017010500-A/46: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACATACTCTGG
>LV513602.1 WO 2017010500-A/45: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGTTGATGGGCC
>LV513601.1 WO 2017010500-A/44: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTGATGGGCCA
>LV513600.1 WO 2017010500-A/43: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTGATGGGCCAC
>LV513599.1 WO 2017010500-A/42: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGATGGGCCACA
>LV513598.1 WO 2017010500-A/41: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGAGAGGGCAG
>LV513597.1 WO 2017010500-A/40: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GACACATAGCCCG
>LV513596.1 WO 2017010500-A/39: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACACATAGCCCGG
>LV513595.1 WO 2017010500-A/38: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATAGCCCGGCTT
>LV513594.1 WO 2017010500-A/37: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAGCCCGGCTTG
>LV513593.1 WO 2017010500-A/36: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCCCGGCTTGC
>LV513592.1 WO 2017010500-A/35: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCCGGCTTGCA
>LV513591.1 WO 2017010500-A/34: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCCGGCTTGCAG
>LV513590.1 WO 2017010500-A/33: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCGGCTTGCAGG
>LV513589.1 WO 2017010500-A/32: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCGGCTTGCAGGA
>LV513588.1 WO 2017010500-A/31: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCCTGGCTCAT
>LV513587.1 WO 2017010500-A/30: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCCTGGCTCATA
>LV513586.1 WO 2017010500-A/29: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTGGCTCATAG
>LV513585.1 WO 2017010500-A/28: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAATCATCTGGCT
>LV513584.1 WO 2017010500-A/27: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AATCATCTGGCTT
>LV513583.1 WO 2017010500-A/26: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCATCTGGCTTG
>LV513582.1 WO 2017010500-A/25: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCATCTGGCTTGG
>LV513581.1 WO 2017010500-A/24: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCTGGCTTGGG
>LV513580.1 WO 2017010500-A/23: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTGGCTTGGGAC
>LV513579.1 WO 2017010500-A/22: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGGCTTGGGACA
>LV513578.1 WO 2017010500-A/21: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCTTGGGACAG
>LV513577.1 WO 2017010500-A/20: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTGGGACAGG
>LV513576.1 WO 2017010500-A/19: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGGACAGGTCC
>LV513575.1 WO 2017010500-A/18: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGGACAGGTCCG
>LV513574.1 WO 2017010500-A/17: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGGTCCGTCCTG
>LV513573.1 WO 2017010500-A/16: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGTCCGTCCTGC
>LV513572.1 WO 2017010500-A/15: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTCCGTCCTGCA
>LV513571.1 WO 2017010500-A/14: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCGTCCTGCAA
>LV513570.1 WO 2017010500-A/13: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCGTCCTGCAAT
>LV513569.1 WO 2017010500-A/12: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCTGCAATAGC
>LV513568.1 WO 2017010500-A/11: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTGCAATAGCA
>LV513567.1 WO 2017010500-A/10: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTGCAATAGCAA
>LV513566.1 WO 2017010500-A/9: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAATAGCAACAT
>LV513565.1 WO 2017010500-A/8: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAATAGCAACATG
>LV513564.1 WO 2017010500-A/7: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAGCAACATGGC
>LV513563.1 WO 2017010500-A/6: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCAACATGGCA
>LV513562.1 WO 2017010500-A/5: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCAACATGGCAG
>LV513561.1 WO 2017010500-A/4: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGATGAGCACTGG
>LV513560.1 WO 2017010500-A/3: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGAGCACTGGAGA
>LV513559.1 WO 2017010500-A/2: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAGCACTGGAGAA
>LV514231.1 WO 2017010500-A/674: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACATACTCTGG
>LV514230.1 WO 2017010500-A/673: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACATACTCTGG
>LV514229.1 WO 2017010500-A/672: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTAGGTTCCTTGG
>LV514228.1 WO 2017010500-A/671: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGGTTCCTTGGA
>LV514227.1 WO 2017010500-A/670: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGTTCCTTGGAT
>LV514226.1 WO 2017010500-A/669: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTTCCTTGGATG
>LV514225.1 WO 2017010500-A/668: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGTGTGACATTT
>LV514224.1 WO 2017010500-A/667: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTGTGACATTTT
>LV514223.1 WO 2017010500-A/666: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTTACATCGG
>LV514119.1 WO 2017010500-A/562: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATCAGTTTTCC
>LV514118.1 WO 2017010500-A/561: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGCCAGAGAACT
>LV514117.1 WO 2017010500-A/560: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCAGAGAACTG
>LV514116.1 WO 2017010500-A/559: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCAGAGAACTGT
>LV514115.1 WO 2017010500-A/558: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGAGAACTGTG
>LV514114.1 WO 2017010500-A/557: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGAGAACTGTGT
>LV514113.1 WO 2017010500-A/556: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAGAACTGTGTT
>LV514112.1 WO 2017010500-A/555: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAGAACTGTGTTC
>LV514111.1 WO 2017010500-A/554: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAACTGTGTTCC
>LV514110.1 WO 2017010500-A/553: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAACTGTGTTCCT
>LV514109.1 WO 2017010500-A/552: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGTGTTCCTT
>LV514108.1 WO 2017010500-A/551: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGTGTTCCTTG
>LV514107.1 WO 2017010500-A/550: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGTGTTCCTTGA
>LV514106.1 WO 2017010500-A/549: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGTTCCTTGAA
>LV514105.1 WO 2017010500-A/548: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGTTCCTTGAAG
>LV514104.1 WO 2017010500-A/547: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTCCTTGAAGC
>LV514103.1 WO 2017010500-A/546: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTCCTTGAAGCA
>LV514102.1 WO 2017010500-A/545: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGAAGCATTTGG
>LV514101.1 WO 2017010500-A/544: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCTACACTTCT
>LV514100.1 WO 2017010500-A/543: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCTACACTTCTT
>LV514099.1 WO 2017010500-A/542: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCATTCCATTCT
>LV514098.1 WO 2017010500-A/541: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATTCCATTCTT
>LV514097.1 WO 2017010500-A/540: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTACTCTCTCTCC
>LV514096.1 WO 2017010500-A/539: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TACTCTCTCTCCT
>LV514095.1 WO 2017010500-A/538: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTCTCTCTCCTT
>LV514094.1 WO 2017010500-A/537: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCTCTCCTTG
>LV514093.1 WO 2017010500-A/536: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCTCTCCTTGG
>LV514092.1 WO 2017010500-A/535: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCTCCTTGGT
>LV514091.1 WO 2017010500-A/534: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCTCCTTGGTA
>LV514090.1 WO 2017010500-A/533: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCTCCTTGGTAC
>LV514089.1 WO 2017010500-A/532: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCCTTGGTACA
>LV514088.1 WO 2017010500-A/531: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCCTTGGTACAC
>LV514087.1 WO 2017010500-A/530: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTGGTACACC
>LV514086.1 WO 2017010500-A/529: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTGGTACACCA
>LV514085.1 WO 2017010500-A/528: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTGGTACACCAC
>LV514084.1 WO 2017010500-A/527: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGTACACCACA
>LV514083.1 WO 2017010500-A/526: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGTACACCACAG
>LV514082.1 WO 2017010500-A/525: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTACACCACAGT
>LV514081.1 WO 2017010500-A/524: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTACACCACAGTG
>LV514080.1 WO 2017010500-A/523: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACACCACAGTGGC
>LV514079.1 WO 2017010500-A/522: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCACAGGTACTTT
>LV514078.1 WO 2017010500-A/521: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTTTACAACTTG
>LV514077.1 WO 2017010500-A/520: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACAACTTGGCATG
>LV514076.1 WO 2017010500-A/519: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAACTTGGCATGG
>LV514075.1 WO 2017010500-A/518: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTTGGCATGGC
>LV514074.1 WO 2017010500-A/517: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTTGGCATGGCA
>LV514073.1 WO 2017010500-A/516: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTGGCATGGCAG
>LV514072.1 WO 2017010500-A/515: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGCATGGCAGA
>LV514071.1 WO 2017010500-A/514: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCATGGCAGAC
>LV514070.1 WO 2017010500-A/513: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCATGGCAGACC
>LV514069.1 WO 2017010500-A/512: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATGGCAGACCA
>LV514068.1 WO 2017010500-A/511: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATGGCAGACCAG
>LV514067.1 WO 2017010500-A/510: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGGCAGACCAGT
>LV514066.1 WO 2017010500-A/509: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCAGACCAGTT
>LV514065.1 WO 2017010500-A/508: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCAGACCAGTTT
>LV514064.1 WO 2017010500-A/507: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAGACCAGTTTC
>LV514063.1 WO 2017010500-A/506: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGACCAGTTTCCC
>LV514062.1 WO 2017010500-A/505: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GACCAGTTTCCCA
>LV514061.1 WO 2017010500-A/504: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACCAGTTTCCCAG
>LV514060.1 WO 2017010500-A/503: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGTTTCCCAGT
>LV514059.1 WO 2017010500-A/502: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGTTTCCCAGTT
>LV514058.1 WO 2017010500-A/501: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTTCCCAGTTTG
>LV514057.1 WO 2017010500-A/500: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTTCCCAGTTTGG
>LV514056.1 WO 2017010500-A/499: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCCAGTTTGGT
>LV514055.1 WO 2017010500-A/498: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCCAGTTTGGTA
>LV514054.1 WO 2017010500-A/497: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCAGTTTGGTAC
>LV514053.1 WO 2017010500-A/496: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATATCCATCATGG
>LV514052.1 WO 2017010500-A/495: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TATCCATCATGGC
>LV514051.1 WO 2017010500-A/494: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCATCATGGCA
>LV514050.1 WO 2017010500-A/493: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCATCATGGCAG
>LV514049.1 WO 2017010500-A/492: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATCATGGCAGC
>LV514048.1 WO 2017010500-A/491: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCATGGCAGCC
>LV514047.1 WO 2017010500-A/490: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGGCTTTATCCT
>LV514046.1 WO 2017010500-A/489: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTTATCCTTG
>LV514045.1 WO 2017010500-A/488: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGTTTTGCAGGA
>LV514044.1 WO 2017010500-A/487: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTTTTGCAGGAT
>LV514043.1 WO 2017010500-A/486: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCAGGATAGTTCA
>LV514042.1 WO 2017010500-A/485: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AATCCATTGTCTG
>LV514041.1 WO 2017010500-A/484: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCATTGTCTGG
>LV514040.1 WO 2017010500-A/483: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCATTGTCTGGT
>LV514039.1 WO 2017010500-A/482: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATTGTCTGGTC
>LV514038.1 WO 2017010500-A/481: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATTGTCTGGTCT
>LV514037.1 WO 2017010500-A/480: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATTGTCTGGTCTT
>LV514036.1 WO 2017010500-A/479: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCCTGCATTCT
>LV514035.1 WO 2017010500-A/478: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCCTGCATTCTG
>LV514034.1 WO 2017010500-A/477: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCTGCATTCTGG
>LV514033.1 WO 2017010500-A/476: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTCCAATTTCCA
>LV514032.1 WO 2017010500-A/475: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCAAACATCGC
>LV514031.1 WO 2017010500-A/474: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACATCGCATGTTG
>LV514030.1 WO 2017010500-A/473: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCGCATGTTGTG
>LV514029.1 WO 2017010500-A/472: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCGCATGTTGTGG
>LV514028.1 WO 2017010500-A/471: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGCATGTTGTGGC
>LV514027.1 WO 2017010500-A/470: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATGTTGTGGCA
>LV514026.1 WO 2017010500-A/469: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTGTGGCAAAC
>LV514025.1 WO 2017010500-A/468: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTGTGGCAAACA
>LV514024.1 WO 2017010500-A/467: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGGCAAACATTC
>LV514023.1 WO 2017010500-A/466: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCAAACATTCA
>LV514022.1 WO 2017010500-A/465: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAAAACTGCTGTG
>LV514021.1 WO 2017010500-A/464: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGCTGTGTCC
>LV514020.1 WO 2017010500-A/463: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGTTTCCAGCTG
>LV514019.1 WO 2017010500-A/462: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTTCCAGCTGA
>LV514018.1 WO 2017010500-A/461: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTTCCAGCTGAT
>LV514017.1 WO 2017010500-A/460: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCAGCTGATGG
>LV514016.1 WO 2017010500-A/459: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCAGCTGATGGC
>LV514015.1 WO 2017010500-A/458: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGCTGATGGCT
>LV514014.1 WO 2017010500-A/457: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGCTGATGGCTT
>LV514013.1 WO 2017010500-A/456: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCTGATGGCTTA
>LV514012.1 WO 2017010500-A/455: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTGATGGCTTAT
>LV514011.1 WO 2017010500-A/454: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTTCCTCAGTG
>LV514010.1 WO 2017010500-A/453: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTTCCTCAGTGC
>LV514009.1 WO 2017010500-A/452: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTCCTCAGTGCA
>LV514008.1 WO 2017010500-A/451: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCCTCAGTGCAC
>LV514007.1 WO 2017010500-A/450: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTCAGTGCACT
>LV514006.1 WO 2017010500-A/449: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCTCAGTGCACTT
>LV514005.1 WO 2017010500-A/448: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCAGTGCACTTG
>LV514004.1 WO 2017010500-A/447: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGTGCACTTGGC
>LV514003.1 WO 2017010500-A/446: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTGCACTTGGCA
>LV514002.1 WO 2017010500-A/445: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGCACTTGGCAG
>LV514001.1 WO 2017010500-A/444: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCACTTGGCAGA
>LV514000.1 WO 2017010500-A/443: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCACTTGGCAGAA
>LV513999.1 WO 2017010500-A/442: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTGGGATATTCA
>LV513998.1 WO 2017010500-A/441: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTCCATTTTCTA
>LV513997.1 WO 2017010500-A/440: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGACATACTCTG
>LV513996.1 WO 2017010500-A/439: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGACATACTCTGG
>LV513995.1 WO 2017010500-A/438: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGTTGATGGGCC
>LV513994.1 WO 2017010500-A/437: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTGATGGGCCA
>LV513993.1 WO 2017010500-A/436: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTGATGGGCCAC
>LV513992.1 WO 2017010500-A/435: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGATGGGCCACA
>LV513991.1 WO 2017010500-A/434: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGAGAGGGCAG
>LV513990.1 WO 2017010500-A/433: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GACACATAGCCCG
>LV513989.1 WO 2017010500-A/432: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACACATAGCCCGG
>LV513988.1 WO 2017010500-A/431: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATAGCCCGGCTT
>LV513987.1 WO 2017010500-A/430: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAGCCCGGCTTG
>LV513986.1 WO 2017010500-A/429: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCCCGGCTTGC
>LV513985.1 WO 2017010500-A/428: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCCCGGCTTGCA
>LV513984.1 WO 2017010500-A/427: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCCGGCTTGCAG
>LV513983.1 WO 2017010500-A/426: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCCGGCTTGCAGG
>LV513982.1 WO 2017010500-A/425: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCGGCTTGCAGGA
>LV513981.1 WO 2017010500-A/424: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTCCTGGCTCAT
>LV513980.1 WO 2017010500-A/423: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTCCTGGCTCATA
>LV513979.1 WO 2017010500-A/422: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTGGCTCATAG
>LV513978.1 WO 2017010500-A/421: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAATCATCTGGCT
>LV513977.1 WO 2017010500-A/420: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AATCATCTGGCTT
>LV513976.1 WO 2017010500-A/419: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCATCTGGCTTG
>LV513975.1 WO 2017010500-A/418: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCATCTGGCTTGG
>LV513974.1 WO 2017010500-A/417: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCTGGCTTGGG
>LV513973.1 WO 2017010500-A/416: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTGGCTTGGGAC
>LV513972.1 WO 2017010500-A/415: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGGCTTGGGACA
>LV513971.1 WO 2017010500-A/414: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGCTTGGGACAG
>LV513970.1 WO 2017010500-A/413: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTTGGGACAGG
>LV513969.1 WO 2017010500-A/412: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTGGGACAGGTCC
>LV513968.1 WO 2017010500-A/411: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGGACAGGTCCG
>LV513967.1 WO 2017010500-A/410: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGGTCCGTCCTG
>LV513966.1 WO 2017010500-A/409: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGTCCGTCCTGC
>LV513965.1 WO 2017010500-A/408: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTCCGTCCTGCA
>LV513964.1 WO 2017010500-A/407: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCGTCCTGCAA
>LV513963.1 WO 2017010500-A/406: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCCTGCAATAGC
>LV513962.1 WO 2017010500-A/405: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAGCAACATGGC
>LV513961.1 WO 2017010500-A/404: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TAGCAACATGGCA
>LV513960.1 WO 2017010500-A/403: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGCAACATGGCAG
>LV513959.1 WO 2017010500-A/402: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGATGAGCACTGG
>LV513958.1 WO 2017010500-A/401: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGAGCACTGGAGA
>LV513957.1 WO 2017010500-A/400: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAGCACTGGAGAA
>LV513956.1 WO 2017010500-A/399: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAGGAACCTAA
>LV513955.1 WO 2017010500-A/398: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCAAGGAACCTA
>LV513954.1 WO 2017010500-A/397: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCAAGGAACCT
>LV513953.1 WO 2017010500-A/396: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATCCAAGGAACC
>LV513952.1 WO 2017010500-A/395: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCATCCAAGGAAC
>LV513951.1 WO 2017010500-A/394: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTTCATCCAAGGA
>LV513950.1 WO 2017010500-A/393: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTTCATCCAAGG
>LV513949.1 WO 2017010500-A/392: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAATGTCACACTT
>LV513948.1 WO 2017010500-A/391: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAAATGTCACACT
>LV513947.1 WO 2017010500-A/390: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCAGATTCCACA
>LV513946.1 WO 2017010500-A/389: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CGATGTAAAGCCA
>LV513945.1 WO 2017010500-A/388: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCGATGTAAAGCC
>LV513944.1 WO 2017010500-A/387: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCGATGTAAAGC
>LV513943.1 WO 2017010500-A/386: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCATCCGATGTAA
>LV513942.1 WO 2017010500-A/385: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCATCCGATGTA
>LV513941.1 WO 2017010500-A/384: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATGCATCCGATGT
>LV513940.1 WO 2017010500-A/383: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GATGCATCCGATG
>LV513939.1 WO 2017010500-A/382: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGATGCATCCGAT
>LV513938.1 WO 2017010500-A/381: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGATGCATCCGA
>LV513937.1 WO 2017010500-A/380: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGATGCATCCG
>LV513936.1 WO 2017010500-A/379: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGATGCATCC
>LV513935.1 WO 2017010500-A/378: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAACTGATGCATC
>LV513934.1 WO 2017010500-A/377: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAAAACTGATGCA
>LV513933.1 WO 2017010500-A/376: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGAAAACTGATGC
>LV513932.1 WO 2017010500-A/375: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGTTCTCTGGCTT
>LV513931.1 WO 2017010500-A/374: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGTTCTCTGGCT
>LV513930.1 WO 2017010500-A/373: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACAGTTCTCTGGC
>LV513929.1 WO 2017010500-A/372: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CACAGTTCTCTGG
>LV513928.1 WO 2017010500-A/371: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACACAGTTCTCTG
>LV513927.1 WO 2017010500-A/370: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACACAGTTCTCT
>LV513926.1 WO 2017010500-A/369: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAACACAGTTCTC
>LV513925.1 WO 2017010500-A/368: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGAACACAGTTCT
>LV513924.1 WO 2017010500-A/367: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGAACACAGTTC
>LV513923.1 WO 2017010500-A/366: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGGAACACAGTT
>LV513922.1 WO 2017010500-A/365: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGGAACACAGT
>LV513921.1 WO 2017010500-A/364: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCAAGGAACACAG
>LV513920.1 WO 2017010500-A/363: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TTCAAGGAACACA
>LV513919.1 WO 2017010500-A/362: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTTCAAGGAACAC
>LV513918.1 WO 2017010500-A/361: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTTCAAGGAACA
>LV513917.1 WO 2017010500-A/360: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCTTCAAGGAAC
>LV513916.1 WO 2017010500-A/359: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAATGCTTCAA
>LV513915.1 WO 2017010500-A/358: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAAGTGTAGCTA
>LV513914.1 WO 2017010500-A/357: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGAAGTGTAGCT
>LV513913.1 WO 2017010500-A/356: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAATGGAATGCT
>LV513912.1 WO 2017010500-A/355: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGAATGGAATGC
>LV513911.1 WO 2017010500-A/354: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGAGAGAGAGTAA
>LV513910.1 WO 2017010500-A/353: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGAGAGAGAGTA
>LV513909.1 WO 2017010500-A/352: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGGAGAGAGAGT
>LV513908.1 WO 2017010500-A/351: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGGAGAGAGAG
>LV513907.1 WO 2017010500-A/350: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAGGAGAGAGA
>LV513906.1 WO 2017010500-A/349: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACCAAGGAGAGAG
>LV513905.1 WO 2017010500-A/348: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TACCAAGGAGAGA
>LV513904.1 WO 2017010500-A/347: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTACCAAGGAGAG
>LV513903.1 WO 2017010500-A/346: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTACCAAGGAGA
>LV513902.1 WO 2017010500-A/345: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGTACCAAGGAG
>LV513901.1 WO 2017010500-A/344: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTGTACCAAGGA
>LV513900.1 WO 2017010500-A/343: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGTGTACCAAGG
>LV513899.1 WO 2017010500-A/342: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTGGTGTACCAAG
>LV513898.1 WO 2017010500-A/341: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGTGGTGTACCAA
>LV513897.1 WO 2017010500-A/340: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGTGGTGTACCA
>LV513896.1 WO 2017010500-A/339: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGTGGTGTACC
>LV513895.1 WO 2017010500-A/338: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CACTGTGGTGTAC
>LV513894.1 WO 2017010500-A/337: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCACTGTGGTGT
>LV513893.1 WO 2017010500-A/336: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAAGTACCTGTGA
>LV513892.1 WO 2017010500-A/335: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGTTGTAAAGC
>LV513891.1 WO 2017010500-A/334: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CATGCCAAGTTGT
>LV513890.1 WO 2017010500-A/333: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATGCCAAGTTG
>LV513889.1 WO 2017010500-A/332: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCATGCCAAGTT
>LV513888.1 WO 2017010500-A/331: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCCATGCCAAGT
>LV513887.1 WO 2017010500-A/330: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGCCATGCCAAG
>LV513886.1 WO 2017010500-A/329: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCTGCCATGCCAA
>LV513885.1 WO 2017010500-A/328: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTCTGCCATGCCA
>LV513884.1 WO 2017010500-A/327: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGTCTGCCATGCC
>LV513883.1 WO 2017010500-A/326: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGTCTGCCATGC
>LV513882.1 WO 2017010500-A/325: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGGTCTGCCATG
>LV513881.1 WO 2017010500-A/324: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGGTCTGCCAT
>LV513880.1 WO 2017010500-A/323: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGGTCTGCCA
>LV513879.1 WO 2017010500-A/322: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAACTGGTCTGCC
>LV513878.1 WO 2017010500-A/321: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GAAACTGGTCTGC
>LV513877.1 WO 2017010500-A/320: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGGAAACTGGTCT
>LV513876.1 WO 2017010500-A/319: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGGGAAACTGGTC
>LV513875.1 WO 2017010500-A/318: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGGGAAACTGGT
>LV513874.1 WO 2017010500-A/317: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACTGGGAAACTGG
>LV513873.1 WO 2017010500-A/316: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AACTGGGAAACTG
>LV513872.1 WO 2017010500-A/315: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAACTGGGAAAC
>LV513871.1 WO 2017010500-A/314: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAAACTGGGAAA
>LV513870.1 WO 2017010500-A/313: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACCAAACTGGGAA
>LV513869.1 WO 2017010500-A/312: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TACCAAACTGGGA
>LV513868.1 WO 2017010500-A/311: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GTACCAAACTGGG
>LV513867.1 WO 2017010500-A/310: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCATGATGGATAT
>LV513866.1 WO 2017010500-A/309: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCCATGATGGATA
>LV513865.1 WO 2017010500-A/308: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGCCATGATGGAT
>LV513864.1 WO 2017010500-A/307: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CTGCCATGATGGA
>LV513863.1 WO 2017010500-A/306: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GCTGCCATGATGG
>LV513862.1 WO 2017010500-A/305: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GGCTGCCATGATG
>LV513861.1 WO 2017010500-A/304: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGCCACATTTGG
>LV513860.1 WO 2017010500-A/303: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATAAAGCCACATT
>LV513859.1 WO 2017010500-A/302: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GATAAAGCCACAT
>LV513858.1 WO 2017010500-A/301: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGGATAAAGCCAC
>LV513857.1 WO 2017010500-A/300: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAAGGATAAAGCC
>LV513856.1 WO 2017010500-A/299: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TCCTGCAAAACCA
>LV513855.1 WO 2017010500-A/298: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ATCCTGCAAAACC
>LV513854.1 WO 2017010500-A/297: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
TGAACTATCCTGC
>LV513853.1 WO 2017010500-A/296: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGACAATGGATT
>LV513852.1 WO 2017010500-A/295: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGACAATGGAT
>LV513851.1 WO 2017010500-A/294: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
ACCAGACAATGGA
>LV513850.1 WO 2017010500-A/293: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
GACCAGACAATGG
>LV513849.1 WO 2017010500-A/292: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGACCAGACAATG
>LV513848.1 WO 2017010500-A/291: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AAGACCAGACAAT
>LV513847.1 WO 2017010500-A/290: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
AGAATGCAGGGAA
>LV513846.1 WO 2017010500-A/289: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CAGAATGCAGGGA
>LV513845.1 WO 2017010500-A/288: Antisense Oligonucleotide for Inhibiting Expression of beta2GPI
CCAGAATGCAGGG
>LV512258.1 JP 2017018109-A/4313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV512256.1 JP 2017018109-A/4311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV512254.1 JP 2017018109-A/4309: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV511684.1 JP 2017018109-A/3739: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATCTATGACAAA
>LV511682.1 JP 2017018109-A/3737: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGCAGAGTACA
>LV511680.1 JP 2017018109-A/3735: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTCAAGCAGA
>LV511678.1 JP 2017018109-A/3733: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATGACAAGTTCA
>LV511676.1 JP 2017018109-A/3731: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAACGAAATCTAA
>LV511674.1 JP 2017018109-A/3729: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>LV511672.1 JP 2017018109-A/3727: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAAAGATGGAGA
>LV511670.1 JP 2017018109-A/3725: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>LV511668.1 JP 2017018109-A/3723: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATATGTTCTTA
>LV511666.1 JP 2017018109-A/3721: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>LV511664.1 JP 2017018109-A/3719: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCAACACATCAA
>LV511662.1 JP 2017018109-A/3717: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCAGAGTACAA
>LV511660.1 JP 2017018109-A/3715: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTACACACAA
>LV511658.1 JP 2017018109-A/3713: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>LV511656.1 JP 2017018109-A/3711: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>LV511654.1 JP 2017018109-A/3709: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>LV511652.1 JP 2017018109-A/3707: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACACACAGCATAA
>LV511650.1 JP 2017018109-A/3705: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>LV511648.1 JP 2017018109-A/3703: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTCAAGCAA
>LV511644.1 JP 2017018109-A/3699: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>LV511642.1 JP 2017018109-A/3697: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>LV511638.1 JP 2017018109-A/3693: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>LV511636.1 JP 2017018109-A/3691: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>LV511634.1 JP 2017018109-A/3689: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>LV511632.1 JP 2017018109-A/3687: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>LV511628.1 JP 2017018109-A/3683: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>LV511626.1 JP 2017018109-A/3681: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>LV511622.1 JP 2017018109-A/3677: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>LV511618.1 JP 2017018109-A/3673: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>LV511616.1 JP 2017018109-A/3671: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>LV511614.1 JP 2017018109-A/3669: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>LV511612.1 JP 2017018109-A/3667: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>LV511610.1 JP 2017018109-A/3665: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>LV511608.1 JP 2017018109-A/3663: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>LV511606.1 JP 2017018109-A/3661: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>LV511604.1 JP 2017018109-A/3659: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>LV511602.1 JP 2017018109-A/3657: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>LV511600.1 JP 2017018109-A/3655: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>LV511598.1 JP 2017018109-A/3653: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>LV511596.1 JP 2017018109-A/3651: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>LV511594.1 JP 2017018109-A/3649: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>LV511592.1 JP 2017018109-A/3647: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>LV511590.1 JP 2017018109-A/3645: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>LV511588.1 JP 2017018109-A/3643: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>LV511586.1 JP 2017018109-A/3641: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>LV511584.1 JP 2017018109-A/3639: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511582.1 JP 2017018109-A/3637: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511580.1 JP 2017018109-A/3635: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511578.1 JP 2017018109-A/3633: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511576.1 JP 2017018109-A/3631: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511574.1 JP 2017018109-A/3629: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511572.1 JP 2017018109-A/3627: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511570.1 JP 2017018109-A/3625: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511568.1 JP 2017018109-A/3623: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511566.1 JP 2017018109-A/3621: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511564.1 JP 2017018109-A/3619: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511562.1 JP 2017018109-A/3617: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511560.1 JP 2017018109-A/3615: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511558.1 JP 2017018109-A/3613: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511548.1 JP 2017018109-A/3603: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>LV511546.1 JP 2017018109-A/3601: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>LV511544.1 JP 2017018109-A/3599: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>LV511542.1 JP 2017018109-A/3597: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>LV511540.1 JP 2017018109-A/3595: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>LV511538.1 JP 2017018109-A/3593: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV511536.1 JP 2017018109-A/3591: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>LV511534.1 JP 2017018109-A/3589: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>LV511532.1 JP 2017018109-A/3587: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>LV511530.1 JP 2017018109-A/3585: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>LV511528.1 JP 2017018109-A/3583: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>LV511738.1 JP 2017018109-A/3793: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511736.1 JP 2017018109-A/3791: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511734.1 JP 2017018109-A/3789: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511732.1 JP 2017018109-A/3787: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511730.1 JP 2017018109-A/3785: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511728.1 JP 2017018109-A/3783: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>LV511726.1 JP 2017018109-A/3781: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511724.1 JP 2017018109-A/3779: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511722.1 JP 2017018109-A/3777: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511720.1 JP 2017018109-A/3775: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511718.1 JP 2017018109-A/3773: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511716.1 JP 2017018109-A/3771: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511714.1 JP 2017018109-A/3769: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511712.1 JP 2017018109-A/3767: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511710.1 JP 2017018109-A/3765: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGATTCAAGTCA
>LV511708.1 JP 2017018109-A/3763: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAAAACCAA
>LV511706.1 JP 2017018109-A/3761: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAGCAAAGAA
>LV511704.1 JP 2017018109-A/3759: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGCAACA
>LV511702.1 JP 2017018109-A/3757: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>LV511700.1 JP 2017018109-A/3755: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATCTATGACAA
>LV511698.1 JP 2017018109-A/3753: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCAAAGATAA
>LV511696.1 JP 2017018109-A/3751: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCTACCAGAAA
>LV511694.1 JP 2017018109-A/3749: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCTACCAGAA
>LV511692.1 JP 2017018109-A/3747: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAAGATAATGA
>LV511690.1 JP 2017018109-A/3745: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAACTCTACCAGA
>LV511688.1 JP 2017018109-A/3743: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATATAGCAAA
>LV511686.1 JP 2017018109-A/3741: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV511086.1 JP 2017018109-A/3141: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATCAAGTTTGA
>LV511084.1 JP 2017018109-A/3139: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGACACGTTT
>LV511082.1 JP 2017018109-A/3137: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTACCAGTGCAC
>LV511080.1 JP 2017018109-A/3135: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACATCTTT
>LV511078.1 JP 2017018109-A/3133: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCAGTAGCACA
>LV511076.1 JP 2017018109-A/3131: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTCTGTGGAG
>LV511074.1 JP 2017018109-A/3129: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGTATGT
>LV511072.1 JP 2017018109-A/3127: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTTGAGCTT
>LV511070.1 JP 2017018109-A/3125: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCCTATCAAGTT
>LV511068.1 JP 2017018109-A/3123: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACGGAGACAT
>LV511066.1 JP 2017018109-A/3121: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCTGTGGAGT
>LV511064.1 JP 2017018109-A/3119: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTATCAAGTTT
>LV511062.1 JP 2017018109-A/3117: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCGAGGAGTG
>LV511060.1 JP 2017018109-A/3115: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTTGCGAAGCT
>LV511058.1 JP 2017018109-A/3113: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTACGGAGACA
>LV511056.1 JP 2017018109-A/3111: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGACTGGAAGA
>LV511054.1 JP 2017018109-A/3109: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTGGAGCGCC
>LV511052.1 JP 2017018109-A/3107: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTACAACTGTC
>LV511050.1 JP 2017018109-A/3105: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTACAACTGTCC
>LV511048.1 JP 2017018109-A/3103: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGCCATTACAAC
>LV511046.1 JP 2017018109-A/3101: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCATTACAACTGT
>LV511044.1 JP 2017018109-A/3099: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGGTCCAGACC
>LV511042.1 JP 2017018109-A/3097: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTGGAGCGC
>LV511040.1 JP 2017018109-A/3095: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACCTGTGCCTG
>LV511038.1 JP 2017018109-A/3093: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTGCCTGGTCC
>LV511036.1 JP 2017018109-A/3091: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTGGAAGACACG
>LV511034.1 JP 2017018109-A/3089: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCCATTACAACT
>LV511032.1 JP 2017018109-A/3087: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTGAGCTTTCT
>LV511030.1 JP 2017018109-A/3085: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGCGCCTGTT
>LV511028.1 JP 2017018109-A/3083: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGAGCGCCTG
>LV511490.1 JP 2017018109-A/3545: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>LV511494.1 JP 2017018109-A/3549: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>LV511498.1 JP 2017018109-A/3553: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>LV511502.1 JP 2017018109-A/3557: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>LV511506.1 JP 2017018109-A/3561: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>LV511510.1 JP 2017018109-A/3565: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>LV511526.1 JP 2017018109-A/3581: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>LV511524.1 JP 2017018109-A/3579: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>LV511522.1 JP 2017018109-A/3577: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>LV511520.1 JP 2017018109-A/3575: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>LV511518.1 JP 2017018109-A/3573: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>LV511514.1 JP 2017018109-A/3569: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>LV511486.1 JP 2017018109-A/3541: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>LV511482.1 JP 2017018109-A/3537: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>LV511480.1 JP 2017018109-A/3535: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>LV511478.1 JP 2017018109-A/3533: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>LV511476.1 JP 2017018109-A/3531: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>LV511474.1 JP 2017018109-A/3529: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>LV511472.1 JP 2017018109-A/3527: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>LV511470.1 JP 2017018109-A/3525: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>LV511468.1 JP 2017018109-A/3523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>LV511466.1 JP 2017018109-A/3521: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>LV511464.1 JP 2017018109-A/3519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>LV511462.1 JP 2017018109-A/3517: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>LV511460.1 JP 2017018109-A/3515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>LV511458.1 JP 2017018109-A/3513: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>LV511456.1 JP 2017018109-A/3511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>LV511454.1 JP 2017018109-A/3509: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>LV511452.1 JP 2017018109-A/3507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511450.1 JP 2017018109-A/3505: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511448.1 JP 2017018109-A/3503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511446.1 JP 2017018109-A/3501: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511444.1 JP 2017018109-A/3499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511442.1 JP 2017018109-A/3497: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511440.1 JP 2017018109-A/3495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511438.1 JP 2017018109-A/3493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511436.1 JP 2017018109-A/3491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511434.1 JP 2017018109-A/3489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511432.1 JP 2017018109-A/3487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511430.1 JP 2017018109-A/3485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511428.1 JP 2017018109-A/3483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511426.1 JP 2017018109-A/3481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511424.1 JP 2017018109-A/3479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511422.1 JP 2017018109-A/3477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511420.1 JP 2017018109-A/3475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511418.1 JP 2017018109-A/3473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511416.1 JP 2017018109-A/3471: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511414.1 JP 2017018109-A/3469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511388.1 JP 2017018109-A/3443: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511386.1 JP 2017018109-A/3441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511384.1 JP 2017018109-A/3439: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511382.1 JP 2017018109-A/3437: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511380.1 JP 2017018109-A/3435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511378.1 JP 2017018109-A/3433: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511376.1 JP 2017018109-A/3431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511374.1 JP 2017018109-A/3429: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511372.1 JP 2017018109-A/3427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511370.1 JP 2017018109-A/3425: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511368.1 JP 2017018109-A/3423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511366.1 JP 2017018109-A/3421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511364.1 JP 2017018109-A/3419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511362.1 JP 2017018109-A/3417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511360.1 JP 2017018109-A/3415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511358.1 JP 2017018109-A/3413: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511356.1 JP 2017018109-A/3411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511354.1 JP 2017018109-A/3409: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511352.1 JP 2017018109-A/3407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511350.1 JP 2017018109-A/3405: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511348.1 JP 2017018109-A/3403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511346.1 JP 2017018109-A/3401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511314.1 JP 2017018109-A/3369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511312.1 JP 2017018109-A/3367: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511310.1 JP 2017018109-A/3365: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511308.1 JP 2017018109-A/3363: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511306.1 JP 2017018109-A/3361: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511304.1 JP 2017018109-A/3359: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511302.1 JP 2017018109-A/3357: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511300.1 JP 2017018109-A/3355: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511298.1 JP 2017018109-A/3353: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511296.1 JP 2017018109-A/3351: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511294.1 JP 2017018109-A/3349: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511292.1 JP 2017018109-A/3347: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511290.1 JP 2017018109-A/3345: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511288.1 JP 2017018109-A/3343: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511286.1 JP 2017018109-A/3341: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV511284.1 JP 2017018109-A/3339: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV511282.1 JP 2017018109-A/3337: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>LV511280.1 JP 2017018109-A/3335: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV511276.1 JP 2017018109-A/3331: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>LV511274.1 JP 2017018109-A/3329: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>LV511270.1 JP 2017018109-A/3325: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>LV511268.1 JP 2017018109-A/3323: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>LV511266.1 JP 2017018109-A/3321: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>LV511262.1 JP 2017018109-A/3317: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>LV511258.1 JP 2017018109-A/3313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>LV511256.1 JP 2017018109-A/3311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>LV511252.1 JP 2017018109-A/3307: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>LV511248.1 JP 2017018109-A/3303: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>LV511246.1 JP 2017018109-A/3301: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>LV511244.1 JP 2017018109-A/3299: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>LV511242.1 JP 2017018109-A/3297: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>LV511240.1 JP 2017018109-A/3295: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>LV511238.1 JP 2017018109-A/3293: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>LV511236.1 JP 2017018109-A/3291: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>LV511232.1 JP 2017018109-A/3287: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>LV511228.1 JP 2017018109-A/3283: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>LV511224.1 JP 2017018109-A/3279: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>LV511222.1 JP 2017018109-A/3277: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGCTGACCTGG
>LV511220.1 JP 2017018109-A/3275: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATCAAGTTTGAG
>LV511218.1 JP 2017018109-A/3273: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGCAAGATCGGC
>LV511216.1 JP 2017018109-A/3271: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACACGTTTGGC
>LV511214.1 JP 2017018109-A/3269: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTAAATTCTGTGG
>LV511212.1 JP 2017018109-A/3267: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAAATTCTGTG
>LV511210.1 JP 2017018109-A/3265: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGACTTCGGC
>LV511208.1 JP 2017018109-A/3263: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTGCGAAGCTG
>LV511206.1 JP 2017018109-A/3261: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCGAAGCTGACC
>LV511204.1 JP 2017018109-A/3259: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACGGAGACATGG
>LV511202.1 JP 2017018109-A/3257: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGTTCCAAGAC
>LV511200.1 JP 2017018109-A/3255: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACCAGTGCACG
>LV511198.1 JP 2017018109-A/3253: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACAACGCC
>LV511196.1 JP 2017018109-A/3251: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCGAAGCTGAC
>LV511194.1 JP 2017018109-A/3249: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAAGCTGACCTG
>LV511192.1 JP 2017018109-A/3247: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCCAAGACCT
>LV511190.1 JP 2017018109-A/3245: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTATCAAGTTTG
>LV511188.1 JP 2017018109-A/3243: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACTGGAAGAC
>LV511186.1 JP 2017018109-A/3241: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCGAAGCTGA
>LV511184.1 JP 2017018109-A/3239: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCCTTGCGAAGC
>LV511182.1 JP 2017018109-A/3237: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGGTCATGAAG
>LV511180.1 JP 2017018109-A/3235: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGACACGTTTGG
>LV511178.1 JP 2017018109-A/3233: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTAAATTCTG
>LV511176.1 JP 2017018109-A/3231: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCAGGCCTTGC
>LV511174.1 JP 2017018109-A/3229: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAGAGAAGCAG
>LV511172.1 JP 2017018109-A/3227: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGTATGTACC
>LV511170.1 JP 2017018109-A/3225: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGAACTGCAG
>LV511168.1 JP 2017018109-A/3223: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGTTTGAGCT
>LV511166.1 JP 2017018109-A/3221: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTCAGGCCTTG
>LV511164.1 JP 2017018109-A/3219: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACTTCGGCTCC
>LV511162.1 JP 2017018109-A/3217: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACTTCGGCTC
>LV511160.1 JP 2017018109-A/3215: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGATGTACGG
>LV511158.1 JP 2017018109-A/3213: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAAGCTGACCT
>LV511156.1 JP 2017018109-A/3211: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAGGCCTTGCGA
>LV511154.1 JP 2017018109-A/3209: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGGAGACATGGC
>LV511152.1 JP 2017018109-A/3207: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACGTTTGGCC
>LV511150.1 JP 2017018109-A/3205: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCGAGGTCATGA
>LV511148.1 JP 2017018109-A/3203: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGACAACGCCT
>LV511146.1 JP 2017018109-A/3201: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGATGTACGGAG
>LV511144.1 JP 2017018109-A/3199: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAAGACACGTT
>LV511142.1 JP 2017018109-A/3197: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAAATTCTGTGGA
>LV511140.1 JP 2017018109-A/3195: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCATGAAGA
>LV511138.1 JP 2017018109-A/3193: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAACGCCTC
>LV511136.1 JP 2017018109-A/3191: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGAGACATGGCA
>LV511134.1 JP 2017018109-A/3189: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGTGGAGTATG
>LV511132.1 JP 2017018109-A/3187: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGCTAAATTCT
>LV511130.1 JP 2017018109-A/3185: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGGCCTTGCGAA
>LV511128.1 JP 2017018109-A/3183: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGCAAGATCGG
>LV511126.1 JP 2017018109-A/3181: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCGACTGGAAG
>LV511124.1 JP 2017018109-A/3179: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGCCTTGCGAAG
>LV511122.1 JP 2017018109-A/3177: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGACACGTTTG
>LV511120.1 JP 2017018109-A/3175: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGTCAGGCCTT
>LV511118.1 JP 2017018109-A/3173: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCATGAAGAAG
>LV511116.1 JP 2017018109-A/3171: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCTGACCTGGA
>LV511114.1 JP 2017018109-A/3169: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGAAGTGTAA
>LV511112.1 JP 2017018109-A/3167: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGTTCCTTAA
>LV511110.1 JP 2017018109-A/3165: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAAAGGTTA
>LV511108.1 JP 2017018109-A/3163: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATACCGAGCTA
>LV511106.1 JP 2017018109-A/3161: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTTGAGAGTGT
>LV511104.1 JP 2017018109-A/3159: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATACCGAGCTAAA
>LV511102.1 JP 2017018109-A/3157: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCCTTTATTA
>LV511100.1 JP 2017018109-A/3155: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGGACAGCTT
>LV511098.1 JP 2017018109-A/3153: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATACGAGTAATA
>LV511096.1 JP 2017018109-A/3151: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATCTAAGTTAA
>LV511094.1 JP 2017018109-A/3149: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGCTCAGATA
>LV511092.1 JP 2017018109-A/3147: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTGATCAGTTT
>LV511090.1 JP 2017018109-A/3145: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGTAGAATGTAA
>LV511088.1 JP 2017018109-A/3143: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTAAATTCTGT
>LV510880.1 JP 2017018109-A/2935: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>LV510878.1 JP 2017018109-A/2933: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>LV510876.1 JP 2017018109-A/2931: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>LV510874.1 JP 2017018109-A/2929: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>LV510872.1 JP 2017018109-A/2927: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>LV510870.1 JP 2017018109-A/2925: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>LV510868.1 JP 2017018109-A/2923: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>LV510866.1 JP 2017018109-A/2921: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>LV510864.1 JP 2017018109-A/2919: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>LV510862.1 JP 2017018109-A/2917: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>LV510860.1 JP 2017018109-A/2915: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>LV510858.1 JP 2017018109-A/2913: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>LV510856.1 JP 2017018109-A/2911: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>LV510854.1 JP 2017018109-A/2909: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>LV510852.1 JP 2017018109-A/2907: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>LV510850.1 JP 2017018109-A/2905: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>LV510848.1 JP 2017018109-A/2903: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>LV510846.1 JP 2017018109-A/2901: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>LV510842.1 JP 2017018109-A/2897: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>LV510838.1 JP 2017018109-A/2893: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>LV510834.1 JP 2017018109-A/2889: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>LV510830.1 JP 2017018109-A/2885: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>LV510826.1 JP 2017018109-A/2881: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>LV510822.1 JP 2017018109-A/2877: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>LV510818.1 JP 2017018109-A/2873: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>LV510816.1 JP 2017018109-A/2871: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCCAGCAAC
>LV510814.1 JP 2017018109-A/2869: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTCGAACGACT
>LV510812.1 JP 2017018109-A/2867: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGCAATTAATA
>LV510810.1 JP 2017018109-A/2865: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCCAGCAATTAA
>LV510808.1 JP 2017018109-A/2863: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGTCTGGAAA
>LV510806.1 JP 2017018109-A/2861: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGTGTATCTAT
>LV510804.1 JP 2017018109-A/2859: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCCGTGAAT
>LV510802.1 JP 2017018109-A/2857: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGTGATTGATA
>LV510800.1 JP 2017018109-A/2855: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGAGTGCTG
>LV510798.1 JP 2017018109-A/2853: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTTATGGACT
>LV510796.1 JP 2017018109-A/2851: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGGTCACTGATT
>LV510794.1 JP 2017018109-A/2849: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACGAAAGCCA
>LV510792.1 JP 2017018109-A/2847: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCATGAGAATTG
>LV510790.1 JP 2017018109-A/2845: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTCAATTGCTTA
>LV510788.1 JP 2017018109-A/2843: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCCACAGCCA
>LV510786.1 JP 2017018109-A/2841: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGCATTCCGAT
>LV510784.1 JP 2017018109-A/2839: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGCTGAAACC
>LV510782.1 JP 2017018109-A/2837: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAACAGGCTGATT
>LV510780.1 JP 2017018109-A/2835: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTACCATGAGAA
>LV510778.1 JP 2017018109-A/2833: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCCGTGAA
>LV510776.1 JP 2017018109-A/2831: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAGTCAGGAACT
>LV510774.1 JP 2017018109-A/2829: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCAATGATGA
>LV510772.1 JP 2017018109-A/2827: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTGTGGTTTAT
>LV510770.1 JP 2017018109-A/2825: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACTCTGATGA
>LV510768.1 JP 2017018109-A/2823: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATTAATAAA
>LV510766.1 JP 2017018109-A/2821: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAATTGCTTAT
>LV510764.1 JP 2017018109-A/2819: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATCACTGTA
>LV510762.1 JP 2017018109-A/2817: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATTCTATAGAA
>LV510760.1 JP 2017018109-A/2815: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAACTAATGTGT
>LV510758.1 JP 2017018109-A/2813: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCCGATGTGATT
>LV510756.1 JP 2017018109-A/2811: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATAAGCGGAAAG
>LV510754.1 JP 2017018109-A/2809: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCTGGATG
>LV510752.1 JP 2017018109-A/2807: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGAATGGTGC
>LV510750.1 JP 2017018109-A/2805: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACCTCACACATG
>LV510748.1 JP 2017018109-A/2803: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGCAACCGAA
>LV510746.1 JP 2017018109-A/2801: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATGAATAGAAA
>LV510744.1 JP 2017018109-A/2799: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAATAACTAAT
>LV510742.1 JP 2017018109-A/2797: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTTGAATGTGTA
>LV510740.1 JP 2017018109-A/2795: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGGTTGAATGT
>LV510738.1 JP 2017018109-A/2793: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCATGAATTT
>LV510736.1 JP 2017018109-A/2791: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAGTGCTGAA
>LV510734.1 JP 2017018109-A/2789: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGAAACGAGTCA
>LV510732.1 JP 2017018109-A/2787: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGCATACAAG
>LV510730.1 JP 2017018109-A/2785: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAGATAGTGCAT
>LV510728.1 JP 2017018109-A/2783: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATGAGCATT
>LV510726.1 JP 2017018109-A/2781: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTTCGCAGAC
>LV510724.1 JP 2017018109-A/2779: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCAACGAAAG
>LV510722.1 JP 2017018109-A/2777: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTTGTGGCTTC
>LV510720.1 JP 2017018109-A/2775: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTGGAAATAA
>LV510718.1 JP 2017018109-A/2773: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCGTGAATTC
>LV510716.1 JP 2017018109-A/2771: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGACGAGGACAT
>LV510714.1 JP 2017018109-A/2769: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGACACATATGA
>LV510712.1 JP 2017018109-A/2767: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTGATGAGTCT
>LV510710.1 JP 2017018109-A/2765: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCATTTAGTCAA
>LV510708.1 JP 2017018109-A/2763: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTCAGGAACTT
>LV510706.1 JP 2017018109-A/2761: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATTCCGATGT
>LV510704.1 JP 2017018109-A/2759: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATTTAGTCAAA
>LV510702.1 JP 2017018109-A/2757: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGTCCAGATT
>LV510700.1 JP 2017018109-A/2755: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGATGGCCGA
>LV510698.1 JP 2017018109-A/2753: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATGGTGCATAC
>LV510696.1 JP 2017018109-A/2751: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACCAAGGAAA
>LV510694.1 JP 2017018109-A/2749: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCATTCTATA
>LV510692.1 JP 2017018109-A/2747: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCAGTTAAACA
>LV510690.1 JP 2017018109-A/2745: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATAAGCGGAAA
>LV510688.1 JP 2017018109-A/2743: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTCCAGATTAT
>LV510686.1 JP 2017018109-A/2741: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATGAAACGAGT
>LV510684.1 JP 2017018109-A/2739: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTGAATGTGT
>LV510682.1 JP 2017018109-A/2737: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGTCCAGATTA
>LV510680.1 JP 2017018109-A/2735: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGAAAGCGA
>LV510678.1 JP 2017018109-A/2733: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCCAGCAATT
>LV510676.1 JP 2017018109-A/2731: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTATAGAAGAA
>LV510674.1 JP 2017018109-A/2729: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTGTATCTATT
>LV510672.1 JP 2017018109-A/2727: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATAGTGCATCT
>LV510670.1 JP 2017018109-A/2725: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATTGATAGTCA
>LV510668.1 JP 2017018109-A/2723: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAGGAGTTGAA
>LV510666.1 JP 2017018109-A/2721: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGATGAGAGCAA
>LV510664.1 JP 2017018109-A/2719: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCAACGAAA
>LV510662.1 JP 2017018109-A/2717: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCTCATGAATAG
>LV510660.1 JP 2017018109-A/2715: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCTCATGAAT
>LV510658.1 JP 2017018109-A/2713: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGCCTTCTGATT
>LV510656.1 JP 2017018109-A/2711: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATTTCGTATT
>LV510654.1 JP 2017018109-A/2709: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGATGATAT
>LV510652.1 JP 2017018109-A/2707: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAGCCATGACCA
>LV510650.1 JP 2017018109-A/2705: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCGTATTTCT
>LV510648.1 JP 2017018109-A/2703: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTTCGTATTT
>LV510646.1 JP 2017018109-A/2701: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGGAAAGCCAAT
>LV510644.1 JP 2017018109-A/2699: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCATGACCAC
>LV510642.1 JP 2017018109-A/2697: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATGACCACAT
>LV510640.1 JP 2017018109-A/2695: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCACATGGATGA
>LV510638.1 JP 2017018109-A/2693: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAAGCCAA
>LV510636.1 JP 2017018109-A/2691: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCGGAAAGCCA
>LV510634.1 JP 2017018109-A/2689: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTCACCATTC
>LV510632.1 JP 2017018109-A/2687: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACAGCCATGAA
>LV510630.1 JP 2017018109-A/2685: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGAGGTCAAA
>LV510628.1 JP 2017018109-A/2683: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTCTCACCATT
>LV510626.1 JP 2017018109-A/2681: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGACTGAGGTCA
>LV510624.1 JP 2017018109-A/2679: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATGAATCT
>LV510622.1 JP 2017018109-A/2677: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCTGGATGA
>LV510620.1 JP 2017018109-A/2675: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGAGGTCAAT
>LV510618.1 JP 2017018109-A/2673: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGGTCAATTAA
>LV510616.1 JP 2017018109-A/2671: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGAGGTCAATT
>LV510614.1 JP 2017018109-A/2669: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCAATTAAA
>LV510612.1 JP 2017018109-A/2667: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGAGGTCAATTA
>LV510610.1 JP 2017018109-A/2665: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCATGAATTAGA
>LV510608.1 JP 2017018109-A/2663: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>LV510606.1 JP 2017018109-A/2661: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATCTATGACAAA
>LV510604.1 JP 2017018109-A/2659: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGCAGAGTACA
>LV510602.1 JP 2017018109-A/2657: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTCAAGCAGA
>LV510600.1 JP 2017018109-A/2655: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATGACAAGTTCA
>LV510598.1 JP 2017018109-A/2653: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAACGAAATCTAA
>LV510596.1 JP 2017018109-A/2651: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>LV510594.1 JP 2017018109-A/2649: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAAAGATGGAGA
>LV510592.1 JP 2017018109-A/2647: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>LV510590.1 JP 2017018109-A/2645: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATATGTTCTTA
>LV510588.1 JP 2017018109-A/2643: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>LV510586.1 JP 2017018109-A/2641: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCAACACATCAA
>LV510584.1 JP 2017018109-A/2639: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCAGAGTACAA
>LV510582.1 JP 2017018109-A/2637: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTACACACAA
>LV510580.1 JP 2017018109-A/2635: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>LV510578.1 JP 2017018109-A/2633: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>LV510576.1 JP 2017018109-A/2631: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>LV510574.1 JP 2017018109-A/2629: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACACACAGCATAA
>LV510572.1 JP 2017018109-A/2627: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>LV510570.1 JP 2017018109-A/2625: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTCAAGCAA
>LV510566.1 JP 2017018109-A/2621: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>LV510564.1 JP 2017018109-A/2619: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>LV510560.1 JP 2017018109-A/2615: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>LV510558.1 JP 2017018109-A/2613: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>LV510556.1 JP 2017018109-A/2611: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>LV510554.1 JP 2017018109-A/2609: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>LV510550.1 JP 2017018109-A/2605: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>LV510548.1 JP 2017018109-A/2603: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>LV510544.1 JP 2017018109-A/2599: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>LV510540.1 JP 2017018109-A/2595: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>LV510538.1 JP 2017018109-A/2593: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>LV510536.1 JP 2017018109-A/2591: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>LV510534.1 JP 2017018109-A/2589: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>LV510532.1 JP 2017018109-A/2587: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>LV510530.1 JP 2017018109-A/2585: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>LV510528.1 JP 2017018109-A/2583: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>LV511026.1 JP 2017018109-A/3081: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTTTCTGGCT
>LV511024.1 JP 2017018109-A/3079: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATTACAACTG
>LV511022.1 JP 2017018109-A/3077: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAGCGCCTGTTC
>LV511020.1 JP 2017018109-A/3075: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACTGGAAGACA
>LV511018.1 JP 2017018109-A/3073: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGGAGCGCCT
>LV511016.1 JP 2017018109-A/3071: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGGAAGATGTA
>LV511014.1 JP 2017018109-A/3069: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV511012.1 JP 2017018109-A/3067: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV511010.1 JP 2017018109-A/3065: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV511008.1 JP 2017018109-A/3063: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510976.1 JP 2017018109-A/3031: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510974.1 JP 2017018109-A/3029: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510972.1 JP 2017018109-A/3027: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510970.1 JP 2017018109-A/3025: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510968.1 JP 2017018109-A/3023: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510964.1 JP 2017018109-A/3019: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>LV510960.1 JP 2017018109-A/3015: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>LV510956.1 JP 2017018109-A/3011: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>LV510952.1 JP 2017018109-A/3007: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>LV510950.1 JP 2017018109-A/3005: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>LV510948.1 JP 2017018109-A/3003: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>LV510890.1 JP 2017018109-A/2945: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>LV510892.1 JP 2017018109-A/2947: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>LV510894.1 JP 2017018109-A/2949: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>LV510896.1 JP 2017018109-A/2951: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>LV510898.1 JP 2017018109-A/2953: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>LV510900.1 JP 2017018109-A/2955: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>LV510902.1 JP 2017018109-A/2957: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>LV510906.1 JP 2017018109-A/2961: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>LV510908.1 JP 2017018109-A/2963: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510912.1 JP 2017018109-A/2967: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>LV510946.1 JP 2017018109-A/3001: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>LV510944.1 JP 2017018109-A/2999: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>LV510942.1 JP 2017018109-A/2997: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>LV510940.1 JP 2017018109-A/2995: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>LV510936.1 JP 2017018109-A/2991: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>LV510934.1 JP 2017018109-A/2989: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>LV510932.1 JP 2017018109-A/2987: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>LV510930.1 JP 2017018109-A/2985: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>LV510928.1 JP 2017018109-A/2983: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>LV510924.1 JP 2017018109-A/2979: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>LV510922.1 JP 2017018109-A/2977: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>LV510918.1 JP 2017018109-A/2973: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>LV510916.1 JP 2017018109-A/2971: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>LV510914.1 JP 2017018109-A/2969: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>LV510292.1 JP 2017018109-A/2347: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAAAGGTTA
>LV510291.1 JP 2017018109-A/2346: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATACCGAGCTA
>LV510290.1 JP 2017018109-A/2345: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTTGAGAGTGT
>LV510289.1 JP 2017018109-A/2344: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATACCGAGCTAAA
>LV510288.1 JP 2017018109-A/2343: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCCTTTATTA
>LV510287.1 JP 2017018109-A/2342: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGGACAGCTT
>LV510286.1 JP 2017018109-A/2341: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATACGAGTAATA
>LV510285.1 JP 2017018109-A/2340: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATCTAAGTTAA
>LV510284.1 JP 2017018109-A/2339: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGCTCAGATA
>LV510283.1 JP 2017018109-A/2338: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTGATCAGTTT
>LV510282.1 JP 2017018109-A/2337: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGTAGAATGTAA
>LV510281.1 JP 2017018109-A/2336: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTAAATTCTGT
>LV510280.1 JP 2017018109-A/2335: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATCAAGTTTGA
>LV510279.1 JP 2017018109-A/2334: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGACACGTTT
>LV510278.1 JP 2017018109-A/2333: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTACCAGTGCAC
>LV510277.1 JP 2017018109-A/2332: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACATCTTT
>LV510276.1 JP 2017018109-A/2331: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCAGTAGCACA
>LV510275.1 JP 2017018109-A/2330: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTCTGTGGAG
>LV510274.1 JP 2017018109-A/2329: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGTATGT
>LV510273.1 JP 2017018109-A/2328: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTTGAGCTT
>LV510272.1 JP 2017018109-A/2327: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCCTATCAAGTT
>LV510271.1 JP 2017018109-A/2326: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACGGAGACAT
>LV510270.1 JP 2017018109-A/2325: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCTGTGGAGT
>LV510269.1 JP 2017018109-A/2324: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTATCAAGTTT
>LV510268.1 JP 2017018109-A/2323: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCGAGGAGTG
>LV510267.1 JP 2017018109-A/2322: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTTGCGAAGCT
>LV510266.1 JP 2017018109-A/2321: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTACGGAGACA
>LV510265.1 JP 2017018109-A/2320: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGACTGGAAGA
>LV510264.1 JP 2017018109-A/2319: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTGGAGCGCC
>LV510263.1 JP 2017018109-A/2318: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTACAACTGTC
>LV510262.1 JP 2017018109-A/2317: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTACAACTGTCC
>LV510261.1 JP 2017018109-A/2316: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGCCATTACAAC
>LV510260.1 JP 2017018109-A/2315: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCATTACAACTGT
>LV510259.1 JP 2017018109-A/2314: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGGTCCAGACC
>LV510258.1 JP 2017018109-A/2313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTGGAGCGC
>LV510257.1 JP 2017018109-A/2312: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACCTGTGCCTG
>LV510256.1 JP 2017018109-A/2311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTGCCTGGTCC
>LV510255.1 JP 2017018109-A/2310: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTGGAAGACACG
>LV510254.1 JP 2017018109-A/2309: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCCATTACAACT
>LV510253.1 JP 2017018109-A/2308: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTGAGCTTTCT
>LV510252.1 JP 2017018109-A/2307: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGCGCCTGTT
>LV510251.1 JP 2017018109-A/2306: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGAGCGCCTG
>LV510250.1 JP 2017018109-A/2305: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTTTCTGGCT
>LV510249.1 JP 2017018109-A/2304: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATTACAACTG
>LV510248.1 JP 2017018109-A/2303: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAGCGCCTGTTC
>LV510247.1 JP 2017018109-A/2302: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACTGGAAGACA
>LV510245.1 JP 2017018109-A/2300: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGGAGCGCCT
>LV510243.1 JP 2017018109-A/2298: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGGAAGATGTA
>LV510239.1 JP 2017018109-A/2294: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>LV510235.1 JP 2017018109-A/2290: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>LV510231.1 JP 2017018109-A/2286: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>LV510227.1 JP 2017018109-A/2282: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>LV510225.1 JP 2017018109-A/2280: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>LV510223.1 JP 2017018109-A/2278: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>LV510221.1 JP 2017018109-A/2276: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>LV510219.1 JP 2017018109-A/2274: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>LV510217.1 JP 2017018109-A/2272: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>LV510215.1 JP 2017018109-A/2270: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>LV510211.1 JP 2017018109-A/2266: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>LV510209.1 JP 2017018109-A/2264: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>LV510207.1 JP 2017018109-A/2262: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>LV510205.1 JP 2017018109-A/2260: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>LV510203.1 JP 2017018109-A/2258: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>LV510199.1 JP 2017018109-A/2254: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>LV510197.1 JP 2017018109-A/2252: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>LV510193.1 JP 2017018109-A/2248: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>LV510191.1 JP 2017018109-A/2246: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>LV510189.1 JP 2017018109-A/2244: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>LV510187.1 JP 2017018109-A/2242: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>LV510183.1 JP 2017018109-A/2238: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV510181.1 JP 2017018109-A/2236: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>LV510177.1 JP 2017018109-A/2232: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>LV510175.1 JP 2017018109-A/2230: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>LV510173.1 JP 2017018109-A/2228: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>LV510171.1 JP 2017018109-A/2226: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>LV510169.1 JP 2017018109-A/2224: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>LV510167.1 JP 2017018109-A/2222: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>LV510165.1 JP 2017018109-A/2220: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>LV510163.1 JP 2017018109-A/2218: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>LV510161.1 JP 2017018109-A/2216: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>LV510159.1 JP 2017018109-A/2214: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>LV510157.1 JP 2017018109-A/2212: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>LV510155.1 JP 2017018109-A/2210: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>LV510153.1 JP 2017018109-A/2208: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>LV510151.1 JP 2017018109-A/2206: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>LV510149.1 JP 2017018109-A/2204: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>LV510147.1 JP 2017018109-A/2202: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>LV510145.1 JP 2017018109-A/2200: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>LV510143.1 JP 2017018109-A/2198: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>LV510141.1 JP 2017018109-A/2196: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>LV510139.1 JP 2017018109-A/2194: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>LV510137.1 JP 2017018109-A/2192: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>LV510135.1 JP 2017018109-A/2190: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>LV510133.1 JP 2017018109-A/2188: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>LV510131.1 JP 2017018109-A/2186: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>LV510129.1 JP 2017018109-A/2184: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>LV510125.1 JP 2017018109-A/2180: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>LV510121.1 JP 2017018109-A/2176: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>LV510117.1 JP 2017018109-A/2172: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>LV510490.1 JP 2017018109-A/2545: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>LV510488.1 JP 2017018109-A/2543: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>LV510486.1 JP 2017018109-A/2541: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>LV510484.1 JP 2017018109-A/2539: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>LV510482.1 JP 2017018109-A/2537: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>LV510480.1 JP 2017018109-A/2535: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>LV510478.1 JP 2017018109-A/2533: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>LV510476.1 JP 2017018109-A/2531: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>LV510472.1 JP 2017018109-A/2527: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>LV510468.1 JP 2017018109-A/2523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>LV510464.1 JP 2017018109-A/2519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>LV510460.1 JP 2017018109-A/2515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>LV510456.1 JP 2017018109-A/2511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>LV510452.1 JP 2017018109-A/2507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>LV510448.1 JP 2017018109-A/2503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>LV510444.1 JP 2017018109-A/2499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>LV510440.1 JP 2017018109-A/2495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>LV510438.1 JP 2017018109-A/2493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>LV510436.1 JP 2017018109-A/2491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>LV510434.1 JP 2017018109-A/2489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>LV510432.1 JP 2017018109-A/2487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>LV510430.1 JP 2017018109-A/2485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>LV510428.1 JP 2017018109-A/2483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>LV510426.1 JP 2017018109-A/2481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>LV510424.1 JP 2017018109-A/2479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>LV510422.1 JP 2017018109-A/2477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>LV510420.1 JP 2017018109-A/2475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>LV510418.1 JP 2017018109-A/2473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>LV510416.1 JP 2017018109-A/2471: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>LV510414.1 JP 2017018109-A/2469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>LV510412.1 JP 2017018109-A/2467: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>LV510410.1 JP 2017018109-A/2465: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV510408.1 JP 2017018109-A/2463: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV510406.1 JP 2017018109-A/2461: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>LV510404.1 JP 2017018109-A/2459: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV510400.1 JP 2017018109-A/2455: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>LV510398.1 JP 2017018109-A/2453: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>LV510394.1 JP 2017018109-A/2449: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>LV510392.1 JP 2017018109-A/2447: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>LV510390.1 JP 2017018109-A/2445: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>LV510352.1 JP 2017018109-A/2407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>LV510349.1 JP 2017018109-A/2404: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>LV510348.1 JP 2017018109-A/2403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGCTGACCTGG
>LV510293.1 JP 2017018109-A/2348: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGTTCCTTAA
>LV510294.1 JP 2017018109-A/2349: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGAAGTGTAA
>LV510295.1 JP 2017018109-A/2350: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCTGACCTGGA
>LV510296.1 JP 2017018109-A/2351: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCATGAAGAAG
>LV510297.1 JP 2017018109-A/2352: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGTCAGGCCTT
>LV510298.1 JP 2017018109-A/2353: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGACACGTTTG
>LV510299.1 JP 2017018109-A/2354: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGCCTTGCGAAG
>LV510300.1 JP 2017018109-A/2355: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCGACTGGAAG
>LV510301.1 JP 2017018109-A/2356: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGCAAGATCGG
>LV510302.1 JP 2017018109-A/2357: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGGCCTTGCGAA
>LV510303.1 JP 2017018109-A/2358: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGCTAAATTCT
>LV510304.1 JP 2017018109-A/2359: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGTGGAGTATG
>LV510305.1 JP 2017018109-A/2360: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGAGACATGGCA
>LV510306.1 JP 2017018109-A/2361: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAACGCCTC
>LV510307.1 JP 2017018109-A/2362: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCATGAAGA
>LV510308.1 JP 2017018109-A/2363: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAAATTCTGTGGA
>LV510386.1 JP 2017018109-A/2441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>LV510382.1 JP 2017018109-A/2437: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>LV510380.1 JP 2017018109-A/2435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>LV510376.1 JP 2017018109-A/2431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>LV510372.1 JP 2017018109-A/2427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>LV510370.1 JP 2017018109-A/2425: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>LV510368.1 JP 2017018109-A/2423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>LV510366.1 JP 2017018109-A/2421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>LV510364.1 JP 2017018109-A/2419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>LV510362.1 JP 2017018109-A/2417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>LV510360.1 JP 2017018109-A/2415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>LV510356.1 JP 2017018109-A/2411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>LV510309.1 JP 2017018109-A/2364: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAAGACACGTT
>LV510310.1 JP 2017018109-A/2365: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGATGTACGGAG
>LV510311.1 JP 2017018109-A/2366: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGACAACGCCT
>LV510312.1 JP 2017018109-A/2367: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCGAGGTCATGA
>LV510313.1 JP 2017018109-A/2368: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACGTTTGGCC
>LV510314.1 JP 2017018109-A/2369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGGAGACATGGC
>LV510315.1 JP 2017018109-A/2370: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAGGCCTTGCGA
>LV510316.1 JP 2017018109-A/2371: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAAGCTGACCT
>LV510347.1 JP 2017018109-A/2402: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATCAAGTTTGAG
>LV510346.1 JP 2017018109-A/2401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGCAAGATCGGC
>LV510345.1 JP 2017018109-A/2400: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACACGTTTGGC
>LV510344.1 JP 2017018109-A/2399: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTAAATTCTGTGG
>LV510343.1 JP 2017018109-A/2398: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAAATTCTGTG
>LV510342.1 JP 2017018109-A/2397: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGACTTCGGC
>LV510341.1 JP 2017018109-A/2396: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTGCGAAGCTG
>LV510340.1 JP 2017018109-A/2395: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCGAAGCTGACC
>LV510339.1 JP 2017018109-A/2394: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACGGAGACATGG
>LV510338.1 JP 2017018109-A/2393: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGTTCCAAGAC
>LV510337.1 JP 2017018109-A/2392: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACCAGTGCACG
>LV510336.1 JP 2017018109-A/2391: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACAACGCC
>LV510335.1 JP 2017018109-A/2390: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCGAAGCTGAC
>LV510334.1 JP 2017018109-A/2389: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAAGCTGACCTG
>LV510333.1 JP 2017018109-A/2388: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCCAAGACCT
>LV510332.1 JP 2017018109-A/2387: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTATCAAGTTTG
>LV510331.1 JP 2017018109-A/2386: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACTGGAAGAC
>LV510330.1 JP 2017018109-A/2385: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCGAAGCTGA
>LV510329.1 JP 2017018109-A/2384: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCCTTGCGAAGC
>LV510328.1 JP 2017018109-A/2383: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGGTCATGAAG
>LV510327.1 JP 2017018109-A/2382: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGACACGTTTGG
>LV510326.1 JP 2017018109-A/2381: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTAAATTCTG
>LV510325.1 JP 2017018109-A/2380: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCAGGCCTTGC
>LV510324.1 JP 2017018109-A/2379: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAGAGAAGCAG
>LV510323.1 JP 2017018109-A/2378: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGTATGTACC
>LV510322.1 JP 2017018109-A/2377: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGAACTGCAG
>LV510321.1 JP 2017018109-A/2376: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGTTTGAGCT
>LV510320.1 JP 2017018109-A/2375: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTCAGGCCTTG
>LV510319.1 JP 2017018109-A/2374: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACTTCGGCTCC
>LV510318.1 JP 2017018109-A/2373: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACTTCGGCTC
>LV510317.1 JP 2017018109-A/2372: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGATGTACGG
>LV510526.1 JP 2017018109-A/2581: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>LV510524.1 JP 2017018109-A/2579: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>LV510522.1 JP 2017018109-A/2577: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>LV510492.1 JP 2017018109-A/2547: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>LV510494.1 JP 2017018109-A/2549: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>LV510496.1 JP 2017018109-A/2551: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV510498.1 JP 2017018109-A/2553: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>LV510500.1 JP 2017018109-A/2555: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>LV510502.1 JP 2017018109-A/2557: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>LV510504.1 JP 2017018109-A/2559: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>LV510506.1 JP 2017018109-A/2561: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>LV510508.1 JP 2017018109-A/2563: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>LV510510.1 JP 2017018109-A/2565: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>LV510512.1 JP 2017018109-A/2567: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>LV510514.1 JP 2017018109-A/2569: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>LV510520.1 JP 2017018109-A/2575: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>LV510518.1 JP 2017018109-A/2573: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>LV510516.1 JP 2017018109-A/2571: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>LV510113.1 JP 2017018109-A/2168: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>LV510109.1 JP 2017018109-A/2164: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>LV510105.1 JP 2017018109-A/2160: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>LV510101.1 JP 2017018109-A/2156: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>LV510099.1 JP 2017018109-A/2154: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCCAGCAAC
>LV510097.1 JP 2017018109-A/2152: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTCGAACGACT
>LV510095.1 JP 2017018109-A/2150: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGCAATTAATA
>LV510093.1 JP 2017018109-A/2148: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCCAGCAATTAA
>LV510091.1 JP 2017018109-A/2146: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGTCTGGAAA
>LV510089.1 JP 2017018109-A/2144: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGTGTATCTAT
>LV510087.1 JP 2017018109-A/2142: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCCGTGAAT
>LV510085.1 JP 2017018109-A/2140: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGTGATTGATA
>LV510083.1 JP 2017018109-A/2138: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGAGTGCTG
>LV510081.1 JP 2017018109-A/2136: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTTATGGACT
>LV510079.1 JP 2017018109-A/2134: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGGTCACTGATT
>LV510077.1 JP 2017018109-A/2132: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACGAAAGCCA
>LV510075.1 JP 2017018109-A/2130: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCATGAGAATTG
>LV510073.1 JP 2017018109-A/2128: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTCAATTGCTTA
>LV510071.1 JP 2017018109-A/2126: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCCACAGCCA
>LV510069.1 JP 2017018109-A/2124: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGCATTCCGAT
>LV510067.1 JP 2017018109-A/2122: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGCTGAAACC
>LV510065.1 JP 2017018109-A/2120: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAACAGGCTGATT
>LV510063.1 JP 2017018109-A/2118: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTACCATGAGAA
>LV510061.1 JP 2017018109-A/2116: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCCGTGAA
>LV510059.1 JP 2017018109-A/2114: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAGTCAGGAACT
>LV510057.1 JP 2017018109-A/2112: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCAATGATGA
>LV510055.1 JP 2017018109-A/2110: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTGTGGTTTAT
>LV510053.1 JP 2017018109-A/2108: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACTCTGATGA
>LV510051.1 JP 2017018109-A/2106: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATTAATAAA
>LV510049.1 JP 2017018109-A/2104: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAATTGCTTAT
>LV510047.1 JP 2017018109-A/2102: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATCACTGTA
>LV510045.1 JP 2017018109-A/2100: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATTCTATAGAA
>LV510043.1 JP 2017018109-A/2098: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAACTAATGTGT
>LV510041.1 JP 2017018109-A/2096: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCCGATGTGATT
>LV510039.1 JP 2017018109-A/2094: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATAAGCGGAAAG
>LV510037.1 JP 2017018109-A/2092: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCTGGATG
>LV510035.1 JP 2017018109-A/2090: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGAATGGTGC
>LV510033.1 JP 2017018109-A/2088: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACCTCACACATG
>LV510031.1 JP 2017018109-A/2086: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGCAACCGAA
>LV510029.1 JP 2017018109-A/2084: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATGAATAGAAA
>LV510027.1 JP 2017018109-A/2082: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAATAACTAAT
>LV510025.1 JP 2017018109-A/2080: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTTGAATGTGTA
>LV510023.1 JP 2017018109-A/2078: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGGTTGAATGT
>LV510021.1 JP 2017018109-A/2076: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCATGAATTT
>LV510019.1 JP 2017018109-A/2074: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAGTGCTGAA
>LV510017.1 JP 2017018109-A/2072: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGAAACGAGTCA
>LV510015.1 JP 2017018109-A/2070: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGCATACAAG
>LV510013.1 JP 2017018109-A/2068: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAGATAGTGCAT
>LV510011.1 JP 2017018109-A/2066: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATGAGCATT
>LV510009.1 JP 2017018109-A/2064: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTTCGCAGAC
>LV510007.1 JP 2017018109-A/2062: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCAACGAAAG
>LV510005.1 JP 2017018109-A/2060: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTTGTGGCTTC
>LV510003.1 JP 2017018109-A/2058: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTGGAAATAA
>LV510001.1 JP 2017018109-A/2056: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCGTGAATTC
>LV509999.1 JP 2017018109-A/2054: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGACGAGGACAT
>LV509997.1 JP 2017018109-A/2052: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGACACATATGA
>LV509995.1 JP 2017018109-A/2050: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTGATGAGTCT
>LV509993.1 JP 2017018109-A/2048: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCATTTAGTCAA
>LV509991.1 JP 2017018109-A/2046: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTCAGGAACTT
>LV509989.1 JP 2017018109-A/2044: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATTCCGATGT
>LV509987.1 JP 2017018109-A/2042: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATTTAGTCAAA
>LV509985.1 JP 2017018109-A/2040: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGTCCAGATT
>LV509983.1 JP 2017018109-A/2038: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGATGGCCGA
>LV509981.1 JP 2017018109-A/2036: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATGGTGCATAC
>LV509979.1 JP 2017018109-A/2034: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACCAAGGAAA
>LV509977.1 JP 2017018109-A/2032: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCATTCTATA
>LV509975.1 JP 2017018109-A/2030: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCAGTTAAACA
>LV509973.1 JP 2017018109-A/2028: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATAAGCGGAAA
>LV509971.1 JP 2017018109-A/2026: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTCCAGATTAT
>LV509969.1 JP 2017018109-A/2024: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATGAAACGAGT
>LV509967.1 JP 2017018109-A/2022: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTGAATGTGT
>LV509965.1 JP 2017018109-A/2020: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGTCCAGATTA
>LV509963.1 JP 2017018109-A/2018: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGAAAGCGA
>LV509961.1 JP 2017018109-A/2016: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCCAGCAATT
>LV509959.1 JP 2017018109-A/2014: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTATAGAAGAA
>LV509957.1 JP 2017018109-A/2012: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTGTATCTATT
>LV509955.1 JP 2017018109-A/2010: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATAGTGCATCT
>LV509953.1 JP 2017018109-A/2008: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATTGATAGTCA
>LV509951.1 JP 2017018109-A/2006: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAGGAGTTGAA
>LV509949.1 JP 2017018109-A/2004: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGATGAGAGCAA
>LV509947.1 JP 2017018109-A/2002: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCAACGAAA
>LV509945.1 JP 2017018109-A/2000: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCTCATGAATAG
>LV509943.1 JP 2017018109-A/1998: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCTCATGAAT
>LV509941.1 JP 2017018109-A/1996: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGCCTTCTGATT
>LV509939.1 JP 2017018109-A/1994: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATTTCGTATT
>LV509937.1 JP 2017018109-A/1992: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGATGATAT
>LV509935.1 JP 2017018109-A/1990: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAGCCATGACCA
>LV509933.1 JP 2017018109-A/1988: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCGTATTTCT
>LV509931.1 JP 2017018109-A/1986: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTTCGTATTT
>LV509929.1 JP 2017018109-A/1984: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGGAAAGCCAAT
>LV509927.1 JP 2017018109-A/1982: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCATGACCAC
>LV509925.1 JP 2017018109-A/1980: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATGACCACAT
>LV509923.1 JP 2017018109-A/1978: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCACATGGATGA
>LV509921.1 JP 2017018109-A/1976: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAAGCCAA
>LV509919.1 JP 2017018109-A/1974: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCGGAAAGCCA
>LV509917.1 JP 2017018109-A/1972: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTCACCATTC
>LV509915.1 JP 2017018109-A/1970: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACAGCCATGAA
>LV509913.1 JP 2017018109-A/1968: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGAGGTCAAA
>LV509911.1 JP 2017018109-A/1966: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTCTCACCATT
>LV509909.1 JP 2017018109-A/1964: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGACTGAGGTCA
>LV509907.1 JP 2017018109-A/1962: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATGAATCT
>LV509905.1 JP 2017018109-A/1960: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCTGGATGA
>LV509903.1 JP 2017018109-A/1958: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGAGGTCAAT
>LV509901.1 JP 2017018109-A/1956: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGGTCAATTAA
>LV509899.1 JP 2017018109-A/1954: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGAGGTCAATT
>LV509897.1 JP 2017018109-A/1952: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCAATTAAA
>LV509895.1 JP 2017018109-A/1950: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGAGGTCAATTA
>LV509893.1 JP 2017018109-A/1948: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCATGAATTAGA
>LV509126.1 JP 2017018109-A/1181: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAATAAATCTTA
>LV509124.1 JP 2017018109-A/1179: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGAATAAATCTA
>LV509122.1 JP 2017018109-A/1177: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGAATAAATCA
>LV509120.1 JP 2017018109-A/1175: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGAGTTCATCTA
>LV509118.1 JP 2017018109-A/1173: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGAGGCAGGCAA
>LV509116.1 JP 2017018109-A/1171: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGGCAGGCAAA
>LV509114.1 JP 2017018109-A/1169: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACCACTGTAA
>LV509112.1 JP 2017018109-A/1167: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCATTTTAA
>LV509110.1 JP 2017018109-A/1165: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTTACAGGAAA
>LV509108.1 JP 2017018109-A/1163: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGGCAAACTTA
>LV509106.1 JP 2017018109-A/1161: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGGAACAGCA
>LV509104.1 JP 2017018109-A/1159: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTCTCAGTTCA
>LV509102.1 JP 2017018109-A/1157: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGTCACTATA
>LV509100.1 JP 2017018109-A/1155: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGAGAAAGAAA
>LV509098.1 JP 2017018109-A/1153: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAAATAGAA
>LV509096.1 JP 2017018109-A/1151: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTCGTTGTTTCA
>LV509094.1 JP 2017018109-A/1149: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>LV509092.1 JP 2017018109-A/1147: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>LV509090.1 JP 2017018109-A/1145: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>LV509088.1 JP 2017018109-A/1143: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>LV509086.1 JP 2017018109-A/1141: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>LV509084.1 JP 2017018109-A/1139: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>LV509082.1 JP 2017018109-A/1137: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>LV509080.1 JP 2017018109-A/1135: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>LV509078.1 JP 2017018109-A/1133: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>LV509076.1 JP 2017018109-A/1131: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>LV509074.1 JP 2017018109-A/1129: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>LV509072.1 JP 2017018109-A/1127: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>LV509070.1 JP 2017018109-A/1125: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>LV509068.1 JP 2017018109-A/1123: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>LV509066.1 JP 2017018109-A/1121: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>LV509064.1 JP 2017018109-A/1119: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>LV509062.1 JP 2017018109-A/1117: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>LV509060.1 JP 2017018109-A/1115: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>LV509056.1 JP 2017018109-A/1111: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>LV509052.1 JP 2017018109-A/1107: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>LV509048.1 JP 2017018109-A/1103: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>LV509044.1 JP 2017018109-A/1099: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>LV509040.1 JP 2017018109-A/1095: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>LV509036.1 JP 2017018109-A/1091: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>LV509032.1 JP 2017018109-A/1087: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>LV509030.1 JP 2017018109-A/1085: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTGCTCTGCAA
>LV509028.1 JP 2017018109-A/1083: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGGCCTGTTAA
>LV509497.1 JP 2017018109-A/1552: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>LV509495.1 JP 2017018109-A/1550: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>LV509493.1 JP 2017018109-A/1548: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>LV509491.1 JP 2017018109-A/1546: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>LV509487.1 JP 2017018109-A/1542: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>LV509485.1 JP 2017018109-A/1540: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>LV509481.1 JP 2017018109-A/1536: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>LV509479.1 JP 2017018109-A/1534: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>LV509477.1 JP 2017018109-A/1532: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>LV509473.1 JP 2017018109-A/1528: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>LV509469.1 JP 2017018109-A/1524: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>LV509467.1 JP 2017018109-A/1522: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>LV509463.1 JP 2017018109-A/1518: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>LV509459.1 JP 2017018109-A/1514: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>LV509457.1 JP 2017018109-A/1512: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>LV509455.1 JP 2017018109-A/1510: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>LV509453.1 JP 2017018109-A/1508: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>LV509451.1 JP 2017018109-A/1506: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>LV509449.1 JP 2017018109-A/1504: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>LV509447.1 JP 2017018109-A/1502: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>LV509443.1 JP 2017018109-A/1498: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>LV509439.1 JP 2017018109-A/1494: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>LV509435.1 JP 2017018109-A/1490: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>LV509026.1 JP 2017018109-A/1081: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAACACACTGCA
>LV509024.1 JP 2017018109-A/1079: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACACACTGCAAA
>LV509022.1 JP 2017018109-A/1077: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTGAATAAAA
>LV509020.1 JP 2017018109-A/1075: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGGAAAATAAA
>LV509018.1 JP 2017018109-A/1073: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATGCAGCTAAA
>LV509016.1 JP 2017018109-A/1071: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATCACGGTGAA
>LV509014.1 JP 2017018109-A/1069: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAGTCTGAGAA
>LV509012.1 JP 2017018109-A/1067: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGTTAGTGTA
>LV509010.1 JP 2017018109-A/1065: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTTGTATGTAA
>LV509008.1 JP 2017018109-A/1063: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCTCGGTATA
>LV509006.1 JP 2017018109-A/1061: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGTGACAATGAA
>LV509002.1 JP 2017018109-A/1057: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGTTGATTAA
>LV509000.1 JP 2017018109-A/1055: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>LV508998.1 JP 2017018109-A/1053: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>LV508996.1 JP 2017018109-A/1051: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>LV508994.1 JP 2017018109-A/1049: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>LV508992.1 JP 2017018109-A/1047: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>LV508990.1 JP 2017018109-A/1045: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>LV508988.1 JP 2017018109-A/1043: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>LV508986.1 JP 2017018109-A/1041: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>LV508984.1 JP 2017018109-A/1039: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>LV508982.1 JP 2017018109-A/1037: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>LV508980.1 JP 2017018109-A/1035: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>LV508978.1 JP 2017018109-A/1033: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>LV508976.1 JP 2017018109-A/1031: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>LV508974.1 JP 2017018109-A/1029: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>LV508972.1 JP 2017018109-A/1027: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>LV508970.1 JP 2017018109-A/1025: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>LV508966.1 JP 2017018109-A/1021: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>LV508962.1 JP 2017018109-A/1017: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>LV508958.1 JP 2017018109-A/1013: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>LV508954.1 JP 2017018109-A/1009: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>LV508950.1 JP 2017018109-A/1005: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>LV508946.1 JP 2017018109-A/1001: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>LV508942.1 JP 2017018109-A/997: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>LV508938.1 JP 2017018109-A/993: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>LV508934.1 JP 2017018109-A/989: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>LV508338.1 JP 2017018109-A/393: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>LV508334.1 JP 2017018109-A/389: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>LV508332.1 JP 2017018109-A/387: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>LV508330.1 JP 2017018109-A/385: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>LV508328.1 JP 2017018109-A/383: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>LV508324.1 JP 2017018109-A/379: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>LV508322.1 JP 2017018109-A/377: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>LV508318.1 JP 2017018109-A/373: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>LV508316.1 JP 2017018109-A/371: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>LV508314.1 JP 2017018109-A/369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>LV508470.1 JP 2017018109-A/525: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGATTCAAGTCA
>LV508468.1 JP 2017018109-A/523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAAAACCAA
>LV508466.1 JP 2017018109-A/521: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAGCAAAGAA
>LV508464.1 JP 2017018109-A/519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGCAACA
>LV508462.1 JP 2017018109-A/517: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>LV508460.1 JP 2017018109-A/515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATCTATGACAA
>LV508458.1 JP 2017018109-A/513: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCAAAGATAA
>LV508456.1 JP 2017018109-A/511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCTACCAGAAA
>LV508454.1 JP 2017018109-A/509: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCTACCAGAA
>LV508452.1 JP 2017018109-A/507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAAGATAATGA
>LV508450.1 JP 2017018109-A/505: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAACTCTACCAGA
>LV508448.1 JP 2017018109-A/503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATATAGCAAA
>LV508444.1 JP 2017018109-A/499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCTATGACAAGA
>LV508442.1 JP 2017018109-A/497: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGTTCAAGCA
>LV508440.1 JP 2017018109-A/495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAACACATCAGA
>LV508438.1 JP 2017018109-A/493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAACGAAATCTA
>LV508436.1 JP 2017018109-A/491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGACTTCCGCAA
>LV508434.1 JP 2017018109-A/489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACGAAATCTATA
>LV508432.1 JP 2017018109-A/487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACACACAGCATA
>LV508430.1 JP 2017018109-A/485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAAGTTCAAA
>LV508428.1 JP 2017018109-A/483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGAGTACACAA
>LV508426.1 JP 2017018109-A/481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>LV508424.1 JP 2017018109-A/479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>LV508422.1 JP 2017018109-A/477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>LV508420.1 JP 2017018109-A/475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>LV508418.1 JP 2017018109-A/473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>LV508414.1 JP 2017018109-A/469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>LV508412.1 JP 2017018109-A/467: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>LV508408.1 JP 2017018109-A/463: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>LV508406.1 JP 2017018109-A/461: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>LV508404.1 JP 2017018109-A/459: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>LV508402.1 JP 2017018109-A/457: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>LV508398.1 JP 2017018109-A/453: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>LV508340.1 JP 2017018109-A/395: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>LV508344.1 JP 2017018109-A/399: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>LV508346.1 JP 2017018109-A/401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>LV508348.1 JP 2017018109-A/403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>LV508350.1 JP 2017018109-A/405: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>LV508352.1 JP 2017018109-A/407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>LV508356.1 JP 2017018109-A/411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>LV508358.1 JP 2017018109-A/413: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>LV508360.1 JP 2017018109-A/415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>LV508362.1 JP 2017018109-A/417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>LV508396.1 JP 2017018109-A/451: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>LV508392.1 JP 2017018109-A/447: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>LV508388.1 JP 2017018109-A/443: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>LV508386.1 JP 2017018109-A/441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>LV508384.1 JP 2017018109-A/439: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>LV508380.1 JP 2017018109-A/435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>LV508376.1 JP 2017018109-A/431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>LV508372.1 JP 2017018109-A/427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>LV508368.1 JP 2017018109-A/423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>LV508366.1 JP 2017018109-A/421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>LV508364.1 JP 2017018109-A/419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>LV508008.1 JP 2017018109-A/63: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>LV508006.1 JP 2017018109-A/61: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>LV508004.1 JP 2017018109-A/59: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>LV508002.1 JP 2017018109-A/57: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>LV508000.1 JP 2017018109-A/55: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>LV507998.1 JP 2017018109-A/53: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>LV507996.1 JP 2017018109-A/51: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>LV507994.1 JP 2017018109-A/49: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>LV507992.1 JP 2017018109-A/47: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>LV507990.1 JP 2017018109-A/45: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>LV507988.1 JP 2017018109-A/43: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>LV507986.1 JP 2017018109-A/41: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>LV507984.1 JP 2017018109-A/39: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>LV507982.1 JP 2017018109-A/37: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>LV507980.1 JP 2017018109-A/35: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>LV507978.1 JP 2017018109-A/33: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>LV507976.1 JP 2017018109-A/31: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>LV507974.1 JP 2017018109-A/29: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>LV507972.1 JP 2017018109-A/27: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>LV507970.1 JP 2017018109-A/25: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>LV507968.1 JP 2017018109-A/23: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>LV507966.1 JP 2017018109-A/21: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>LV507964.1 JP 2017018109-A/19: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>LV507962.1 JP 2017018109-A/17: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>LV507960.1 JP 2017018109-A/15: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>LV507958.1 JP 2017018109-A/13: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>LV507956.1 JP 2017018109-A/11: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>LV507954.1 JP 2017018109-A/9: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>LV507952.1 JP 2017018109-A/7: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>LV507950.1 JP 2017018109-A/5: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>LV507948.1 JP 2017018109-A/3: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>LV507946.1 JP 2017018109-A/1: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>LV501310.1 JP 2017006118-A/17: Vectors Conditionally Expressing Therapeutic Proteins, Host Comprising the Vectors, and Uses Thereof
AGGTCANAGGTCA
>KH354896.1 Sequence 27 from patent US 9487835
CTACATTGGATGG
>KH351065.1 Sequence 86 from patent US 9487784
GTTGTGGTCTCCC
>KH351059.1 Sequence 77 from patent US 9487784
GGGGCATCGTCGC
>KH351047.1 Sequence 65 from patent US 9487784
ACGTTGAGGGGCA
>KH329462.1 Sequence 2 from patent US 9487774
CAAATGAGCAGCC
>KH329461.1 Sequence 1 from patent US 9487774
TGATGACGAACGG
>KH329434.1 Sequence 13 from patent US 9487773
CAATGTCGGTACA
>KH329432.1 Sequence 9 from patent US 9487773
CAAAAATCGAGCT
>KH328768.1 Sequence 20 from patent US 9487767
TCATTGCAACTTG
>KH326573.1 Sequence 40 from patent US 9481907
CGGCGGGTGTGGA
>KH326551.1 Sequence 18 from patent US 9481907
GCCGTGGTGGTGA
>KH318033.1 Sequence 640 from patent US 9481875
CGGCGCCGTGCCG
>KH316037.1 Sequence 17 from patent US 9476101
TAAAATATATAAA
>KH315853.1 Sequence 727 from patent US 9476097
GGTTTATCTATCT
>KH315850.1 Sequence 723 from patent US 9476097
GTCAAGATATCTG
>KH307388.1 Sequence 30 from patent US 9475849
CGAGCCACCACCG
>KH307387.1 Sequence 29 from patent US 9475849
TGAGCCACCACCG
>KH307385.1 Sequence 27 from patent US 9475849
GAGGGTCGTCGCT
>KH306867.1 Sequence 9 from patent US 9475054
TCTCTCTCAACAA
>KH306727.1 Sequence 51 from patent US 9474798
GGGGGGAGCAAAA
>KH306696.1 Sequence 18 from patent US 9474798
TTTTGCTCCCCCC
>KH305912.1 Sequence 80 from patent US 9469857
GGCCNNNNNGGCC
>KH305909.1 Sequence 77 from patent US 9469857
GGCCNNNNNGGCC
>KH305894.1 Sequence 20 from patent US 9469857
GGCCNNNNNGGCC
>KH305879.1 Sequence 5 from patent US 9469857
GCAGCNNNNNNNN
>KH293365.1 Sequence 10125 from patent US 9469685
CTTTGGCTACTGG
>KH293324.1 Sequence 10084 from patent US 9469685
TTTGAATATCTGG
>KH293320.1 Sequence 10080 from patent US 9469685
ATTAGATACTATC
>KH293318.1 Sequence 10078 from patent US 9469685
TTTGGAGTGGTTA
>KH293304.1 Sequence 10064 from patent US 9469685
CTACAGAGACTAC
>KH293299.1 Sequence 10059 from patent US 9469685
ATTGCTATGGGGA
>KH293288.1 Sequence 10048 from patent US 9469685
TTTTTGGAGTGGT
>KH293281.1 Sequence 10041 from patent US 9469685
TGGCCGGGAGAGG
>KH293236.1 Sequence 9996 from patent US 9469685
CCGCTCGAGGGCG
>KH293191.1 Sequence 9951 from patent US 9469685
TGTGCAAAAGATA
>KH291787.1 Sequence 7627 from patent US 9469685
CTTTGACTACTGG
>KH291774.1 Sequence 7614 from patent US 9469685
CTTTGACTACTGG
>KH291759.1 Sequence 7599 from patent US 9469685
CTTTGACTACTGG
>KH291758.1 Sequence 7598 from patent US 9469685
CTTTGACTACTGG
>KH291749.1 Sequence 7589 from patent US 9469685
CATGGACGTCTGG
>KH291746.1 Sequence 7586 from patent US 9469685
CTTTGACTCCTGG
>KH291694.1 Sequence 7534 from patent US 9469685
CTTTGACTACTGG
>KH291633.1 Sequence 7473 from patent US 9469685
CTTTGACTCTTGG
>KH291622.1 Sequence 7462 from patent US 9469685
TTTTGATGTGTGG
>KH291620.1 Sequence 7460 from patent US 9469685
CTTTGACTACTGG
>KH291616.1 Sequence 7456 from patent US 9469685
CTTTGACTCCTGG
>KH291611.1 Sequence 7451 from patent US 9469685
GTGGGGGGATCAA
>KH291610.1 Sequence 7450 from patent US 9469685
CCTATAAAGGTTG
>KH291608.1 Sequence 7448 from patent US 9469685
GATTTTTCGCAGA
>KH291602.1 Sequence 7442 from patent US 9469685
CCCCGTCCCCCGC
>KH291601.1 Sequence 7441 from patent US 9469685
TCTTCCCTACAAG
>KH291592.1 Sequence 7432 from patent US 9469685
GATTTTTCGCAGC
>KH291570.1 Sequence 7410 from patent US 9469685
GACACGGGGGAGG
>KH291564.1 Sequence 7404 from patent US 9469685
CGGGTCCCTCAGG
>KH291555.1 Sequence 7395 from patent US 9469685
TTCGGCTGTCCAC
>KH291516.1 Sequence 7356 from patent US 9469685
GAGTATAGCAGCT
>KH291505.1 Sequence 7345 from patent US 9469685
TAGCAGCAGCTGG
>KH291495.1 Sequence 7335 from patent US 9469685
AGTGGGAGCTACT
>KH291489.1 Sequence 7329 from patent US 9469685
GGGGTGATACGCT
>KH291481.1 Sequence 7321 from patent US 9469685
CATATTGTAGAGG
>KH291479.1 Sequence 7319 from patent US 9469685
GTATAGTTTTGTT
>KH291475.1 Sequence 7315 from patent US 9469685
TAGTCTTTATTAC
>KH291473.1 Sequence 7313 from patent US 9469685
TGAGTACGGTGAC
>KH291469.1 Sequence 7309 from patent US 9469685
TGAATACGGCGAC
>KH291466.1 Sequence 7306 from patent US 9469685
TAGCAGTGGCTGG
>KH291424.1 Sequence 7264 from patent US 9469685
TATGGCCCGAGCC
>KH291405.1 Sequence 7245 from patent US 9469685
AGAGATGCCTACA
>KH291403.1 Sequence 7243 from patent US 9469685
GGGGGGTATGGTT
>KH291401.1 Sequence 7241 from patent US 9469685
GGGAGGGCTATGC
>KH291399.1 Sequence 7239 from patent US 9469685
GGGAGGGCTATGC
>KH291393.1 Sequence 7233 from patent US 9469685
GTGGTCCTAGGTG
>KH291372.1 Sequence 7212 from patent US 9469685
TGGGTGATGTTGT
>KH291369.1 Sequence 7209 from patent US 9469685
GATCCCGACCAAC
>KH291366.1 Sequence 7206 from patent US 9469685
GATCCCGACCAAC
>KH291364.1 Sequence 7204 from patent US 9469685
GATCCCGACCAAC
>KH291360.1 Sequence 7200 from patent US 9469685
GATCCCGACCAAC
>KH291359.1 Sequence 7199 from patent US 9469685
GATCCCGACCAAC
>KH291349.1 Sequence 7189 from patent US 9469685
GTTGTTGGCCCAT
>KH291347.1 Sequence 7187 from patent US 9469685
CACCCCTCGTATC
>KH291334.1 Sequence 7174 from patent US 9469685
AGGGGTCCCGCTA
>KH291330.1 Sequence 7170 from patent US 9469685
AATCAACGTTCCT
>KH291316.1 Sequence 7156 from patent US 9469685
GAGACTCTCCTAA
>KH291203.1 Sequence 7043 from patent US 9469685
TTGTATCCCGTTC
>KH291148.1 Sequence 6988 from patent US 9469685
CGTGGATGGGGGA
>KH291033.1 Sequence 6873 from patent US 9469685
TGTGTAAAACATA
>KH291031.1 Sequence 6871 from patent US 9469685
TGTGTAAAACATA
>KH291028.1 Sequence 6868 from patent US 9469685
TGTGTAAAAGATA
>KH288773.1 Sequence 2199 from patent US 9469685
CTTCGACCACTGG
>KH288765.1 Sequence 2191 from patent US 9469685
CTTTGACTACTGG
>KH288748.1 Sequence 2174 from patent US 9469685
TTTTAATATCTGG
>KH288739.1 Sequence 2165 from patent US 9469685
TTTTGATATTTGG
>KH288725.1 Sequence 2151 from patent US 9469685
CTTTGACTACTGG
>KH288714.1 Sequence 2140 from patent US 9469685
CCCCTACTTGGCC
>KH288710.1 Sequence 2136 from patent US 9469685
TAACTCCTTCTCA
>KH288681.1 Sequence 2107 from patent US 9469685
GGATAGTGAACTA
>KH288674.1 Sequence 2100 from patent US 9469685
GTGGTCCTAGGTG
>KH288668.1 Sequence 2094 from patent US 9469685
TGGGTCCAGTTAC
>KH288667.1 Sequence 2093 from patent US 9469685
ATTACAGCGCTTC
>KH288617.1 Sequence 2043 from patent US 9469685
GCGGAATAGAGTA
>KH287666.1 Sequence 45 from patent US 9469685
ATTAGATACTATC
>KH285823.1 Sequence 330 from patent US 9464330
CCTTCCAGCGGCT
>KH285808.1 Sequence 315 from patent US 9464330
CCTCACCAATTAC
>KH285597.1 Sequence 104 from patent US 9464330
CCTTCCAGCGGCT
>KH285155.1 Sequence 16 from patent US 9464320
CATGCAAAGAGAC
>KH280821.1 Sequence 2 from patent US 9463228
GCCGCCACCATGG
>KH280623.1 Sequence 8 from patent US 9463200
AAAAAAAAAAAAA
>KH280622.1 Sequence 7 from patent US 9463200
AAAAAAAAAAAAA
>KH280621.1 Sequence 6 from patent US 9463200
CAAAGAACACCAG
>KH280620.1 Sequence 5 from patent US 9463200
CAAAGAACACCAG
>KH278799.1 Sequence 346 from patent US 9458504
CGTCACGGCGGAG
>KH278780.1 Sequence 327 from patent US 9458504
TGCGCCAATGCAT
>KH278728.1 Sequence 275 from patent US 9458504
CACCGCCGGTATG
>KH278720.1 Sequence 267 from patent US 9458504
CGGCGGCGGAGAG
>KH278616.1 Sequence 163 from patent US 9458504
CCGTCCGCGGTGT
>KH278386.1 Sequence 6 from patent US 9458502
GTCGTACGGCTAA
>KH272546.1 Sequence 143 from patent US 9458205
TGATACTGACTGT
>KH272346.1 Sequence 20 from patent US 9457076
ACTTACTGAGACG
>KH199716.1 Sequence 31 from patent US 9447465
ACGGTGGACGCGT
>KH199700.1 Sequence 15 from patent US 9447465
AGGTCGCATCGCG
>KH199688.1 Sequence 3 from patent US 9447465
AGGTACGTTCGCT
>KH187156.1 Sequence 788 from patent US 9447413
TGCTGCATCTCTG
>KH185036.1 Sequence 788 from patent US 9447412
TGCTGCATCTCTG
>KH183127.1 Sequence 286 from patent US 9447387
GCCGCCRCCATGG
>KH181591.1 Sequence 17 from patent US 9446097
AGGTGAAATTTAA
>KH181590.1 Sequence 16 from patent US 9446097
AGATAAAAGGACA
>KH181589.1 Sequence 15 from patent US 9446097
AGGTGAAAGGGCA
>KH181588.1 Sequence 14 from patent US 9446097
AGGCGAAAGGACC
>KH181587.1 Sequence 13 from patent US 9446097
AGGTGAAAGGCTA
>KH181586.1 Sequence 12 from patent US 9446097
AGGTGAAAGGACA
>KH181585.1 Sequence 11 from patent US 9446097
AGGTGAAAGGACA
>KH181584.1 Sequence 10 from patent US 9446097
AGGTCAAAGGTCA
>KH174176.1 Sequence 12 from patent US 9441232
GCCGCCRCCATGG
>KH173216.1 Sequence 58 from patent US 9441221
GCCAGGTAAGTAT
>KH173214.1 Sequence 56 from patent US 9441221
GCCAGGTAAGTAT
>KH173191.1 Sequence 33 from patent US 9441221
GCCAGGTAAGTAT
>KH172099.1 Sequence 5820 from patent US 9441016
ACACATTTTTTAA
>KH171963.1 Sequence 5678 from patent US 9441016
TATCGGTGATAAC
>KH171953.1 Sequence 5668 from patent US 9441016
AAAATAAAAATTG
>KH171951.1 Sequence 5666 from patent US 9441016
AAGAGGTGAGCAA
>KH171950.1 Sequence 5665 from patent US 9441016
TTAAAAAACTATT
>KH171938.1 Sequence 5653 from patent US 9441016
AAAAGGATTTAGT
>KH171934.1 Sequence 5649 from patent US 9441016
AATAAATAAAGGA
>KH171874.1 Sequence 5587 from patent US 9441016
TAATATCAAACTC
>KH171447.1 Sequence 5135 from patent US 9441016
ATTAAAAAAAAAG
>KH171246.1 Sequence 4926 from patent US 9441016
TTTAAAAATAGAT
>KH171211.1 Sequence 4887 from patent US 9441016
ATAACTCCTCCTT
>KH170975.1 Sequence 4645 from patent US 9441016
ATAAACACTTCCT
>KH170903.1 Sequence 4569 from patent US 9441016
AAAAAACATCCCC
>KH170890.1 Sequence 4555 from patent US 9441016
ATAATCACATATC
>KH170882.1 Sequence 4547 from patent US 9441016
AAGTCAGTTAATA
>KH170805.1 Sequence 4466 from patent US 9441016
ATTTATTCTATCC
>KH170562.1 Sequence 4218 from patent US 9441016
ATTGGTTAGATAT
>KH170518.1 Sequence 4173 from patent US 9441016
GTATGGTGATTAA
>KH170465.1 Sequence 4119 from patent US 9441016
AGTAAAGGATCTG
>KH170342.1 Sequence 3987 from patent US 9441016
CGGATTTTTTAAA
>KH170278.1 Sequence 3920 from patent US 9441016
TTAAATAACCTTC
>KH170189.1 Sequence 3825 from patent US 9441016
AAGGTAGAATATT
>KH170078.1 Sequence 3710 from patent US 9441016
TTTTTTTATTTTT
>KH169968.1 Sequence 3596 from patent US 9441016
AGCTCGTTCCGCT
>KH169960.1 Sequence 3586 from patent US 9441016
TTTGGTGATATAT
>KH169901.1 Sequence 3524 from patent US 9441016
TTTTTAATTACGG
>KH169831.1 Sequence 3445 from patent US 9441016
TTTCTTTTTTTTC
>KH169796.1 Sequence 3405 from patent US 9441016
ATGATTTTTGAAA
>KH169697.1 Sequence 3301 from patent US 9441016
TTTAATTTTAAGT
>KH169518.1 Sequence 3115 from patent US 9441016
TTAATAAAAAATA
>KH169018.1 Sequence 2615 from patent US 9441016
GGATTTTTAATCC
>KH168988.1 Sequence 2585 from patent US 9441016
CTCCTTAAAGGAG
>KH168959.1 Sequence 2556 from patent US 9441016
GTTAAAATTTAAC
>KH168933.1 Sequence 2530 from patent US 9441016
GATTAAAATAATC
>KH168918.1 Sequence 2515 from patent US 9441016
GAGATTTAATCTC
>KH168837.1 Sequence 2434 from patent US 9441016
GTATTTTAGATAC
>KH168818.1 Sequence 2415 from patent US 9441016
TGCATTTAATGCA
>KH168817.1 Sequence 2414 from patent US 9441016
TGCATTTAATGCA
>KH168374.1 Sequence 1971 from patent US 9441016
TTAGTTTAACTAA
>KH168335.1 Sequence 1932 from patent US 9441016
GCTACATTGTAGC
>KH168312.1 Sequence 1909 from patent US 9441016
CAGAACTCTTCTG
>KH168308.1 Sequence 1905 from patent US 9441016
TTATTATAAATAA
>KH168132.1 Sequence 1729 from patent US 9441016
GTAAGCAACTTAC
>KH168122.1 Sequence 1719 from patent US 9441016
GATGATTTTCATC
>KH166132.1 Sequence 2 from patent US 9439956
GCCGCCACCATGG
>KH152387.1 Sequence 8 from patent US 9434981
TTTTTTTTTTTTT
>KH151233.1 Sequence 215 from patent US 9434966
AAWNRTAAAYARG
>KH151210.1 Sequence 192 from patent US 9434966
TTCTTKTYYTTTT
>KH151182.1 Sequence 164 from patent US 9434966
GRTGYAYGGRTGY
>KH151119.1 Sequence 101 from patent US 9434966
RMACCCANNCAYY
>KH151115.1 Sequence 97 from patent US 9434966
GAANNTTCNNGAA
>KH150960.1 Sequence 9 from patent US 9434958
AGCTTGGCCAAAT
>KH122753.1 Sequence 24 from patent US 9434776
CATCTGCTACTCG
>KH122456.1 Sequence 14 from patent US 9433943
TGTAGCTAAGCCT
>KH122455.1 Sequence 13 from patent US 9433943
AGGCTTAGCTACA
>KH121943.1 Sequence 2 from patent US 9433670
GCCGCCACCATGG
>KH121939.1 Sequence 2 from patent US 9433669
GCCGCCACCATGG
>LV500214.1 JP 2016535604-A/5505: OPTIMAL MAIZE LOCI
TTCACGTCATGCT
>LV488716.1 JP 2016535603-A/7069: OPTIMAL SOYBEAN LOCI
AAAGTGTCATGCC
>LV488715.1 JP 2016535603-A/7068: OPTIMAL SOYBEAN LOCI
GGAGAAACAACTG
>LF953912.1 JP 2016534116-A/109: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TACTGACTGTATG
>LF953906.1 JP 2016534116-A/103: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953846.1 JP 2016534116-A/43: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATTCAGTCAGTA
>LF953845.1 JP 2016534116-A/42: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
GATACAGTCAGTA
>LF953844.1 JP 2016534116-A/41: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTAAGTA
>LF953843.1 JP 2016534116-A/40: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACTATCAGTA
>LF953842.1 JP 2016534116-A/39: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CACACATTCAGTA
>LF953841.1 JP 2016534116-A/38: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
GATACAGTAAGTA
>LF953840.1 JP 2016534116-A/37: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953839.1 JP 2016534116-A/36: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953838.1 JP 2016534116-A/35: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953837.1 JP 2016534116-A/34: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCGGTA
>LF953836.1 JP 2016534116-A/33: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATTCAGTCAGTA
>LF953835.1 JP 2016534116-A/32: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
GATACAGTCAGTA
>LF953834.1 JP 2016534116-A/31: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTAAGTA
>LF953833.1 JP 2016534116-A/30: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953832.1 JP 2016534116-A/29: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953831.1 JP 2016534116-A/28: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953830.1 JP 2016534116-A/27: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
CATACAGTCAGTA
>LF953829.1 JP 2016534116-A/26: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGT
>LF953828.1 JP 2016534116-A/25: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATAACACCTGC
>LF953827.1 JP 2016534116-A/24: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGT
>LF953826.1 JP 2016534116-A/23: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953825.1 JP 2016534116-A/22: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953824.1 JP 2016534116-A/21: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953823.1 JP 2016534116-A/20: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTGCACCCGC
>LF953822.1 JP 2016534116-A/19: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTATACCTAC
>LF953821.1 JP 2016534116-A/18: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATAACACCTGT
>LF953820.1 JP 2016534116-A/17: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953819.1 JP 2016534116-A/16: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953818.1 JP 2016534116-A/15: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953817.1 JP 2016534116-A/14: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF953816.1 JP 2016534116-A/13: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCCGC
>LF953815.1 JP 2016534116-A/12: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATAACACCTGC
>LF953814.1 JP 2016534116-A/11: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGT
>LF953813.1 JP 2016534116-A/10: ENGINEERED TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) DOMAINS AND USES THEREOF
TCATTACACCTGC
>LF952968.1 JP 2016534094-A/114: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952965.1 JP 2016534094-A/111: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952926.1 JP 2016534094-A/72: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952897.1 JP 2016534094-A/43: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952884.1 JP 2016534094-A/30: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952881.1 JP 2016534094-A/27: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952860.1 JP 2016534094-A/6: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952857.1 JP 2016534094-A/3: SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
TGCTGGATGGGAA
>LF952547.1 WO 2016208773-A/17: oligonucleotide derivative
NTAGCACTGGCCT
>LF952546.1 WO 2016208773-A/16: oligonucleotide derivative
NNAGCACNGGCCT
>LF952545.1 WO 2016208773-A/15: oligonucleotide derivative
TTAGCACTGGCCT
>LF952544.1 WO 2016208773-A/14: oligonucleotide derivative
NNAGCACTGGCCT
>LV472904.1 JP 2016535987-A/56: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
AGTTTGGCCAGCC
>LV472903.1 JP 2016535987-A/55: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
AGTTTGGCCAGCC
>LV472901.1 JP 2016535987-A/53: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
TTTTGGGCTGGCC
>LV472900.1 JP 2016535987-A/52: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
TTTTGGGCTGGCC
>LF947890.1 JP 2016211882-A/3: Method for treating electrode surface of microelectrode, method for making surface-treated microelectrode and surface-treated microelectrode
ACGAGCTAACTTT
>LF947357.1 JP 2016202037-A/2: Method for Nucleic Acid Detection
GCTACATCAACGA
>LF947131.1 JP 2016198027-A/22: A method for diagnosis of ovarian cancer
CTGATTCAGGAAG
>LF947130.1 JP 2016198027-A/21: A method for diagnosis of ovarian cancer
CTGATTGAGGAAG
>LV500093.1 JP 2016535604-A/5384: OPTIMAL MAIZE LOCI
AGCTTCAATAGTA
>LV500000.1 JP 2016535604-A/5291: OPTIMAL MAIZE LOCI
TGCATGCGCAGTA
>LV494261.1 JP 2016534759-A/5384: OPTIMAL MAIZE LOCI
AGCTTCAATAGTA
>LV494168.1 JP 2016534759-A/5291: OPTIMAL MAIZE LOCI
TGCATGCGCAGTA
>LV481108.1 JP 2016534729-A/7069: OPTIMAL SOYBEAN LOCI
AAAGTGTCATGCC
>LV481107.1 JP 2016534729-A/7068: OPTIMAL SOYBEAN LOCI
GGAGAAACAACTG
>LV473897.1 JP 2016534727-A/5: A UNIVERSAL DONOR SYSTEM FOR GENE TARGETING
TGCATGCGCAGTA
>LV472878.1 JP 2016535987-A/30: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
TCATCACGCAGCT
>LV472877.1 JP 2016535987-A/29: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
CATCACGCAGCTC
>LV472876.1 JP 2016535987-A/28: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
CATCACGCAGCTC
>LV472871.1 JP 2016535987-A/23: SYNTHESIS AND ENRICHMENT OF NUCLEIC ACID SEQUENCES
AGGTTAAAGGTCT
>LV468323.1 JP 2016533759-A/5: RAPID TARGETING ANALYSIS IN CROPS FOR DETERMINING DONOR INSERTION
TGCATGCGCAGTA
>LV494382.1 JP 2016534759-A/5505: OPTIMAL MAIZE LOCI
TTCACGTCATGCT
>HL998353.1 Sequence 3 from patent US 9453257
CGTGGAGGCGTGN
>HL998167.1 Sequence 34 from patent US 9453240
GGTAGTAGTTATT
>HL998164.1 Sequence 31 from patent US 9453240
CCATCATCAATAA
>HL998158.1 Sequence 25 from patent US 9453240
CCATCATCAATAA
>HL996619.1 Sequence 31 from patent US 9453224
GTGTGAATGAATG
>HL996615.1 Sequence 27 from patent US 9453224
TACTCTGAATGTT
>HL996595.1 Sequence 7 from patent US 9453224
GTTAATGTGTTCT
>HL996591.1 Sequence 3 from patent US 9453224
TTGCCCTTGCTCA
>HL996495.1 Sequence 5 from patent US 9453221
GCCCAAGCTGGCA
>HL995092.1 Sequence 118 from patent US 9453054
TACACCCTTTTTT
>HL995091.1 Sequence 117 from patent US 9453054
TACACCCGGGGGG
>HL995090.1 Sequence 116 from patent US 9453054
TACACCCCCCCCC
>HL995089.1 Sequence 115 from patent US 9453054
TACACCCAAAAAA
>HL995088.1 Sequence 114 from patent US 9453054
TTGTATATAACTT
>HL995041.1 Sequence 63 from patent US 9453054
TACACCCNNNCAT
>HL995031.1 Sequence 53 from patent US 9453054
GACACCCAAACAT
>HL995030.1 Sequence 52 from patent US 9453054
CACACCCAAACAT
>HL995029.1 Sequence 51 from patent US 9453054
AACACCCAAACAT
>HL994982.1 Sequence 4 from patent US 9453054
TACACCCAAACAT
>HL994448.1 Sequence 5 from patent US 9452219
TGGTGGTGGTGGT
>LF855362.1 JP 2015130885-A/86: Compositions of asymmetric interfering RNA and uses thereof
CTGATATTGATGG
>LF851594.1 JP 2015119735-A/12: Recombinant influenza viruses for vaccines and gene therapy
AAAACGAGGGGGG
>LF851593.1 JP 2015119735-A/11: Recombinant influenza viruses for vaccines and gene therapy
TTTTGCTCCCCCC
>LF942578.1 JP 2016532451-A/67: Composition and Vaccine for Treating Prostate Cancer
GCCGCCACCATGG
>LF941344.1 JP 2016531569-A/215: NUCLEASE PROFILING SYSTEM
ACATATCACAGGG
>LF941320.1 JP 2016531569-A/191: NUCLEASE PROFILING SYSTEM
ACTCCTCAGCCGG
>LF939115.1 WO 2016181897-A/5: Dried reagents for enzymatic reaction and its preparative methods
GTTCGCGCCAGTG
>LF939114.1 WO 2016181897-A/4: Dried reagents for enzymatic reaction and its preparative methods
AAACCGTCCTGCC
>LF938056.1 JP 2016193913-A/1422: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF938055.1 JP 2016193913-A/1421: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGGAAGTCTA
>LF938051.1 JP 2016193913-A/1417: RNA INTERFERENCE IN OCULAR INDICATIONS
TATTGCTCTGCAA
>LF938049.1 JP 2016193913-A/1415: RNA INTERFERENCE IN OCULAR INDICATIONS
CGGTGACAATGAA
>LF938047.1 JP 2016193913-A/1413: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGTATATA
>LF938037.1 JP 2016193913-A/1403: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF938035.1 JP 2016193913-A/1401: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF938033.1 JP 2016193913-A/1399: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF938031.1 JP 2016193913-A/1397: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCGGATCAAACA
>LF938017.1 JP 2016193913-A/1383: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>LF938016.1 JP 2016193913-A/1382: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>LF938015.1 JP 2016193913-A/1381: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>LF938013.1 JP 2016193913-A/1379: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>LF938009.1 JP 2016193913-A/1375: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTAGCTTATCA
>LF938007.1 JP 2016193913-A/1373: RNA INTERFERENCE IN OCULAR INDICATIONS
TCACTAGCTTATA
>LF938005.1 JP 2016193913-A/1371: RNA INTERFERENCE IN OCULAR INDICATIONS
ATCTTTTGCTCTA
>LF938003.1 JP 2016193913-A/1369: RNA INTERFERENCE IN OCULAR INDICATIONS
TATCTTTTGCTCA
>LF938001.1 JP 2016193913-A/1367: RNA INTERFERENCE IN OCULAR INDICATIONS
AACCACTAGTTCA
>LF937999.1 JP 2016193913-A/1365: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAACCACTAGTA
>LF937997.1 JP 2016193913-A/1363: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAAAGACAGAA
>LF937995.1 JP 2016193913-A/1361: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGACTGCTGTGA
>LF937993.1 JP 2016193913-A/1359: RNA INTERFERENCE IN OCULAR INDICATIONS
GGATTCGCCATTA
>LF937991.1 JP 2016193913-A/1357: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCGGATCAAACA
>LF937989.1 JP 2016193913-A/1355: RNA INTERFERENCE IN OCULAR INDICATIONS
GATTATGCGGATA
>LF937987.1 JP 2016193913-A/1353: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCAGATTATGCA
>LF937985.1 JP 2016193913-A/1351: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAACAGTCCTA
>LF937983.1 JP 2016193913-A/1349: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCTACTGTTTAA
>LF937981.1 JP 2016193913-A/1347: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTGGTGCTACTA
>LF937979.1 JP 2016193913-A/1345: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCTCTCCTTTTA
>LF937977.1 JP 2016193913-A/1343: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTCTCTCCTTTA
>LF937975.1 JP 2016193913-A/1341: RNA INTERFERENCE IN OCULAR INDICATIONS
AATCTCTCTCCTA
>LF937973.1 JP 2016193913-A/1339: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATAAGGTTTCA
>LF937971.1 JP 2016193913-A/1337: RNA INTERFERENCE IN OCULAR INDICATIONS
ACACTCAGCTCTA
>LF937969.1 JP 2016193913-A/1335: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAAAGAGAAAGA
>LF937967.1 JP 2016193913-A/1333: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAAAAGAGAAAA
>LF937965.1 JP 2016193913-A/1331: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGAAAAGAGAAA
>LF937963.1 JP 2016193913-A/1329: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAAACCACTAA
>LF937961.1 JP 2016193913-A/1327: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTATTGGTGTA
>LF937959.1 JP 2016193913-A/1325: RNA INTERFERENCE IN OCULAR INDICATIONS
TTAATCCAGAAAA
>LF937957.1 JP 2016193913-A/1323: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCCTTAATCCAA
>LF937955.1 JP 2016193913-A/1321: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGTCCTTAATCA
>LF937953.1 JP 2016193913-A/1319: RNA INTERFERENCE IN OCULAR INDICATIONS
GAACAGTCCTTAA
>LF937951.1 JP 2016193913-A/1317: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>LF937949.1 JP 2016193913-A/1315: RNA INTERFERENCE IN OCULAR INDICATIONS
GATGAGCTTCCTA
>LF937947.1 JP 2016193913-A/1313: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937945.1 JP 2016193913-A/1311: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937943.1 JP 2016193913-A/1309: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937941.1 JP 2016193913-A/1307: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937939.1 JP 2016193913-A/1305: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937938.1 JP 2016193913-A/1304: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937937.1 JP 2016193913-A/1303: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937935.1 JP 2016193913-A/1301: RNA INTERFERENCE IN OCULAR INDICATIONS
AGATTCAAGTCAA
>LF937933.1 JP 2016193913-A/1299: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937931.1 JP 2016193913-A/1297: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937929.1 JP 2016193913-A/1295: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937927.1 JP 2016193913-A/1293: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937925.1 JP 2016193913-A/1291: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937923.1 JP 2016193913-A/1289: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937921.1 JP 2016193913-A/1287: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937919.1 JP 2016193913-A/1285: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937917.1 JP 2016193913-A/1283: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGATTCAAGTCA
>LF937915.1 JP 2016193913-A/1281: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGACAAAACCAA
>LF937913.1 JP 2016193913-A/1279: RNA INTERFERENCE IN OCULAR INDICATIONS
TGACAGCAAAGAA
>LF937911.1 JP 2016193913-A/1277: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGGAGCAACA
>LF937909.1 JP 2016193913-A/1275: RNA INTERFERENCE IN OCULAR INDICATIONS
AGATTCAAGTCAA
>LF937907.1 JP 2016193913-A/1273: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATCTATGACAA
>LF937905.1 JP 2016193913-A/1271: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAGCAAAGATAA
>LF937903.1 JP 2016193913-A/1269: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTCTACCAGAAA
>LF937901.1 JP 2016193913-A/1267: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTCTACCAGAA
>LF937899.1 JP 2016193913-A/1265: RNA INTERFERENCE IN OCULAR INDICATIONS
GCAAAGATAATGA
>LF937897.1 JP 2016193913-A/1263: RNA INTERFERENCE IN OCULAR INDICATIONS
GAACTCTACCAGA
>LF937895.1 JP 2016193913-A/1261: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAATATAGCAAA
>LF937893.1 JP 2016193913-A/1259: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>LF937891.1 JP 2016193913-A/1257: RNA INTERFERENCE IN OCULAR INDICATIONS
AATCTATGACAAA
>LF937889.1 JP 2016193913-A/1255: RNA INTERFERENCE IN OCULAR INDICATIONS
CAAGCAGAGTACA
>LF937887.1 JP 2016193913-A/1253: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTTCAAGCAGA
>LF937885.1 JP 2016193913-A/1251: RNA INTERFERENCE IN OCULAR INDICATIONS
TATGACAAGTTCA
>LF937883.1 JP 2016193913-A/1249: RNA INTERFERENCE IN OCULAR INDICATIONS
CAACGAAATCTAA
>LF937881.1 JP 2016193913-A/1247: RNA INTERFERENCE IN OCULAR INDICATIONS
CTATGACAAGTTA
>LF937879.1 JP 2016193913-A/1245: RNA INTERFERENCE IN OCULAR INDICATIONS
TTAAAGATGGAGA
>LF937877.1 JP 2016193913-A/1243: RNA INTERFERENCE IN OCULAR INDICATIONS
GACAAGTTCAAGA
>LF937875.1 JP 2016193913-A/1241: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATATGTTCTTA
>LF937873.1 JP 2016193913-A/1239: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAGAGTACACA
>LF937871.1 JP 2016193913-A/1237: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCAACACATCAA
>LF937869.1 JP 2016193913-A/1235: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCAGAGTACAA
>LF937867.1 JP 2016193913-A/1233: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAGTACACACAA
>LF937865.1 JP 2016193913-A/1231: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCATATATATGA
>LF937863.1 JP 2016193913-A/1229: RNA INTERFERENCE IN OCULAR INDICATIONS
TCAAGCAGAGTAA
>LF937861.1 JP 2016193913-A/1227: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCATATATATA
>LF937859.1 JP 2016193913-A/1225: RNA INTERFERENCE IN OCULAR INDICATIONS
ACACACAGCATAA
>LF937857.1 JP 2016193913-A/1223: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAGTACACACA
>LF937855.1 JP 2016193913-A/1221: RNA INTERFERENCE IN OCULAR INDICATIONS
CAAGTTCAAGCAA
>LF937851.1 JP 2016193913-A/1217: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTGCTTCAGCTA
>LF937849.1 JP 2016193913-A/1215: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAGCATATATAA
>LF937845.1 JP 2016193913-A/1211: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCTTCAGCTCA
>LF937843.1 JP 2016193913-A/1209: RNA INTERFERENCE IN OCULAR INDICATIONS
CATATATATGTTA
>LF937841.1 JP 2016193913-A/1207: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCAACAATTCA
>LF937839.1 JP 2016193913-A/1205: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCATATATATGA
>LF937835.1 JP 2016193913-A/1201: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTACATTGACTA
>LF937833.1 JP 2016193913-A/1199: RNA INTERFERENCE IN OCULAR INDICATIONS
GCATATATATGTA
>LF937829.1 JP 2016193913-A/1195: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTATTGCTTCA
>LF937825.1 JP 2016193913-A/1191: RNA INTERFERENCE IN OCULAR INDICATIONS
GTACATTGACTTA
>LF937823.1 JP 2016193913-A/1189: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCATATATATA
>LF937821.1 JP 2016193913-A/1187: RNA INTERFERENCE IN OCULAR INDICATIONS
CACAGCATATATA
>LF937819.1 JP 2016193913-A/1185: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTCCACGGAGAA
>LF937817.1 JP 2016193913-A/1183: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTGCAAGACTA
>LF937815.1 JP 2016193913-A/1181: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTATCGACATG
>LF937813.1 JP 2016193913-A/1179: RNA INTERFERENCE IN OCULAR INDICATIONS
GCATCGAGGCCAT
>LF937811.1 JP 2016193913-A/1177: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCGGAAGCGCAT
>LF937809.1 JP 2016193913-A/1175: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAACATGATCGT
>LF937807.1 JP 2016193913-A/1173: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCAAGGTCCTG
>LF937805.1 JP 2016193913-A/1171: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATGATCGTGCG
>LF937803.1 JP 2016193913-A/1169: RNA INTERFERENCE IN OCULAR INDICATIONS
AACATGATCGTGC
>LF937801.1 JP 2016193913-A/1167: RNA INTERFERENCE IN OCULAR INDICATIONS
TACAGCAAGGTCC
>LF937799.1 JP 2016193913-A/1165: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTGGATCCACGA
>LF937797.1 JP 2016193913-A/1163: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATTCCTGGCGA
>LF937795.1 JP 2016193913-A/1161: RNA INTERFERENCE IN OCULAR INDICATIONS
TGATCGTGCGCTC
>LF937793.1 JP 2016193913-A/1159: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTAATGGTGGAA
>LF937791.1 JP 2016193913-A/1157: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937789.1 JP 2016193913-A/1155: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937787.1 JP 2016193913-A/1153: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937785.1 JP 2016193913-A/1151: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937783.1 JP 2016193913-A/1149: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937781.1 JP 2016193913-A/1147: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937779.1 JP 2016193913-A/1145: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937777.1 JP 2016193913-A/1143: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937775.1 JP 2016193913-A/1141: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937773.1 JP 2016193913-A/1139: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937771.1 JP 2016193913-A/1137: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937769.1 JP 2016193913-A/1135: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937767.1 JP 2016193913-A/1133: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937765.1 JP 2016193913-A/1131: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937755.1 JP 2016193913-A/1121: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTCTACATTTCA
>LF937753.1 JP 2016193913-A/1119: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTGCCTAAGGAA
>LF937751.1 JP 2016193913-A/1117: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGACAACGATGA
>LF937749.1 JP 2016193913-A/1115: RNA INTERFERENCE IN OCULAR INDICATIONS
CGACAACAACAAA
>LF937747.1 JP 2016193913-A/1113: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTCAAACGAGA
>LF937745.1 JP 2016193913-A/1111: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>LF937743.1 JP 2016193913-A/1109: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTCAGTTTAGA
>LF937741.1 JP 2016193913-A/1107: RNA INTERFERENCE IN OCULAR INDICATIONS
GTAAACCAGTGAA
>LF937739.1 JP 2016193913-A/1105: RNA INTERFERENCE IN OCULAR INDICATIONS
CGACGACAACGAA
>LF937737.1 JP 2016193913-A/1103: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATGACCGAGAA
>LF937735.1 JP 2016193913-A/1101: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTCAAACGAGCA
>LF937733.1 JP 2016193913-A/1099: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAGAAACTCATA
>LF937731.1 JP 2016193913-A/1097: RNA INTERFERENCE IN OCULAR INDICATIONS
GTATTGCTATGCA
>LF937729.1 JP 2016193913-A/1095: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAAACTCATGA
>LF937727.1 JP 2016193913-A/1093: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGCTTGTAACAA
>LF937725.1 JP 2016193913-A/1091: RNA INTERFERENCE IN OCULAR INDICATIONS
GACAACAACAACA
>LF937721.1 JP 2016193913-A/1087: RNA INTERFERENCE IN OCULAR INDICATIONS
ATAAAACAGGTGA
>LF937717.1 JP 2016193913-A/1083: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCACTACAAAA
>LF937713.1 JP 2016193913-A/1079: RNA INTERFERENCE IN OCULAR INDICATIONS
GAATTTATTAGTA
>LF937709.1 JP 2016193913-A/1075: RNA INTERFERENCE IN OCULAR INDICATIONS
CTTGCACTACAAA
>LF937705.1 JP 2016193913-A/1071: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATACTTTGCCA
>LF937701.1 JP 2016193913-A/1067: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTGTTCTGTTA
>LF937697.1 JP 2016193913-A/1063: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGGCTTAAGGAA
>LF937693.1 JP 2016193913-A/1059: RNA INTERFERENCE IN OCULAR INDICATIONS
ATCAGTGTTAAAA
>LF937689.1 JP 2016193913-A/1055: RNA INTERFERENCE IN OCULAR INDICATIONS
TATTTATTGTGTA
>LF937687.1 JP 2016193913-A/1053: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGCCAAGGAGGT
>LF937685.1 JP 2016193913-A/1051: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCCACTAGGAA
>LF937683.1 JP 2016193913-A/1049: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTGATCAGAAA
>LF937681.1 JP 2016193913-A/1047: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTCCACTAGGA
>LF937679.1 JP 2016193913-A/1045: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTCCACATATA
>LF937677.1 JP 2016193913-A/1043: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCCTGCTAATGT
>LF937675.1 JP 2016193913-A/1041: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGGTGATCAGAA
>LF937673.1 JP 2016193913-A/1039: RNA INTERFERENCE IN OCULAR INDICATIONS
CGCCAAGGAGGTT
>LF937671.1 JP 2016193913-A/1037: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTCCATCTACAA
>LF937669.1 JP 2016193913-A/1035: RNA INTERFERENCE IN OCULAR INDICATIONS
TCCATCTACAACA
>LF937667.1 JP 2016193913-A/1033: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTCCATCTACA
>LF937665.1 JP 2016193913-A/1031: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAAGGAGGTTTA
>LF937663.1 JP 2016193913-A/1029: RNA INTERFERENCE IN OCULAR INDICATIONS
GACAGGAACCTGG
>LF937661.1 JP 2016193913-A/1027: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCTCTCCTTCGA
>LF937659.1 JP 2016193913-A/1025: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937657.1 JP 2016193913-A/1023: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937655.1 JP 2016193913-A/1021: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937653.1 JP 2016193913-A/1019: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937651.1 JP 2016193913-A/1017: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937649.1 JP 2016193913-A/1015: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937647.1 JP 2016193913-A/1013: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937645.1 JP 2016193913-A/1011: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937643.1 JP 2016193913-A/1009: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937641.1 JP 2016193913-A/1007: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937639.1 JP 2016193913-A/1005: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937637.1 JP 2016193913-A/1003: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937635.1 JP 2016193913-A/1001: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937633.1 JP 2016193913-A/999: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937631.1 JP 2016193913-A/997: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937629.1 JP 2016193913-A/995: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937627.1 JP 2016193913-A/993: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937625.1 JP 2016193913-A/991: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937623.1 JP 2016193913-A/989: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937621.1 JP 2016193913-A/987: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937595.1 JP 2016193913-A/961: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937593.1 JP 2016193913-A/959: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937591.1 JP 2016193913-A/957: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937589.1 JP 2016193913-A/955: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937587.1 JP 2016193913-A/953: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937585.1 JP 2016193913-A/951: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937583.1 JP 2016193913-A/949: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937581.1 JP 2016193913-A/947: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937579.1 JP 2016193913-A/945: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937577.1 JP 2016193913-A/943: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937575.1 JP 2016193913-A/941: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937573.1 JP 2016193913-A/939: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937571.1 JP 2016193913-A/937: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937569.1 JP 2016193913-A/935: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937567.1 JP 2016193913-A/933: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937565.1 JP 2016193913-A/931: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937563.1 JP 2016193913-A/929: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937561.1 JP 2016193913-A/927: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937559.1 JP 2016193913-A/925: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937557.1 JP 2016193913-A/923: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937555.1 JP 2016193913-A/921: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937553.1 JP 2016193913-A/919: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937521.1 JP 2016193913-A/887: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937519.1 JP 2016193913-A/885: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937517.1 JP 2016193913-A/883: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937515.1 JP 2016193913-A/881: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937513.1 JP 2016193913-A/879: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937511.1 JP 2016193913-A/877: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937509.1 JP 2016193913-A/875: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937507.1 JP 2016193913-A/873: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937505.1 JP 2016193913-A/871: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937503.1 JP 2016193913-A/869: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937501.1 JP 2016193913-A/867: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937499.1 JP 2016193913-A/865: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937497.1 JP 2016193913-A/863: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937495.1 JP 2016193913-A/861: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937493.1 JP 2016193913-A/859: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>LF937491.1 JP 2016193913-A/857: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>LF937489.1 JP 2016193913-A/855: RNA INTERFERENCE IN OCULAR INDICATIONS
GACCAAAAGTTAA
>LF937487.1 JP 2016193913-A/853: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>LF937483.1 JP 2016193913-A/849: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTGACCAAAAGA
>LF937481.1 JP 2016193913-A/847: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGTGACCAAAAA
>LF937477.1 JP 2016193913-A/843: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTGTGACCAAAA
>LF937475.1 JP 2016193913-A/841: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAGAGTGTGACA
>LF937473.1 JP 2016193913-A/839: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAGCTTTCTGA
>LF937469.1 JP 2016193913-A/835: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCACCTTTCTAA
>LF937465.1 JP 2016193913-A/831: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTGAGAGTGTA
>LF937463.1 JP 2016193913-A/829: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGTTTATTTGTA
>LF937459.1 JP 2016193913-A/825: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAAGCCAGATTA
>LF937455.1 JP 2016193913-A/821: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTGCCTGTAACA
>LF937453.1 JP 2016193913-A/819: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTCGATTAGAA
>LF937451.1 JP 2016193913-A/817: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGATTCGAAA
>LF937449.1 JP 2016193913-A/815: RNA INTERFERENCE IN OCULAR INDICATIONS
CATTCTGATTCGA
>LF937447.1 JP 2016193913-A/813: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAGAAGGAAAA
>LF937445.1 JP 2016193913-A/811: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTGAGAAGGAA
>LF937443.1 JP 2016193913-A/809: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAAGTGTAATTA
>LF937439.1 JP 2016193913-A/805: RNA INTERFERENCE IN OCULAR INDICATIONS
GATAGCATCTTAA
>LF937435.1 JP 2016193913-A/801: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAAGAATGTTAA
>LF937431.1 JP 2016193913-A/797: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATTAACTCATA
>LF937429.1 JP 2016193913-A/795: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAGCTGACCTGG
>LF937427.1 JP 2016193913-A/793: RNA INTERFERENCE IN OCULAR INDICATIONS
TATCAAGTTTGAG
>LF937425.1 JP 2016193913-A/791: RNA INTERFERENCE IN OCULAR INDICATIONS
CCGCAAGATCGGC
>LF937423.1 JP 2016193913-A/789: RNA INTERFERENCE IN OCULAR INDICATIONS
AGACACGTTTGGC
>LF937421.1 JP 2016193913-A/787: RNA INTERFERENCE IN OCULAR INDICATIONS
CTAAATTCTGTGG
>LF937419.1 JP 2016193913-A/785: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTAAATTCTGTG
>LF937417.1 JP 2016193913-A/783: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGACTTCGGC
>LF937415.1 JP 2016193913-A/781: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTGCGAAGCTG
>LF937413.1 JP 2016193913-A/779: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCGAAGCTGACC
>LF937411.1 JP 2016193913-A/777: RNA INTERFERENCE IN OCULAR INDICATIONS
TACGGAGACATGG
>LF937409.1 JP 2016193913-A/775: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTGTTCCAAGAC
>LF937407.1 JP 2016193913-A/773: RNA INTERFERENCE IN OCULAR INDICATIONS
GTACCAGTGCACG
>LF937405.1 JP 2016193913-A/771: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATGACAACGCC
>LF937403.1 JP 2016193913-A/769: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCGAAGCTGAC
>LF937401.1 JP 2016193913-A/767: RNA INTERFERENCE IN OCULAR INDICATIONS
CGAAGCTGACCTG
>LF937399.1 JP 2016193913-A/765: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTCCAAGACCT
>LF937397.1 JP 2016193913-A/763: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTATCAAGTTTG
>LF937395.1 JP 2016193913-A/761: RNA INTERFERENCE IN OCULAR INDICATIONS
CCGACTGGAAGAC
>LF937393.1 JP 2016193913-A/759: RNA INTERFERENCE IN OCULAR INDICATIONS
CTTGCGAAGCTGA
>LF937391.1 JP 2016193913-A/757: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCCTTGCGAAGC
>LF937389.1 JP 2016193913-A/755: RNA INTERFERENCE IN OCULAR INDICATIONS
CGAGGTCATGAAG
>LF937387.1 JP 2016193913-A/753: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGACACGTTTGG
>LF937385.1 JP 2016193913-A/751: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGCTAAATTCTG
>LF937383.1 JP 2016193913-A/749: RNA INTERFERENCE IN OCULAR INDICATIONS
GGTCAGGCCTTGC
>LF937381.1 JP 2016193913-A/747: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTAGAGAAGCAG
>LF937379.1 JP 2016193913-A/745: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGAGTATGTACC
>LF937377.1 JP 2016193913-A/743: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCAGAACTGCAG
>LF937375.1 JP 2016193913-A/741: RNA INTERFERENCE IN OCULAR INDICATIONS
TCAAGTTTGAGCT
>LF937373.1 JP 2016193913-A/739: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTCAGGCCTTG
>LF937371.1 JP 2016193913-A/737: RNA INTERFERENCE IN OCULAR INDICATIONS
TGACTTCGGCTCC
>LF937369.1 JP 2016193913-A/735: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACTTCGGCTC
>LF937367.1 JP 2016193913-A/733: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAAGATGTACGG
>LF937365.1 JP 2016193913-A/731: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGAAGCTGACCT
>LF937363.1 JP 2016193913-A/729: RNA INTERFERENCE IN OCULAR INDICATIONS
TCAGGCCTTGCGA
>LF937361.1 JP 2016193913-A/727: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGGAGACATGGC
>LF937359.1 JP 2016193913-A/725: RNA INTERFERENCE IN OCULAR INDICATIONS
GACACGTTTGGCC
>LF937357.1 JP 2016193913-A/723: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCGAGGTCATGA
>LF937355.1 JP 2016193913-A/721: RNA INTERFERENCE IN OCULAR INDICATIONS
AATGACAACGCCT
>LF937353.1 JP 2016193913-A/719: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGATGTACGGAG
>LF937351.1 JP 2016193913-A/717: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGAAGACACGTT
>LF937349.1 JP 2016193913-A/715: RNA INTERFERENCE IN OCULAR INDICATIONS
TAAATTCTGTGGA
>LF937347.1 JP 2016193913-A/713: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGGTCATGAAGA
>LF937345.1 JP 2016193913-A/711: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGACAACGCCTC
>LF937343.1 JP 2016193913-A/709: RNA INTERFERENCE IN OCULAR INDICATIONS
CGGAGACATGGCA
>LF937341.1 JP 2016193913-A/707: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTGTGGAGTATG
>LF937339.1 JP 2016193913-A/705: RNA INTERFERENCE IN OCULAR INDICATIONS
CGAGCTAAATTCT
>LF937337.1 JP 2016193913-A/703: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGGCCTTGCGAA
>LF937335.1 JP 2016193913-A/701: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCGCAAGATCGG
>LF937333.1 JP 2016193913-A/699: RNA INTERFERENCE IN OCULAR INDICATIONS
TACCGACTGGAAG
>LF937331.1 JP 2016193913-A/697: RNA INTERFERENCE IN OCULAR INDICATIONS
AGGCCTTGCGAAG
>LF937329.1 JP 2016193913-A/695: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAGACACGTTTG
>LF937327.1 JP 2016193913-A/693: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGGTCAGGCCTT
>LF937325.1 JP 2016193913-A/691: RNA INTERFERENCE IN OCULAR INDICATIONS
GGTCATGAAGAAG
>LF937323.1 JP 2016193913-A/689: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCTGACCTGGA
>LF937321.1 JP 2016193913-A/687: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTGAAGTGTAA
>LF937319.1 JP 2016193913-A/685: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTTGTTCCTTAA
>LF937317.1 JP 2016193913-A/683: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAGAAAGGTTA
>LF937315.1 JP 2016193913-A/681: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATACCGAGCTA
>LF937313.1 JP 2016193913-A/679: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTTGAGAGTGT
>LF937311.1 JP 2016193913-A/677: RNA INTERFERENCE IN OCULAR INDICATIONS
ATACCGAGCTAAA
>LF937309.1 JP 2016193913-A/675: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGGCCTTTATTA
>LF937307.1 JP 2016193913-A/673: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTGGACAGCTT
>LF937305.1 JP 2016193913-A/671: RNA INTERFERENCE IN OCULAR INDICATIONS
TATACGAGTAATA
>LF937303.1 JP 2016193913-A/669: RNA INTERFERENCE IN OCULAR INDICATIONS
TTATCTAAGTTAA
>LF937301.1 JP 2016193913-A/667: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGCTCAGATA
>LF937299.1 JP 2016193913-A/665: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCTGATCAGTTT
>LF937297.1 JP 2016193913-A/663: RNA INTERFERENCE IN OCULAR INDICATIONS
AGGTAGAATGTAA
>LF937295.1 JP 2016193913-A/661: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCTAAATTCTGT
>LF937293.1 JP 2016193913-A/659: RNA INTERFERENCE IN OCULAR INDICATIONS
CTATCAAGTTTGA
>LF937291.1 JP 2016193913-A/657: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAAGACACGTTT
>LF937289.1 JP 2016193913-A/655: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTACCAGTGCAC
>LF937287.1 JP 2016193913-A/653: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATGACATCTTT
>LF937285.1 JP 2016193913-A/651: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTCAGTAGCACA
>LF937283.1 JP 2016193913-A/649: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATTCTGTGGAG
>LF937281.1 JP 2016193913-A/647: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGGAGTATGT
>LF937279.1 JP 2016193913-A/645: RNA INTERFERENCE IN OCULAR INDICATIONS
CAAGTTTGAGCTT
>LF937277.1 JP 2016193913-A/643: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCCTATCAAGTT
>LF937275.1 JP 2016193913-A/641: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTACGGAGACAT
>LF937273.1 JP 2016193913-A/639: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTCTGTGGAGT
>LF937271.1 JP 2016193913-A/637: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCTATCAAGTTT
>LF937269.1 JP 2016193913-A/635: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTGCGAGGAGTG
>LF937267.1 JP 2016193913-A/633: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCTTGCGAAGCT
>LF937265.1 JP 2016193913-A/631: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGTACGGAGACA
>LF937263.1 JP 2016193913-A/629: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCGACTGGAAGA
>LF937261.1 JP 2016193913-A/627: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAGTGGAGCGCC
>LF937259.1 JP 2016193913-A/625: RNA INTERFERENCE IN OCULAR INDICATIONS
CATTACAACTGTC
>LF937257.1 JP 2016193913-A/623: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTACAACTGTCC
>LF937255.1 JP 2016193913-A/621: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGCCATTACAAC
>LF937253.1 JP 2016193913-A/619: RNA INTERFERENCE IN OCULAR INDICATIONS
CCATTACAACTGT
>LF937251.1 JP 2016193913-A/617: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTGGTCCAGACC
>LF937249.1 JP 2016193913-A/615: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAGTGGAGCGC
>LF937247.1 JP 2016193913-A/613: RNA INTERFERENCE IN OCULAR INDICATIONS
AGACCTGTGCCTG
>LF937245.1 JP 2016193913-A/611: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTGCCTGGTCC
>LF937243.1 JP 2016193913-A/609: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTGGAAGACACG
>LF937241.1 JP 2016193913-A/607: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCCATTACAACT
>LF937239.1 JP 2016193913-A/605: RNA INTERFERENCE IN OCULAR INDICATIONS
GTTTGAGCTTTCT
>LF937237.1 JP 2016193913-A/603: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGAGCGCCTGTT
>LF937235.1 JP 2016193913-A/601: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTGGAGCGCCTG
>LF937233.1 JP 2016193913-A/599: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGCTTTCTGGCT
>LF937231.1 JP 2016193913-A/597: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCATTACAACTG
>LF937229.1 JP 2016193913-A/595: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAGCGCCTGTTC
>LF937227.1 JP 2016193913-A/593: RNA INTERFERENCE IN OCULAR INDICATIONS
CGACTGGAAGACA
>LF937225.1 JP 2016193913-A/591: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGTGGAGCGCCT
>LF937223.1 JP 2016193913-A/589: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAGGAAGATGTA
>LF937221.1 JP 2016193913-A/587: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937219.1 JP 2016193913-A/585: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937217.1 JP 2016193913-A/583: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937215.1 JP 2016193913-A/581: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937183.1 JP 2016193913-A/549: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937181.1 JP 2016193913-A/547: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937179.1 JP 2016193913-A/545: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937177.1 JP 2016193913-A/543: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937175.1 JP 2016193913-A/541: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937171.1 JP 2016193913-A/537: RNA INTERFERENCE IN OCULAR INDICATIONS
CATCTGCAATAAA
>LF937167.1 JP 2016193913-A/533: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTGATTGACAA
>LF937163.1 JP 2016193913-A/529: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATTTGATTGAA
>LF937159.1 JP 2016193913-A/525: RNA INTERFERENCE IN OCULAR INDICATIONS
TCACATTTGATTA
>LF937157.1 JP 2016193913-A/523: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGAAGAAAGTTA
>LF937155.1 JP 2016193913-A/521: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAGTCTAATGAA
>LF937153.1 JP 2016193913-A/519: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCAGTATAAGTA
>LF937151.1 JP 2016193913-A/517: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGCAACACTTGA
>LF937149.1 JP 2016193913-A/515: RNA INTERFERENCE IN OCULAR INDICATIONS
TACTGATAGGAGA
>LF937147.1 JP 2016193913-A/513: RNA INTERFERENCE IN OCULAR INDICATIONS
TCCAGATCACATA
>LF937143.1 JP 2016193913-A/509: RNA INTERFERENCE IN OCULAR INDICATIONS
ATCACATTTGATA
>LF937141.1 JP 2016193913-A/507: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTTCATGTCTA
>LF937139.1 JP 2016193913-A/505: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCTTTTAATGAA
>LF937137.1 JP 2016193913-A/503: RNA INTERFERENCE IN OCULAR INDICATIONS
GACCAGTATAAGA
>LF937135.1 JP 2016193913-A/501: RNA INTERFERENCE IN OCULAR INDICATIONS
AATACCAGTCTTA
>LF937131.1 JP 2016193913-A/497: RNA INTERFERENCE IN OCULAR INDICATIONS
CCACCAACTTACA
>LF937129.1 JP 2016193913-A/495: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTCCAAACACA
>LF937127.1 JP 2016193913-A/493: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTCCAAACAAA
>LF937125.1 JP 2016193913-A/491: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTCCAAACACAA
>LF937123.1 JP 2016193913-A/489: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTCCTTCGAAA
>LF937121.1 JP 2016193913-A/487: RNA INTERFERENCE IN OCULAR INDICATIONS
GTTGACATCCAGA
>LF937119.1 JP 2016193913-A/485: RNA INTERFERENCE IN OCULAR INDICATIONS
AACCTCTCCTATA
>LF937115.1 JP 2016193913-A/481: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>LF937113.1 JP 2016193913-A/479: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCCTATTATACA
>LF937109.1 JP 2016193913-A/475: RNA INTERFERENCE IN OCULAR INDICATIONS
TCCACCAACTTAA
>LF937107.1 JP 2016193913-A/473: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTCTCCTATTA
>LF937105.1 JP 2016193913-A/471: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAAACTGCTCAA
>LF937103.1 JP 2016193913-A/469: RNA INTERFERENCE IN OCULAR INDICATIONS
CATTTGATTGACA
>LF937101.1 JP 2016193913-A/467: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATACCAGTCTT
>LF937099.1 JP 2016193913-A/465: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTGCCTCAATT
>LF937097.1 JP 2016193913-A/463: RNA INTERFERENCE IN OCULAR INDICATIONS
CACATTTGATTGA
>LF937087.1 JP 2016193913-A/453: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCTGATTCTGGA
>LF937085.1 JP 2016193913-A/451: RNA INTERFERENCE IN OCULAR INDICATIONS
GAATTGCAGTGAA
>LF937083.1 JP 2016193913-A/449: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTGAAATTTCA
>LF937081.1 JP 2016193913-A/447: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAAAGAGAACAA
>LF937079.1 JP 2016193913-A/445: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCAGTGATTTGA
>LF937077.1 JP 2016193913-A/443: RNA INTERFERENCE IN OCULAR INDICATIONS
AATGAAAGAGAAA
>LF937075.1 JP 2016193913-A/441: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTCCAGTTGTA
>LF937073.1 JP 2016193913-A/439: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTCACTTTGCA
>LF937071.1 JP 2016193913-A/437: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCACTTTGCATA
>LF937069.1 JP 2016193913-A/435: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTGCATTTAGTA
>LF937067.1 JP 2016193913-A/433: RNA INTERFERENCE IN OCULAR INDICATIONS
CTTTGCATTTAGA
>LF937065.1 JP 2016193913-A/431: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAAGAGAACATA
>LF937063.1 JP 2016193913-A/429: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTTTCTCAGTTA
>LF937061.1 JP 2016193913-A/427: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTTTCTCAGTA
>LF937059.1 JP 2016193913-A/425: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTAGTCAAAAA
>LF937057.1 JP 2016193913-A/423: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTTTGCATTTAA
>LF937055.1 JP 2016193913-A/421: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCATTTAGTCA
>LF937053.1 JP 2016193913-A/419: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTCTCAGTTTAA
>LF937049.1 JP 2016193913-A/415: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCTTTTGCCTA
>LF937045.1 JP 2016193913-A/411: RNA INTERFERENCE IN OCULAR INDICATIONS
GATTTGCTTTTGA
>LF937041.1 JP 2016193913-A/407: RNA INTERFERENCE IN OCULAR INDICATIONS
CACAGCCATGAAA
>LF937037.1 JP 2016193913-A/403: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTTCGTATTTA
>LF937033.1 JP 2016193913-A/399: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGATTTGCTTTA
>LF937029.1 JP 2016193913-A/395: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTGCTTTTGCA
>LF937025.1 JP 2016193913-A/391: RNA INTERFERENCE IN OCULAR INDICATIONS
GATGAATCTGATA
>LF937023.1 JP 2016193913-A/389: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTGCCAGCAAC
>LF937021.1 JP 2016193913-A/387: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTCGAACGACT
>LF937019.1 JP 2016193913-A/385: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAGCAATTAATA
>LF937017.1 JP 2016193913-A/383: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCCAGCAATTAA
>LF937015.1 JP 2016193913-A/381: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAGTCTGGAAA
>LF937013.1 JP 2016193913-A/379: RNA INTERFERENCE IN OCULAR INDICATIONS
AATGTGTATCTAT
>LF937011.1 JP 2016193913-A/377: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCAGCCGTGAAT
>LF937009.1 JP 2016193913-A/375: RNA INTERFERENCE IN OCULAR INDICATIONS
GATGTGATTGATA
>LF937007.1 JP 2016193913-A/373: RNA INTERFERENCE IN OCULAR INDICATIONS
GACCAGAGTGCTG
>LF937005.1 JP 2016193913-A/371: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTTTATGGACT
>LF937003.1 JP 2016193913-A/369: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGGTCACTGATT
>LF937001.1 JP 2016193913-A/367: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAACGAAAGCCA
>LF936999.1 JP 2016193913-A/365: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCATGAGAATTG
>LF936997.1 JP 2016193913-A/363: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTCAATTGCTTA
>LF936995.1 JP 2016193913-A/361: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTCCACAGCCA
>LF936993.1 JP 2016193913-A/359: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAGCATTCCGAT
>LF936991.1 JP 2016193913-A/357: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGTGCTGAAACC
>LF936989.1 JP 2016193913-A/355: RNA INTERFERENCE IN OCULAR INDICATIONS
AAACAGGCTGATT
>LF936987.1 JP 2016193913-A/353: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTACCATGAGAA
>LF936985.1 JP 2016193913-A/351: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCAGCCGTGAA
>LF936983.1 JP 2016193913-A/349: RNA INTERFERENCE IN OCULAR INDICATIONS
ATAGTCAGGAACT
>LF936981.1 JP 2016193913-A/347: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCCAATGATGA
>LF936979.1 JP 2016193913-A/345: RNA INTERFERENCE IN OCULAR INDICATIONS
TAGTGTGGTTTAT
>LF936977.1 JP 2016193913-A/343: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGACTCTGATGA
>LF936975.1 JP 2016193913-A/341: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAATTAATAAA
>LF936973.1 JP 2016193913-A/339: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCAATTGCTTAT
>LF936971.1 JP 2016193913-A/337: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTATCACTGTA
>LF936969.1 JP 2016193913-A/335: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATTCTATAGAA
>LF936967.1 JP 2016193913-A/333: RNA INTERFERENCE IN OCULAR INDICATIONS
ATAACTAATGTGT
>LF936965.1 JP 2016193913-A/331: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCCGATGTGATT
>LF936963.1 JP 2016193913-A/329: RNA INTERFERENCE IN OCULAR INDICATIONS
TATAAGCGGAAAG
>LF936961.1 JP 2016193913-A/327: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCAGCTGGATG
>LF936959.1 JP 2016193913-A/325: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTTGAATGGTGC
>LF936957.1 JP 2016193913-A/323: RNA INTERFERENCE IN OCULAR INDICATIONS
CACCTCACACATG
>LF936955.1 JP 2016193913-A/321: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCAGCAACCGAA
>LF936953.1 JP 2016193913-A/319: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATGAATAGAAA
>LF936951.1 JP 2016193913-A/317: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAAATAACTAAT
>LF936949.1 JP 2016193913-A/315: RNA INTERFERENCE IN OCULAR INDICATIONS
GGTTGAATGTGTA
>LF936947.1 JP 2016193913-A/313: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTGGTTGAATGT
>LF936945.1 JP 2016193913-A/311: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCCATGAATTT
>LF936943.1 JP 2016193913-A/309: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAGAGTGCTGAA
>LF936941.1 JP 2016193913-A/307: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGAAACGAGTCA
>LF936939.1 JP 2016193913-A/305: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTGCATACAAG
>LF936937.1 JP 2016193913-A/303: RNA INTERFERENCE IN OCULAR INDICATIONS
TTAGATAGTGCAT
>LF936935.1 JP 2016193913-A/301: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAATGAGCATT
>LF936933.1 JP 2016193913-A/299: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTTTCGCAGAC
>LF936931.1 JP 2016193913-A/297: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCCAACGAAAG
>LF936929.1 JP 2016193913-A/295: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTTTGTGGCTTC
>LF936927.1 JP 2016193913-A/293: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCTGGAAATAA
>LF936925.1 JP 2016193913-A/291: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCCGTGAATTC
>LF936923.1 JP 2016193913-A/289: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGACGAGGACAT
>LF936921.1 JP 2016193913-A/287: RNA INTERFERENCE IN OCULAR INDICATIONS
TAGACACATATGA
>LF936919.1 JP 2016193913-A/285: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCTGATGAGTCT
>LF936917.1 JP 2016193913-A/283: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCATTTAGTCAA
>LF936915.1 JP 2016193913-A/281: RNA INTERFERENCE IN OCULAR INDICATIONS
TAGTCAGGAACTT
>LF936913.1 JP 2016193913-A/279: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCATTCCGATGT
>LF936911.1 JP 2016193913-A/277: RNA INTERFERENCE IN OCULAR INDICATIONS
GCATTTAGTCAAA
>LF936909.1 JP 2016193913-A/275: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAGTCCAGATT
>LF936907.1 JP 2016193913-A/273: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATGATGGCCGA
>LF936905.1 JP 2016193913-A/271: RNA INTERFERENCE IN OCULAR INDICATIONS
GAATGGTGCATAC
>LF936903.1 JP 2016193913-A/269: RNA INTERFERENCE IN OCULAR INDICATIONS
CCGACCAAGGAAA
>LF936901.1 JP 2016193913-A/267: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTCATTCTATA
>LF936899.1 JP 2016193913-A/265: RNA INTERFERENCE IN OCULAR INDICATIONS
TACCAGTTAAACA
>LF936897.1 JP 2016193913-A/263: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATAAGCGGAAA
>LF936895.1 JP 2016193913-A/261: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGTCCAGATTAT
>LF936893.1 JP 2016193913-A/259: RNA INTERFERENCE IN OCULAR INDICATIONS
TTATGAAACGAGT
>LF936891.1 JP 2016193913-A/257: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTTGAATGTGT
>LF936889.1 JP 2016193913-A/255: RNA INTERFERENCE IN OCULAR INDICATIONS
GCAGTCCAGATTA
>LF936887.1 JP 2016193913-A/253: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATGGAAAGCGA
>LF936885.1 JP 2016193913-A/251: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTCCAGCAATT
>LF936883.1 JP 2016193913-A/249: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTATAGAAGAA
>LF936881.1 JP 2016193913-A/247: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGTGTATCTATT
>LF936879.1 JP 2016193913-A/245: RNA INTERFERENCE IN OCULAR INDICATIONS
AGATAGTGCATCT
>LF936877.1 JP 2016193913-A/243: RNA INTERFERENCE IN OCULAR INDICATIONS
TGATTGATAGTCA
>LF936875.1 JP 2016193913-A/241: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGAGGAGTTGAA
>LF936873.1 JP 2016193913-A/239: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGATGAGAGCAA
>LF936871.1 JP 2016193913-A/237: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTCCAACGAAA
>LF936869.1 JP 2016193913-A/235: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCTCATGAATAG
>LF936867.1 JP 2016193913-A/233: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTCTCATGAAT
>LF936865.1 JP 2016193913-A/231: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGCCTTCTGATT
>LF936863.1 JP 2016193913-A/229: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAATTTCGTATT
>LF936861.1 JP 2016193913-A/227: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATGGATGATAT
>LF936859.1 JP 2016193913-A/225: RNA INTERFERENCE IN OCULAR INDICATIONS
AAAGCCATGACCA
>LF936857.1 JP 2016193913-A/223: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTCGTATTTCT
>LF936855.1 JP 2016193913-A/221: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATTTCGTATTT
>LF936853.1 JP 2016193913-A/219: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGGAAAGCCAAT
>LF936851.1 JP 2016193913-A/217: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCCATGACCAC
>LF936849.1 JP 2016193913-A/215: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCATGACCACAT
>LF936847.1 JP 2016193913-A/213: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCACATGGATGA
>LF936845.1 JP 2016193913-A/211: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCGGAAAGCCAA
>LF936843.1 JP 2016193913-A/209: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCGGAAAGCCA
>LF936841.1 JP 2016193913-A/207: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCTCACCATTC
>LF936839.1 JP 2016193913-A/205: RNA INTERFERENCE IN OCULAR INDICATIONS
TCACAGCCATGAA
>LF936837.1 JP 2016193913-A/203: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTGAGGTCAAA
>LF936835.1 JP 2016193913-A/201: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGTCTCACCATT
>LF936833.1 JP 2016193913-A/199: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGACTGAGGTCA
>LF936831.1 JP 2016193913-A/197: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGATGAATCT
>LF936829.1 JP 2016193913-A/195: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCAGCTGGATGA
>LF936827.1 JP 2016193913-A/193: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGAGGTCAAT
>LF936825.1 JP 2016193913-A/191: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAGGTCAATTAA
>LF936823.1 JP 2016193913-A/189: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTGAGGTCAATT
>LF936821.1 JP 2016193913-A/187: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGGTCAATTAAA
>LF936819.1 JP 2016193913-A/185: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGAGGTCAATTA
>LF936817.1 JP 2016193913-A/183: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCATGAATTAGA
>LF936032.1 JP 2016189774-A/25: Brassica plant comprising a mutant INDEHISCENT allele
CGAGCCACCACCG
>LF936031.1 JP 2016189774-A/24: Brassica plant comprising a mutant INDEHISCENT allele
TGAGCCACCACCG
>LF936029.1 JP 2016189774-A/22: Brassica plant comprising a mutant INDEHISCENT allele
GAGGGTCGTCGCT
>LF935690.1 JP 2016192939-A/1: A probe for detecting CYP2C19*2 and a probe for detecting CYP2C19*3
TTTCCCRGGAACC
>LF935654.1 JP 2016192918-A/6: A nucleic acid molecule for suppressing activity of pre-miRNA or shRNA
CCTCCGAAGGAGG
>LF935074.1 JP 2016192940-A/5: A probe for detecting CYP3A4*1b and a probe for detecting CYP3A5*3
CTTTCARTATCTC
>LF935071.1 JP 2016192940-A/2: A probe for detecting CYP3A4*1b and a probe for detecting CYP3A5*3
AGGGCARGAGAGA
>LF935013.1 JP 2016189726-A/22: Primers and methods for detecting Streptococcus uberis
TTACCTGGGAAGG
>LF935005.1 JP 2016189726-A/14: Primers and methods for detecting Streptococcus uberis
AGGTAATTCTTCT
>LF934995.1 JP 2016189726-A/4: Primers and methods for detecting Streptococcus uberis
ACAGCCTCGTATT
>LF934984.1 JP 2016189715-A/6: Primers and methods for detecting Klebsiella pneumoniae
GTTCGCGCCAGTG
>LF934983.1 JP 2016189715-A/5: Primers and methods for detecting Klebsiella pneumoniae
AAACCGTCCTGCC
>LF934218.1 JP 2015077145-A/73147: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
TGCTGGCCGTCCA
>LF934209.1 JP 2015077145-A/73138: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
CGCGCGCTAACCA
>LF934208.1 JP 2015077145-A/73137: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
CGCGCGCTAACCG
>LF933725.1 JP 2015077145-A/72654: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
GCTGGGCCGTCTG
>LF933722.1 JP 2015077145-A/72651: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
GCGCGTCTTCCCC
>LF933606.1 JP 2015077145-A/72535: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
GGGTGCAGAACCC
>LF933605.1 JP 2015077145-A/72534: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
GGGTGCAGAACCT
>LF933522.1 JP 2015077145-A/72451: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
AGCCCTGCGCACC
>LF933459.1 JP 2015077145-A/72388: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
CGCCCCTCCCGCA
>LF933458.1 JP 2015077145-A/72387: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
CGCCCCTCCCGCT
>LF933444.1 JP 2015077145-A/72373: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
CCCAGTGGGTCCC
>LF933443.1 JP 2015077145-A/72372: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
CCCAGTGGGTCCT
>LF933384.1 JP 2015077145-A/72313: GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
GCATTGCCGTCCC
>HL993274.1 Sequence 22 from patent US 9428807
GATCTAAGCATCT
>HL993239.1 Sequence 9 from patent US 9428799
GTCGCAACATGAA
>HL993238.1 Sequence 8 from patent US 9428799
GTCGAAACATGAA
>HL991818.1 Sequence 130 from patent US 9428767
CCCTAGAAAGATA
>HL991815.1 Sequence 127 from patent US 9428767
CCCAGATTAGCCT
>HL991298.1 Sequence 9 from patent US 9428759
TCACACAGGAAAG
>HL981817.1 Sequence 64 from patent US 9428749
TTTGTTCGTCTTA
>HL981816.1 Sequence 63 from patent US 9428749
TTTGTTCGTCTTA
>HL981815.1 Sequence 62 from patent US 9428749
TTTGTTCGTCTTA
>HL981814.1 Sequence 61 from patent US 9428749
TTTGTTCGTCTTA
>HL981813.1 Sequence 60 from patent US 9428749
TTTGCTCGTCTTA
>HL981812.1 Sequence 59 from patent US 9428749
TTTGCTCGTCTTA
>HL981811.1 Sequence 58 from patent US 9428749
TTTGCTCGTCTTA
>HL981810.1 Sequence 57 from patent US 9428749
TTTGCTCGTCTTA
>HL980699.1 Sequence 14 from patent US 9428536
TTTTTGTGTGTGT
>HL980697.1 Sequence 12 from patent US 9428536
GGGGGGTGTGTGT
>HL980524.1 Sequence 16 from patent US 9427460
TGAAACATACACG
>HL980108.1 Sequence 23 from patent US 9422599
GACATCGTCCTCG
>HL979389.1 Sequence 137 from patent US 9422582
GGCCCTGCAGGCC
>HL978757.1 Sequence 137 from patent US 9422581
GGCCCTGCAGGCC
>HL978213.1 Sequence 102 from patent US 9422564
TCGAACGTTCGAG
>HL966316.1 Sequence 71 from patent US 9421255
GGGTTTTTTTGGG
>HL966306.1 Sequence 60 from patent US 9421255
GGTTTTTTTTTGG
>HL994149.1 Sequence 431 from patent US 9430610
AGCAAAAAGCAGG
>HL993651.1 Sequence 14 from patent US 9429561
TAGGGGATCCGTA
>HL993650.1 Sequence 13 from patent US 9429561
TAGGGATCCCGTA
>HL993610.1 Sequence 3 from patent US 9429518
AAGACAGTGCTTA
>HL965470.1 Sequence 5 from patent US 9416424
CGTGGTACCCCTT
>HL965468.1 Sequence 3 from patent US 9416424
CGTGGTGACCCTT
>HL964955.1 Sequence 29 from patent US 9416402
AGTCTGATAAGCT
>HL964954.1 Sequence 28 from patent US 9416402
CACTATAAGCACT
>HL957187.1 Sequence 32 from patent US 9416365
TCCTATAAAAGGA
>HL952725.1 Sequence 7 from patent US 9410201
GAACNNNNNNTAC
>HL952723.1 Sequence 5 from patent US 9410201
GAAGNNNNNNTAC
>HL952722.1 Sequence 4 from patent US 9410201
GAACNNNNNNTCC
>HL952719.1 Sequence 1 from patent US 9410201
GGCCNNNNNGGCC
>HL948759.1 Sequence 35 from patent US 9409941
GTGTGTGTGTGTC
>HL948747.1 Sequence 23 from patent US 9409941
GTGTGTGTGTGTT
>HL944595.1 Sequence 3 from patent US 9404154
CGNTGACTNNNAC
>HL943872.1 Sequence 17 from patent US 9404123
CCTAGAACGACAG
>HL943871.1 Sequence 16 from patent US 9404123
CGACAGACAAACA
>HL943870.1 Sequence 15 from patent US 9404123
ATATATATCCTAG
>HL943359.1 Sequence 21 from patent US 9404112
CAGTTAGGGTTAG
>HL943354.1 Sequence 14 from patent US 9404112
GTTAGGGTTAGAC
>HL943352.1 Sequence 12 from patent US 9404112
TAGGGTTAGACAA
>HL943348.1 Sequence 8 from patent US 9404112
ACGGTGGAAGGCG
>HL943347.1 Sequence 7 from patent US 9404112
CGGTGGAAGGCGG
>HL943345.1 Sequence 5 from patent US 9404112
GTGGAAGGCGGCA
>HL943344.1 Sequence 4 from patent US 9404112
GGAAGGCGGCAGG
>HL943340.1 Sequence 3 from patent US 9404111
CTGAGAAAGTACC
>HL943338.1 Sequence 1 from patent US 9404111
CAGACAATGTAGC
>HL941559.1 Sequence 41 from patent US 9403900
GGCCNNNNNGGCC
>HL941077.1 Sequence 2 from patent US 9402919
AGGTCANAGGTCA
>HL940648.1 Sequence 14 from patent US 9402887
NCCACCCNTCNCC
>HL940647.1 Sequence 13 from patent US 9402887
GCCGCCACCATGG
>HL940333.1 Sequence 220 from patent US 9399800
AGACCCCAGTTGC
>HL940329.1 Sequence 216 from patent US 9399800
CCCCTCCTCAGAG
>HL935364.1 Sequence 21 from patent US 9395356
CGCCGGTAGCTCT
>HL935335.1 Sequence 26 from patent US 9395354
GAGGCCTGGAAGA
>HL935334.1 Sequence 25 from patent US 9395354
GAGGCCCGGAAGA
>HL920222.1 Sequence 33 from patent US 9388465
GAACNNNNNNTAC
>HL920220.1 Sequence 31 from patent US 9388465
GAAGNNNNNNTAC
>HL920219.1 Sequence 30 from patent US 9388465
GAACNNNNNNTCC
>HL920216.1 Sequence 27 from patent US 9388465
GGCCNNNNNGGCC
>HL920148.1 Sequence 22 from patent US 9388453
CAGATAACATTTT
>HL920147.1 Sequence 21 from patent US 9388453
NAGNNNNCWTWNN
>HL917684.1 Sequence 21 from patent US 9388416
CAGTTAGGGTTAG
>HL917679.1 Sequence 14 from patent US 9388416
GTTAGGGTTAGAC
>HL917677.1 Sequence 12 from patent US 9388416
TAGGGTTAGACAA
>HL917673.1 Sequence 8 from patent US 9388416
ACGGTGGAAGGCG
>HL917672.1 Sequence 7 from patent US 9388416
CGGTGGAAGGCGG
>HL917670.1 Sequence 5 from patent US 9388416
GTGGAAGGCGGCA
>HL917669.1 Sequence 4 from patent US 9388416
GGAAGGCGGCAGG
>HL917665.1 Sequence 21 from patent US 9388415
CAGTTAGGGTTAG
>HL917660.1 Sequence 14 from patent US 9388415
GTTAGGGTTAGAC
>HL917658.1 Sequence 12 from patent US 9388415
TAGGGTTAGACAA
>HL917654.1 Sequence 8 from patent US 9388415
ACGGTGGAAGGCG
>HL917653.1 Sequence 7 from patent US 9388415
CGGTGGAAGGCGG
>HL917651.1 Sequence 5 from patent US 9388415
GTGGAAGGCGGCA
>HL917650.1 Sequence 4 from patent US 9388415
GGAAGGCGGCAGG
>HL917486.1 Sequence 6 from patent US 9388410
CACAGGAAGGGGA
>HL914701.1 Sequence 25 from patent US 9388225
GCCCGCGGGGACC
>HL913922.1 Sequence 102 from patent US 9382586
CGGCGGNCGGCGG
>HL913904.1 Sequence 84 from patent US 9382586
CCGCCGNCCGCCG
>HL913865.1 Sequence 45 from patent US 9382586
CGGCGGCCGGCGG
>HL913864.1 Sequence 44 from patent US 9382586
CGGCGGGCGGCGG
>HL913863.1 Sequence 43 from patent US 9382586
CGGCGGTCGGCGG
>HL913862.1 Sequence 42 from patent US 9382586
CGGCGGACGGCGG
>HL913838.1 Sequence 18 from patent US 9382586
CCGCCGCCCGCCG
>HL913837.1 Sequence 17 from patent US 9382586
CCGCCGGCCGCCG
>HL913836.1 Sequence 16 from patent US 9382586
CCGCCGTCCGCCG
>HL913835.1 Sequence 15 from patent US 9382586
CCGCCGACCGCCG
>HL913456.1 Sequence 198 from patent US 9382545
CGGCGCCGTGCCG
>HL913413.1 Sequence 155 from patent US 9382545
NCGGCGGCCGCCG
>HL904985.1 Sequence 472 from patent US 9382535
GGTGANNNNNNNN
>HL904979.1 Sequence 466 from patent US 9382535
GAAGANNNNNNNN
>HL904978.1 Sequence 465 from patent US 9382535
GGTGANNNNNNNN
>HL904942.1 Sequence 429 from patent US 9382535
GGCCNNNNNGGCC
>HL904219.1 Sequence 21 from patent US 9382518
TAGTTAAATAAAA
>HL904216.1 Sequence 18 from patent US 9382518
TAGTTAATTAAAA
>HL903536.1 Sequence 9 from patent US 9381517
TCTCTCTCAACAA
>HL902845.1 Sequence 543 from patent US 9376726
CGAAAAAAACGCG
>HL902555.1 Sequence 68 from patent US 9376724
CAACCTCGCGAGA
>HL902534.1 Sequence 47 from patent US 9376724
AGGGTGCAAGCGT
>HL902520.1 Sequence 33 from patent US 9376724
TCTCGCGAGGTTG
>HL902499.1 Sequence 12 from patent US 9376724
ACGCTTGCACCCT
>HL897565.1 Sequence 22 from patent US 9375485
TAGGGTTAGACAA
>HL897560.1 Sequence 17 from patent US 9375485
GTTAGGGTTAGAC
>HL897556.1 Sequence 13 from patent US 9375485
CAGTTAGGGTTAG
>HL897555.1 Sequence 12 from patent US 9375485
TAGGGTTAGACAA
>HL897552.1 Sequence 9 from patent US 9375485
ACGGTGGAAGGCG
>HL897551.1 Sequence 8 from patent US 9375485
CGGTGGAAGGCGG
>HL897549.1 Sequence 6 from patent US 9375485
GTGGAAGGCGGCA
>HL897548.1 Sequence 5 from patent US 9375485
GGAAGGCGGCAGG
>HL871253.1 Sequence 92 from patent US 9371531
GCGATCGCNATGG
>HL871243.1 Sequence 80 from patent US 9371531
GGCCNNNNNGGCC
>HL871240.1 Sequence 77 from patent US 9371531
GGCCNNNNNGGCC
>HL871225.1 Sequence 20 from patent US 9371531
GGCCNNNNNGGCC
>HL871210.1 Sequence 5 from patent US 9371531
GCAGCNNNNNNNN
>HL870516.1 Sequence 286 from patent US 9371517
GCCGCCRCCATGG
>HL868530.1 Sequence 30 from patent US 9370551
CAAGCAGAACCGG
>HL868376.1 Sequence 21 from patent US 9366667
CGCCGGTAGCTCT
>HL868247.1 Sequence 79 from patent US 9365903
GCCCGACCGCCGC
>HL867261.1 Sequence 32 from patent US 9365855
NNGNGGANGNGAN
>HL861989.1 Sequence 41 from patent US 9365638
GGCCNNNNNGGCC
>HL856784.1 Sequence 36 from patent US 9364495
GCATTGGTATTCA
>HL856783.1 Sequence 35 from patent US 9364495
GTCTGTGGAAGCG
>HL856769.1 Sequence 21 from patent US 9364495
CCATTGTCACACT
>HL856766.1 Sequence 18 from patent US 9364495
CATTGTCACACTC
>HL856754.1 Sequence 6 from patent US 9364495
ATTGTCACACTCC
>HL855896.1 Sequence 2 from patent US 9359642
GCTCTTCCGATCT
>HL855600.1 Sequence 278 from patent US 9359636
AAGCACTCTGTAC
>HL855595.1 Sequence 273 from patent US 9359636
TACTCTGGGTTCT
>HL855588.1 Sequence 266 from patent US 9359636
CACACAGTCACAC
>HL855587.1 Sequence 265 from patent US 9359636
CACATCACTCTGG
>HL855581.1 Sequence 259 from patent US 9359636
CATCGTGTACTTC
>HL855579.1 Sequence 257 from patent US 9359636
GTCCAAAACAGGT
>HL855571.1 Sequence 249 from patent US 9359636
CCTGTGATCTCTT
>HL855565.1 Sequence 243 from patent US 9359636
CTCTTGGTTGTGC
>HL855563.1 Sequence 241 from patent US 9359636
CAGTCACACAGCT
>HL855548.1 Sequence 226 from patent US 9359636
CTGGTAGAGGTGG
>HL855545.1 Sequence 223 from patent US 9359636
GCGCAGTAAAGGG
>HL855543.1 Sequence 221 from patent US 9359636
GTACAGAGTGCTT
>HL855538.1 Sequence 216 from patent US 9359636
AGAACCCAGAGTA
>HL855531.1 Sequence 209 from patent US 9359636
GTGTGACTGTGTG
>HL855530.1 Sequence 208 from patent US 9359636
CCAGAGTGATGTG
>HL855524.1 Sequence 202 from patent US 9359636
GAAGTACACGATG
>HL855522.1 Sequence 200 from patent US 9359636
ACCTGTTTTGGAC
>HL855514.1 Sequence 192 from patent US 9359636
AAGAGATCACAGG
>HL855508.1 Sequence 186 from patent US 9359636
GCACAACCAAGAG
>HL855506.1 Sequence 184 from patent US 9359636
AGCTGTGTGACTG
>HL855491.1 Sequence 169 from patent US 9359636
CCACCTCTACCAG
>HL855488.1 Sequence 166 from patent US 9359636
CCCTTTACTGCGC
>HL851802.1 Sequence 20 from patent US 9359604
TCGCCATGCTGCT
>HL851397.1 Sequence 728 from patent US 9359603
CACATACCTGAAT
>HL850113.1 Sequence 154 from patent US 9359599
TACTGACTGTATG
>HL850107.1 Sequence 148 from patent US 9359599
TCATTACACCTGC
>HL850047.1 Sequence 88 from patent US 9359599
CATTCAGTCAGTA
>HL850046.1 Sequence 87 from patent US 9359599
GATACAGTCAGTA
>HL850045.1 Sequence 86 from patent US 9359599
CATACAGTAAGTA
>HL850044.1 Sequence 85 from patent US 9359599
CATACTATCAGTA
>HL850043.1 Sequence 84 from patent US 9359599
CACACATTCAGTA
>HL850042.1 Sequence 83 from patent US 9359599
GATACAGTAAGTA
>HL850041.1 Sequence 82 from patent US 9359599
CATACAGTCAGTA
>HL850040.1 Sequence 81 from patent US 9359599
CATACAGTCAGTA
>HL850039.1 Sequence 80 from patent US 9359599
CATACAGTCAGTA
>HL850038.1 Sequence 79 from patent US 9359599
CATACAGTCGGTA
>HL850037.1 Sequence 78 from patent US 9359599
CATTCAGTCAGTA
>HL850036.1 Sequence 77 from patent US 9359599
GATACAGTCAGTA
>HL850035.1 Sequence 76 from patent US 9359599
CATACAGTAAGTA
>HL850034.1 Sequence 75 from patent US 9359599
CATACAGTCAGTA
>HL850033.1 Sequence 74 from patent US 9359599
CATACAGTCAGTA
>HL850032.1 Sequence 73 from patent US 9359599
CATACAGTCAGTA
>HL850031.1 Sequence 72 from patent US 9359599
CATACAGTCAGTA
>HL850030.1 Sequence 71 from patent US 9359599
TCATTACACCTGT
>HL850029.1 Sequence 70 from patent US 9359599
TCATAACACCTGC
>HL850028.1 Sequence 69 from patent US 9359599
TCATTACACCTGT
>HL850027.1 Sequence 68 from patent US 9359599
TCATTACACCTGC
>HL850026.1 Sequence 67 from patent US 9359599
TCATTACACCTGC
>HL850025.1 Sequence 66 from patent US 9359599
TCATTACACCTGC
>HL850024.1 Sequence 65 from patent US 9359599
TCATTGCACCCGC
>HL850023.1 Sequence 64 from patent US 9359599
TCATTATACCTAC
>HL850022.1 Sequence 63 from patent US 9359599
TCATAACACCTGT
>HL850021.1 Sequence 62 from patent US 9359599
TCATTACACCTGC
>HL850020.1 Sequence 61 from patent US 9359599
TCATTACACCTGC
>HL850019.1 Sequence 60 from patent US 9359599
TCATTACACCTGC
>HL850018.1 Sequence 59 from patent US 9359599
TCATTACACCTGC
>HL850017.1 Sequence 58 from patent US 9359599
TCATTACACCCGC
>HL850016.1 Sequence 57 from patent US 9359599
TCATAACACCTGC
>HL850015.1 Sequence 56 from patent US 9359599
TCATTACACCTGT
>HL850014.1 Sequence 55 from patent US 9359599
TCATTACACCTGC
>HL848165.1 Sequence 8751 from patent US 9354228
NNTTTTGATATCT
>HL848164.1 Sequence 8750 from patent US 9354228
GCTTTTGATATCT
>HL842898.1 Sequence 27 from patent US 9353408
GCAACGCGGCGTC
>HL842893.1 Sequence 22 from patent US 9353408
CGACGCCGCGTTG
>HL842143.1 Sequence 115 from patent US 9353378
TTGTATATAACTT
>HL842096.1 Sequence 63 from patent US 9353378
TACACCCNNNCAT
>HL842086.1 Sequence 53 from patent US 9353378
GACACCCAAACAT
>HL842085.1 Sequence 52 from patent US 9353378
CACACCCAAACAT
>HL842084.1 Sequence 51 from patent US 9353378
AACACCCAAACAT
>HL842037.1 Sequence 4 from patent US 9353378
TACACCCAAACAT
>HL841329.1 Sequence 14 from patent US 9353370
CATAGGGTTCATT
>HL833853.1 Sequence 27 from patent US 9352028
GCCGCCACCATGG
>HL832621.1 Sequence 67 from patent US 9347100
CGGAGATGGCCCA
